| Case | No. | |
|------|-----|--|
| | | |

In the Supreme Court of Nevada

UNITED HEALTHCARE INSURANCE COMPANY, UNITED HEALTH CARE SERVICES, INC., UMR, INC., SIERRA HEALTH AND LIFE INSURANCE COMPANY, INC., HEALTH PLAN OF NEVADA, INC., Electronically Filed Nov 17 2022 10:56 AM Elizabeth A. Brown Clerk of Supreme Court

Petitioners,

vs.

THE EIGHTH JUDICIAL DISTRICT COURT of the State of Nevada, in and for the County of Clark; and THE HONORABLE NANCY L. ALLF, District Judge,

Respondents,

and

FREMONT EMERGENCY SERVICES (MANDAVIA), LTD., TEAM PHYSICIANS OF NEVADA-MANDAVIA, P.C., CRUM STEFANKO AND JONES, LTD.,

Real Parties in Interest.

PETITIONERS' APPENDIX VOLUME 4 PAGES 751-1000

D. LEE ROBERTS (SBN 8877)
COLBY L. BALKENBUSH (SBN 13,066)
BRITTANY M. LLEWELLYN (SBN 13,527)
WEINBERG, WHEELER,
HUDGINS, GUNN & DIAL, LLC
6385 South Rainbow Blvd., Suite 400
Las Vegas, Nevada 89118

Daniel F. Polsenberg (SBN 2376)
Joel D. Henriod (SBN 8492)
Abraham G. Smith (SBN 13,250)
Kory J. Koerperich (SBN 14,559)
Lewis Roca Rothgerber Christie Llp
3993 Howard Hughes Pkwy., Suite 600
Las Vegas, Nevada 89169

Attorneys for Petitioners

CHRONOLOGICAL TABLE OF CONTENTS TO APPENDIX

| Tab | Document | Date | Vol. | Pages |
|-----|---|----------|--------|-----------------------|
| 1 | Notice of Entry of Stipulated Confidentiality and Protective Order | 06/24/20 | 1 | 1–24 |
| 2 | Second Amended Complaint | 10/07/21 | 1 | 25–43 |
| 3 | Defendants' Answer to Plaintiffs' Second Amended Complaint | 10/08/21 | 1 | 44–51 |
| 4 | Media Request and Order Allowing Camera Access to Court Proceedings (Legal Newsline) | 10/18/21 | 1 | 52–56 |
| 5 | Media Request and Order Allowing Camera Access to Court Proceedings (Dolcefino Communications, LLC) | 10/28/21 | 1 | 57–62 |
| 6 | Media Request and Order Allowing Camera Access to Court Proceedings (Dolcefino Communications, LLC) | 10/28/21 | 1 | 63–68 |
| 7 | Defendants' Objection to Media Requests | 10/28/21 | 1 | 69–83 |
| 8 | Supplement to Defendants' Objection to Media Requests | 10/31/21 | 1 | 84–104 |
| 9 | Plaintiffs' Response to Defendants' Objection to Media Requests | 11/01/21 | 1 | 105–115 |
| 10 | Recorder's Transcript of Jury Trial – Day 5 | 11/01/21 | 1 2 | 116–250 251–317 |
| 11 | Recorder's Transcript of Jury Trial – Day 6 | 11/02/21 | 2 | 318–489 |
| 12 | Recorder's Transcript of Jury Trial – Day 7 | 11/03/21 | 2 3 | 490–500 501–706 |
| 13 | Recorder's Transcript of Jury Trial – Day 9 | 11/09/21 | 3 4 | 707–750 751–915 |
| 14 | Recorder's Transcript of Jury Trial – Day 10 | 11/10/21 | 4 5 | 916–1000 1001–1135 |

| 15 | Defendants' Motion for Leave to File Defendants' Preliminary Motion to Seal Attorneys' Eyes Only Documents Used at Trial Under Seal | 11/12/21 | 5 | 1136–1144 |
|----|---|----------|-------------|-------------------------------------|
| 16 | Recorder's Transcript of Jury Trial – Day 12 | 11/15/21 | 5 6 | 1145–1250 1251–1421 |
| 17 | Recorder's Transcript of Jury Trial – Day 13 | 11/16/21 | 6 7 | 1422–1500 1501–1717 |
| 18 | Recorder's Transcript of Jury Trial – Day 14 | 11/17/21 | 7 8 9 | 1718–1750 1751–2000 2001–2021 |
| 19 | Recorder's Transcript of Jury Trial – Day 15 | 11/18/21 | 9 10 | 2022–2250 2251–2344 |
| 20 | Recorder's Transcript of Jury Trial – Day 17 | 11/22/21 | 10 11 | 2345–2500 2501–2665 |
| 21 | Recorder's Transcript of Jury Trial – Day 18 | 11/23/21 | 11 12 | 2666–2750 2751–2940 |
| 22 | Special Verdict Form | 11/29/21 | 12 | 2941–2952 |
| 23 | Special Verdict Form | 12/07/21 | 12 | 2953–2955 |
| 24 | Motion to Seal Defendants' Motion to Seal Certain Confidential Trial Exhibits | 12/15/21 | 12 | 2956–2964 |
| 25 | Motion to Seal Defendants' Supplement to Motion to Seal Certain Confidential Trial Exhibits | 12/15/21 | 12 | 2965–2973 |
| 26 | Notice of Entry of Order Granting Defendants' Motion for Leave to File Defendants' Preliminary Motion to Seal Attorneys' Eyes Only Documents Used at Trial Under Seal | 12/27/21 | 12 | 2974–2984 |
| 27 | Plaintiffs' Opposition to United's Motion to Seal | 12/29/21 | 12 13 | 2985–3000 3001–3003 |
| 28 | Motion to Seal Defendants' Reply in Support of Motion to Seal Certain | 01/10/22 | 13 | 3004–3012 |

| | Confidential Trial Exhibits | | | |
|----|---|----------|----|-----------|
| 29 | Motion to Seal Defendants' Second Supplemental Appendix of Exhibits to Motion to Seal Certain Confidential Trial Exhibits | 01/10/22 | 13 | 3013–3021 |
| 30 | Defendants' Motion to Seal Courtroom During January 12, 2022 Hearing on Defendants' Motion to Seal Certain Confidential Trial Exhibits on Order Shortening Time | 01/11/22 | 13 | 3022–3033 |
| 31 | Plaintiffs' Opposition to Defendants' Motion to Seal Courtroom During January 12, 2022 Hearing | 01/12/22 | 13 | 3034–3037 |
| 32 | Notice of Entry of Order Granting Plaintiffs' Proposed Schedule for Submission of Final Redactions | 01/31/22 | 13 | 3038–3048 |
| 33 | Notice of Entry of Stipulation and Order Regarding Schedule for Submission of Redactions | 02/08/22 | 13 | 3049–3065 |
| 34 | Notice of Entry of Order Shortening Time for Hearing Re: Plaintiffs' Motion to Unlock Certain Admitted Trial Exhibits | 02/14/22 | 13 | 3066–3083 |
| 35 | Defendants' Response to Plaintiffs' Motion to Unlock Certain Admitted Trial Exhibits on Order Shortening Time | 02/15/22 | 13 | 3084–3090 |
| 36 | Defendants' Index of Trial Exhibit Redactions in Dispute | 02/16/22 | 13 | 3091–3101 |
| 37 | Notice of Entry of Stipulation and Order Regarding Certain Admitted Trial Exhibits | 02/17/22 | 13 | 3102–3125 |
| 38 | Notice of Entry of Judgment | 03/09/22 | 13 | 3126–3136 |
| 39 | Notice of Posting Supersedeas Bond | 04/29/22 | 13 | 3137–3144 |
| 40 | Limited Objection to "Order Unsealing Trial Transcripts and Restoring Public Access to | 10/06/22 | 13 | 3145–3150 |

| | Docket" | | | |
|-----|--|----------|----------------|-------------------------------------|
| 41 | Defendants' Motion to Redact Portions of Trial Transcript | 10/06/22 | 13 | 3151–3161 |
| 42 | Plaintiffs' Opposition to Defendants' Motion to Redact Portions of Trial Transcript | 10/07/22 | 13 | 3162–3165 |
| 43 | Notice of Entry of Order Unsealing Trial Transcripts and Restoring Public Access to Docket | 10/12/22 | 13 | 3166–3176 |
| 44 | Notice of Appeal | 10/12/22 | 13 14 15 | 3177–3250 3251–3500 3501–3518 |
| 45 | Case Appeal Statement | 10/12/22 | 15 | 3519–3649 |
| 46 | Notice of Entry of Order Denying "Motion to Redact Portions of Trial Transcript" | 10/13/22 | 15 | 3650–3659 |
| 47 | Notice of Entry of Order Granting in Part and Denying in Part Defendants' Motion to Seal Certain Confidential Trial Exhibits | 10/18/22 | 15 16 | 3660–3750 3751–3806 |
| 48 | Notice of Entry of Stipulation and Order Regarding Expiration of Temporary Stay for Sealed Redacted Transcripts | 10/25/22 | 16 | 3807–3817 |
| 48A | Order Granting Temporary Stay, filed in Case No. 85525 | 11/10/22 | 16 | 3817A-3817B |

Filed Under Seal

| Tab | Document | Date | Vol. | Pages |
|-----|---|----------|------|-----------|
| 49 | Excerpts of Recorder's Transcript of Jury Trial – Day 9 | 11/09/21 | 17 | 3818–3823 |
| 50 | Preliminary Motion to Seal Attorneys' Eyes Documents Used at Trial | 11/11/21 | 17 | 3824–3875 |
| 51 | Excerpts of Recorder's Transcript of Jury Trial – Day 13 | 11/16/21 | 17 | 3876–3882 |

| 52 | Motion to Seal Certain Confidential Trial Exhibits | 12/05/21 | 17 | 3883–3977 |
|----|--|----------|----------|------------------------|
| 53 | Supplement to Defendants' Motion to Seal Certain Confidential Trial Exhibits | 12/08/21 | 17 | 3978–3995 |
| 54 | Motion to Seal Certain Confidential Trial Exhibits | 12/13/21 | 17 18 | 3996–4067 4068–4090 |
| 55 | Supplemental Appendix of Exhibits to Motion to Seal Certain Confidential Trial Exhibits – Volume 1 of 18 | 12/24/21 | 18 | 4091–4192 |
| 56 | Supplemental Appendix of Exhibits to Motion to Seal Certain Confidential Trial Exhibits – Volume 2 of 18 | 12/24/21 | 18 19 | 4193–4317 4318–4386 |
| 57 | Supplemental Appendix of Exhibits to Motion to Seal Certain Confidential Trial Exhibits – Volume 3 of 18 | 12/24/21 | 19 20 | 4387–4567 4568–4644 |
| 58 | Supplemental Appendix of Exhibits to Motion to Seal Certain Confidential Trial Exhibits – Volume 4 of 18 | 12/24/21 | 20 21 | 4645–4817 4818–4840 |
| 59 | Supplemental Appendix of Exhibits to Motion to Seal Certain Confidential Trial Exhibits – Volume 5 of 18 | 12/24/21 | 21 | 4841–4986 |
| 60 | Supplemental Appendix of Exhibits to Motion to Seal Certain Confidential Trial Exhibits – Volume 6 of 18 | 12/24/21 | 21 22 | 4987–5067 5068–5121 |
| 61 | Supplemental Appendix of Exhibits to Motion to Seal Certain Confidential Trial Exhibits – Volume 7 of 18 | 12/24/21 | 22 | 5122–5286 |
| 62 | Supplemental Appendix of Exhibits to Motion to Seal Certain Confidential Trial Exhibits – Volume 8 of 18 | 12/24/21 | 22 23 | 5287–5317 5318–5429 |
| 63 | Supplemental Appendix of Exhibits to Motion to Seal Certain Confidential Trial Exhibits – Volume 9 of 18 | 12/24/21 | 23 24 | 5430–5567 5568–5629 |

| 64 | Supplemental Appendix of Exhibits to Motion to Seal Certain Confidential Trial Exhibits – Volume 10 of 18 | 12/24/21 | 24 | 5630–5809 |
|----|---|----------|----------|------------------------|
| 65 | Supplemental Appendix of Exhibits to Motion to Seal Certain Confidential Trial Exhibits – Volume 11 of 18 | 12/24/21 | 24 25 | 5810–5817 5818–5953 |
| 66 | Supplemental Appendix of Exhibits to Motion to Seal Certain Confidential Trial Exhibits – Volume 12 of 18 | 12/24/21 | 25 26 | 5954–6067 6068–6199 |
| 67 | Supplemental Appendix of Exhibits to Motion to Seal Certain Confidential Trial Exhibits – Volume 13 of 18 | 12/24/21 | 26 27 | 6200–6317 6318–6418 |
| 68 | Supplemental Appendix of Exhibits to Motion to Seal Certain Confidential Trial Exhibits – Volume 14 of 18 | 12/24/21 | 27 28 | 6419–6567 6568–6579 |
| 69 | Supplemental Appendix of Exhibits to Motion to Seal Certain Confidential Trial Exhibits – Volume 15 of 18 | 12/24/21 | 28 | 6580–6737 |
| 70 | Supplemental Appendix of Exhibits to Motion to Seal Certain Confidential Trial Exhibits – Volume 16 of 18 | 12/24/21 | 28 29 | 6738–6817 6818–6854 |
| 71 | Supplemental Appendix of Exhibits to Motion to Seal Certain Confidential Trial Exhibits – Volume 17 of 18 | 12/24/21 | 29 | 6855-7024 |
| 72 | Supplemental Appendix of Exhibits to Motion to Seal Certain Confidential Trial Exhibits – Volume 18 of 18 | 12/24/21 | 29 30 | 7025–7067 7068–7160 |
| 73 | Defendants' Reply in Support of Motion to Seal Certain Confidential Trial Exhibits | 01/05/22 | 30 | 7161–7210 |
| 74 | Second Supplemental Appendix of Exhibits to Motion to Seal Certain Confidential Trial Exhibits | 01/05/22 | 30 31 | 7211–7317 7318–7402 |
| 75 | Transcript of Proceedings Re: Motions | 01/12/22 | 31 | 7403–7498 |

| 76 | Transcript of Proceedings Re: Motions | 01/20/22 | 31 | 7499–7552 |
|----|---|----------|----------|------------------------|
| 77 | Transcript of Proceedings Re: Motions | 01/27/22 | 31 | 7553–7563 |
| 78 | Defendants' Index of Trial Exhibit Redactions in Dispute | 02/10/22 | 31 32 | 7564–7567 7568–7574 |
| 79 | Transcript of Proceedings Re: Motions Hearing | 02/10/22 | 32 | 7575–7695 |
| 80 | Transcript of Proceedings Re: Motions Hearing | 02/16/22 | 32 | 7696–7789 |
| 81 | Joint Status Report and Table Identifying the Redactions to Trial Exhibits That Remain in Dispute | 03/04/22 | 32 33 | 7790–7817 7818–7824 |
| 82 | Transcript of Hearing Regarding Unsealing Record | 10/05/22 | 33 | 7825–7845 |
| 83 | Transcript of Status Check | 10/06/22 | 33 | 7846–7855 |
| 84 | Appendix B to Order Granting in Part and Denying in Part Defendants' Motion to Seal Certain Confidential Trial Exhibits (Volume 1) | 10/07/22 | 33 34 | 7856–8067 8068–8109 |
| 85 | Appendix B to Order Granting in Part and Denying in Part Defendants' Motion to Seal Certain Confidential Trial Exhibits (Volume 2) | 10/07/22 | 34 35 | 8110–8317 8318–8378 |
| 86 | Appendix B to Order Granting in Part and Denying in Part Defendants' Motion to Seal Certain Confidential Trial Exhibits (Volume 3) | 10/07/22 | 35 36 | 8379–8567 8568–8653 |
| 87 | Appendix B to Order Granting in Part and Denying in Part Defendants' Motion to Seal Certain Confidential Trial Exhibits (Volume 4) | 10/07/22 | 36 37 | 8654–8817 8818–8918 |
| 88 | Appendix B to Order Granting in Part and Denying in Part Defendants' Motion to Seal Certain Confidential Trial Exhibits (Volume | 10/07/22 | 37 38 | 8919–9067 9068–9203 |

| | 5) | | | |
|----|--|----------|----------------|---|
| 89 | Appendix B to Order Granting in Part and Denying in Part Defendants' Motion to Seal Certain Confidential Trial Exhibits (Volume 6) | 10/07/22 | 38 39 | 9204–9317 9318–9431 |
| 90 | Appendix B to Order Granting in Part and Denying in Part Defendants' Motion to Seal Certain Confidential Trial Exhibits (Volume 7) | 10/07/22 | 39 40 | 9432–9567 9568–9742 |
| 91 | Appendix B to Order Granting in Part and Denying in Part Defendants' Motion to Seal Certain Confidential Trial Exhibits (Volume 8) | 10/07/22 | 40 41 | 9743–9817 9818–10,011 |
| 92 | Appendix B to Order Granting in Part and Denying in Part Defendants' Motion to Seal Certain Confidential Trial Exhibits (Volume 9) | 10/07/22 | 41 42 | 10,012–10,067 10,068–10,279 |
| 93 | Appendix B to Order Granting in Part and Denying in Part Defendants' Motion to Seal Certain Confidential Trial Exhibits (Volume 10) | 10/07/22 | 42 43 44 | 10,280–10,317 10,318–10,567 10,568–10,570 |
| 94 | Appendix B to Order Granting in Part and Denying in Part Defendants' Motion to Seal Certain Confidential Trial Exhibits (Volume 11) | 10/07/22 | 44 | 10,571–10,809 |
| 95 | Appendix B to Order Granting in Part and Denying in Part Defendants' Motion to Seal Certain Confidential Trial Exhibits (Volume 12) | 10/07/22 | 44 45 | 10,810–10,817 10,818–11,064 |
| 96 | Appendix B to Order Granting in Part and Denying in Part Defendants' Motion to Seal Certain Confidential Trial Exhibits (Volume 13) | 10/07/22 | 45 46 | 11,065–11,067 11,068–11,144 |
| 97 | Exhibits P473_NEW, 4002, 4003, 4005, | 10/07/22 | 46 | 11,145–11,149 |

| | 4006, 4166, 4168, 4455, 4457, 4774, and 5322 to "Appendix B to Order Granting in Part and Denying in Part Defendants' Motion to Seal Certain Confidential Trial Exhibits" (Tabs 98, 106, 107, 108, 109, 111, 112, 113, 114, 118, and 119) | | | |
|----|---|----------|----|---------------|
| 98 | Transcript of Status Check | 10/11/22 | 46 | 11,150–11,160 |
| 99 | Recorder's Transcript of Hearing | 10/13/22 | 46 | 11,161–11,165 |

ALPHABETICAL TABLE OF CONTENTS TO APPENDIX

| Tab | Document | Date | Vol. | Pages |
|-----|--|----------|----------|--------------------------|
| 84 | Appendix B to Order Granting in Part and Denying in Part Defendants' Motion to Seal Certain Confidential Trial Exhibits (Volume 1) (FILED UNDER SEAL) | 10/07/22 | 33 34 | 7856–8067 8068–8109 |
| 85 | Appendix B to Order Granting in Part and Denying in Part Defendants' Motion to Seal Certain Confidential Trial Exhibits (Volume 2) (FILED UNDER SEAL) | 10/07/22 | 34 35 | 8110–8317 8318–8378 |
| 86 | Appendix B to Order Granting in Part and Denying in Part Defendants' Motion to Seal Certain Confidential Trial Exhibits (Volume 3) (FILED UNDER SEAL) | 10/07/22 | 35 36 | 8379–8567 8568–8653 |
| 87 | Appendix B to Order Granting in Part and Denying in Part Defendants' Motion to Seal Certain Confidential Trial Exhibits (Volume 4) (FILED UNDER SEAL) | 10/07/22 | 36 37 | 8654–8817 8818–8918 |
| 88 | Appendix B to Order Granting in Part and Denying in Part Defendants' Motion to Seal Certain Confidential Trial Exhibits (Volume 5) (FILED UNDER SEAL) | 10/07/22 | 37 38 | 8919–9067 9068–9203 |
| 89 | Appendix B to Order Granting in Part and Denying in Part Defendants' Motion to Seal Certain Confidential Trial Exhibits (Volume 6) (FILED UNDER SEAL) | 10/07/22 | 38 39 | 9204–9317 9318–9431 |
| 90 | Appendix B to Order Granting in Part and Denying in Part Defendants' Motion to Seal Certain Confidential Trial Exhibits (Volume 7) (FILED UNDER SEAL) | 10/07/22 | 39 40 | 9432–9567 9568–9742 |
| 91 | Appendix B to Order Granting in Part and Denying in Part Defendants' Motion to Seal Certain Confidential Trial Exhibits | 10/07/22 | 40 41 | 9743–9817 9818–10,011 |

| | (Volume 8) (FILED UNDER SEAL) | | | |
|----|---|----------|----------------|---|
| 92 | Appendix B to Order Granting in Part and Denying in Part Defendants' Motion to Seal Certain Confidential Trial Exhibits (Volume 9) (FILED UNDER SEAL) | 10/07/22 | 41 42 | 10,012–10,067 10,068–10,279 |
| 93 | Appendix B to Order Granting in Part and Denying in Part Defendants' Motion to Seal Certain Confidential Trial Exhibits (Volume 10) (FILED UNDER SEAL) | 10/07/22 | 42 43 44 | 10,280–10,317 10,318–10,567 10,568–10,570 |
| 94 | Appendix B to Order Granting in Part and Denying in Part Defendants' Motion to Seal Certain Confidential Trial Exhibits (Volume 11) (FILED UNDER SEAL) | 10/07/22 | 44 | 10,571–10,809 |
| 95 | Appendix B to Order Granting in Part and Denying in Part Defendants' Motion to Seal Certain Confidential Trial Exhibits (Volume 12) (FILED UNDER SEAL) | 10/07/22 | 44 45 | 10,810–10,817 10,818–11,064 |
| 96 | Appendix B to Order Granting in Part and Denying in Part Defendants' Motion to Seal Certain Confidential Trial Exhibits (Volume 13) (FILED UNDER SEAL) | 10/07/22 | 45 46 | 11,065–11,067 11,068–11,144 |
| 45 | Case Appeal Statement | 10/12/22 | 15 | 3519–3649 |
| 3 | Defendants' Answer to Plaintiffs' Second Amended Complaint | 10/08/21 | 1 | 44–51 |
| 36 | Defendants' Index of Trial Exhibit Redactions in Dispute | 02/16/22 | 13 | 3091–3101 |
| 78 | Defendants' Index of Trial Exhibit Redactions in Dispute (FILED UNDER SEAL) | 02/10/22 | 31 32 | 7564–7567 7568–7574 |
| 15 | Defendants' Motion for Leave to File Defendants' Preliminary Motion to Seal Attorneys' Eyes Only Documents Used at Trial Under Seal | 11/12/21 | 5 | 1136–1144 |

| 41 | Defendants' Motion to Redact Portions of Trial Transcript | 10/06/22 | 13 | 3151–3161 |
|----|---|----------|----------|------------------------|
| 30 | Defendants' Motion to Seal Courtroom During January 12, 2022 Hearing on Defendants' Motion to Seal Certain Confidential Trial Exhibits on Order Shortening Time | 01/11/22 | 13 | 3022–3033 |
| 7 | Defendants' Objection to Media Requests | 10/28/21 | 1 | 69–83 |
| 73 | Defendants' Reply in Support of Motion to Seal Certain Confidential Trial Exhibits (FILED UNDER SEAL) | 01/05/22 | 30 | 7161–7210 |
| 35 | Defendants' Response to Plaintiffs' Motion to Unlock Certain Admitted Trial Exhibits on Order Shortening Time | 02/15/22 | 13 | 3084–3090 |
| 51 | Excerpts of Recorder's Transcript of Jury Trial – Day 13 (FILED UNDER SEAL) | 11/16/21 | 17 | 3876–3882 |
| 49 | Excerpts of Recorder's Transcript of Jury Trial – Day 9 (FILED UNDER SEAL) | 11/09/21 | 17 | 3818–3823 |
| 97 | Exhibits P473_NEW, 4002, 4003, 4005, 4006, 4166, 4168, 4455, 4457, 4774, and 5322 to "Appendix B to Order Granting in Part and Denying in Part Defendants' Motion to Seal Certain Confidential Trial Exhibits" (Tabs 98, 106, 107, 108, 109, 111, 112, 113, 114, 118, and 119) (FILED UNDER SEAL) | 10/07/22 | 46 | 11,145–11,149 |
| 81 | Joint Status Report and Table Identifying the Redactions to Trial Exhibits That Remain in Dispute (FILED UNDER SEAL) | 03/04/22 | 32 33 | 7790–7817 7818–7824 |
| 40 | Limited Objection to "Order Unsealing Trial Transcripts and Restoring Public Access to Docket" | 10/06/22 | 13 | 3145–3150 |
| 4 | Media Request and Order Allowing Camera Access to Court Proceedings (Legal | 10/18/21 | 1 | 52–56 |

| | Newsline) | | | |
|----|--|----------|----------------|-------------------------------------|
| 5 | Media Request and Order Allowing Camera Access to Court Proceedings (Dolcefino Communications, LLC) | 10/28/21 | 1 | 57–62 |
| 6 | Media Request and Order Allowing Camera Access to Court Proceedings (Dolcefino Communications, LLC) | 10/28/21 | 1 | 63–68 |
| 52 | Motion to Seal Certain Confidential Trial Exhibits (FILED UNDER SEAL) | 12/05/21 | 17 | 3883–3977 |
| 54 | Motion to Seal Certain Confidential Trial Exhibits (FILED UNDER SEAL) | 12/13/21 | 17 18 | 3996–4067 4068–4090 |
| 24 | Motion to Seal Defendants' Motion to Seal Certain Confidential Trial Exhibits | 12/15/21 | 12 | 2956–2964 |
| 28 | Motion to Seal Defendants' Reply in Support of Motion to Seal Certain Confidential Trial Exhibits | 01/10/22 | 13 | 3004–3012 |
| 29 | Motion to Seal Defendants' Second Supplemental Appendix of Exhibits to Motion to Seal Certain Confidential Trial Exhibits | 01/10/22 | 13 | 3013–3021 |
| 25 | Motion to Seal Defendants' Supplement to Motion to Seal Certain Confidential Trial Exhibits | 12/15/21 | 12 | 2965–2973 |
| 44 | Notice of Appeal | 10/12/22 | 13 14 15 | 3177–3250 3251–3500 3501–3518 |
| 38 | Notice of Entry of Judgment | 03/09/22 | 13 | 3126–3136 |
| 46 | Notice of Entry of Order Denying "Motion to Redact Portions of Trial Transcript" | 10/13/22 | 15 | 3650–3659 |
| 26 | Notice of Entry of Order Granting Defendants' Motion for Leave to File Defendants' Preliminary Motion to Seal Attorneys' Eyes Only Documents Used at | 12/27/21 | 12 | 2974–2984 |

| | Trial Under Seal | | | |
|-----|--|----------|----------|------------------------|
| 47 | Notice of Entry of Order Granting in Part and Denying in Part Defendants' Motion to Seal Certain Confidential Trial Exhibits | 10/18/22 | 15 16 | 3660–3750 3751–3806 |
| 32 | Notice of Entry of Order Granting Plaintiffs' Proposed Schedule for Submission of Final Redactions | 01/31/22 | 13 | 3038–3048 |
| 34 | Notice of Entry of Order Shortening Time for Hearing Re: Plaintiffs' Motion to Unlock Certain Admitted Trial Exhibits | 02/14/22 | 13 | 3066–3083 |
| 43 | Notice of Entry of Order Unsealing Trial Transcripts and Restoring Public Access to Docket | 10/12/22 | 13 | 3166–3176 |
| 1 | Notice of Entry of Stipulated Confidentiality and Protective Order | 06/24/20 | 1 | 1–24 |
| 37 | Notice of Entry of Stipulation and Order Regarding Certain Admitted Trial Exhibits | 02/17/22 | 13 | 3102–3125 |
| 48 | Notice of Entry of Stipulation and Order Regarding Expiration of Temporary Stay for Sealed Redacted Transcripts | 10/25/22 | 16 | 3807–3817 |
| 33 | Notice of Entry of Stipulation and Order Regarding Schedule for Submission of Redactions | 02/08/22 | 13 | 3049–3065 |
| 39 | Notice of Posting Supersedeas Bond | 04/29/22 | 13 | 3137–3144 |
| 48A | Order Granting Temporary Stay, filed in Case No. 85525 | 11/10/22 | 16 | 3817A-3817B |
| 42 | Plaintiffs' Opposition to Defendants' Motion to Redact Portions of Trial Transcript | 10/07/22 | 13 | 3162–3165 |
| 31 | Plaintiffs' Opposition to Defendants' Motion to Seal Courtroom During January 12, 2022 Hearing | 01/12/22 | 13 | 3034–3037 |

| 27 | Plaintiffs' Opposition to United's Motion to Seal | 12/29/21 | 12 13 | 2985–3000 3001–3003 |
|----|---|----------|-------------|-------------------------------------|
| 9 | Plaintiffs' Response to Defendants' Objection to Media Requests | 11/01/21 | 1 | 105–115 |
| 50 | Preliminary Motion to Seal Attorneys' Eyes Documents Used at Trial (FILED UNDER SEAL) | 11/11/21 | 17 | 3824–3875 |
| 99 | Recorder's Transcript of Hearing (FILED UNDER SEAL) | 10/13/22 | 46 | 11,161–11,165 |
| 14 | Recorder's Transcript of Jury Trial – Day 10 | 11/10/21 | 4 5 | 916–1000 1001–1135 |
| 16 | Recorder's Transcript of Jury Trial – Day 12 | 11/15/21 | 5 6 | 1145–1250 1251–1421 |
| 17 | Recorder's Transcript of Jury Trial – Day 13 | 11/16/21 | 6 7 | 1422–1500 1501–1717 |
| 18 | Recorder's Transcript of Jury Trial – Day 14 | 11/17/21 | 7 8 9 | 1718–1750 1751–2000 2001–2021 |
| 19 | Recorder's Transcript of Jury Trial – Day 15 | 11/18/21 | 9 10 | 2022–2250 2251–2344 |
| 20 | Recorder's Transcript of Jury Trial – Day 17 | 11/22/21 | 10 11 | 2345–2500 2501–2665 |
| 21 | Recorder's Transcript of Jury Trial – Day 18 | 11/23/21 | 11 12 | 2666–2750 2751–2940 |
| 10 | Recorder's Transcript of Jury Trial – Day 5 | 11/01/21 | 1 2 | 116–250 251–317 |
| 11 | Recorder's Transcript of Jury Trial – Day 6 | 11/02/21 | 2 | 318–489 |
| 12 | Recorder's Transcript of Jury Trial – Day 7 | 11/03/21 | 2 3 | 490–500 501–706 |
| 13 | Recorder's Transcript of Jury Trial – Day 9 | 11/09/21 | 3 4 | 707–750 751–915 |
| 2 | Second Amended Complaint | 10/07/21 | 1 | 25–43 |

| 74 | Second Supplemental Appendix of Exhibits to Motion to Seal Certain Confidential Trial Exhibits (FILED UNDER SEAL) | 01/05/22 | 30 31 | 7211–7317 7318–7402 |
|----|--|----------|----------|------------------------|
| 22 | Special Verdict Form | 11/29/21 | 12 | 2941–2952 |
| 23 | Special Verdict Form | 12/07/21 | 12 | 2953–2955 |
| 53 | Supplement to Defendants' Motion to Seal Certain Confidential Trial Exhibits (FILED UNDER SEAL) | 12/08/21 | 17 | 3978–3995 |
| 8 | Supplement to Defendants' Objection to Media Requests | 10/31/21 | 1 | 84–104 |
| 55 | Supplemental Appendix of Exhibits to Motion to Seal Certain Confidential Trial Exhibits – Volume 1 of 18 (FILED UNDER SEAL) | 12/24/21 | 18 | 4091–4192 |
| 56 | Supplemental Appendix of Exhibits to Motion to Seal Certain Confidential Trial Exhibits – Volume 2 of 18 (FILED UNDER SEAL) | 12/24/21 | 18 19 | 4193–4317 4318–4386 |
| 57 | Supplemental Appendix of Exhibits to Motion to Seal Certain Confidential Trial Exhibits – Volume 3 of 18 (FILED UNDER SEAL) | 12/24/21 | 19 20 | 4387–4567 4568–4644 |
| 58 | Supplemental Appendix of Exhibits to Motion to Seal Certain Confidential Trial Exhibits – Volume 4 of 18 (FILED UNDER SEAL) | 12/24/21 | 20 21 | 4645–4817 4818–4840 |
| 59 | Supplemental Appendix of Exhibits to Motion to Seal Certain Confidential Trial Exhibits – Volume 5 of 18 (FILED UNDER SEAL) | 12/24/21 | 21 | 4841–4986 |
| 60 | Supplemental Appendix of Exhibits to Motion to Seal Certain Confidential Trial Exhibits – Volume 6 of 18 (FILED UNDER | 12/24/21 | 21 22 | 4987–5067 5068–5121 |

| | SEAL) | | | |
|----|---|----------|----------|------------------------|
| 61 | Supplemental Appendix of Exhibits to Motion to Seal Certain Confidential Trial Exhibits – Volume 7 of 18 (FILED UNDER SEAL) | 12/24/21 | 22 | 5122-5286 |
| 62 | Supplemental Appendix of Exhibits to Motion to Seal Certain Confidential Trial Exhibits – Volume 8 of 18 (FILED UNDER SEAL) | 12/24/21 | 22 23 | 5287–5317 5318–5429 |
| 63 | Supplemental Appendix of Exhibits to Motion to Seal Certain Confidential Trial Exhibits – Volume 9 of 18 (FILED UNDER SEAL) | 12/24/21 | 23 24 | 5430–5567 5568–5629 |
| 64 | Supplemental Appendix of Exhibits to Motion to Seal Certain Confidential Trial Exhibits – Volume 10 of 18 (FILED UNDER SEAL) | 12/24/21 | 24 | 5630–5809 |
| 65 | Supplemental Appendix of Exhibits to Motion to Seal Certain Confidential Trial Exhibits – Volume 11 of 18 (FILED UNDER SEAL) | 12/24/21 | 24 25 | 5810–5817 5818–5953 |
| 66 | Supplemental Appendix of Exhibits to Motion to Seal Certain Confidential Trial Exhibits – Volume 12 of 18 (FILED UNDER SEAL) | 12/24/21 | 25 26 | 5954–6067 6068–6199 |
| 67 | Supplemental Appendix of Exhibits to Motion to Seal Certain Confidential Trial Exhibits – Volume 13 of 18 (FILED UNDER SEAL) | 12/24/21 | 26 27 | 6200–6317 6318–6418 |
| 68 | Supplemental Appendix of Exhibits to Motion to Seal Certain Confidential Trial Exhibits – Volume 14 of 18 (FILED UNDER SEAL) | 12/24/21 | 27 28 | 6419–6567 6568–6579 |
| 69 | Supplemental Appendix of Exhibits to | 12/24/21 | 28 | 6580-6737 |

| | Motion to Seal Certain Confidential Trial Exhibits – Volume 15 of 18 (FILED UNDER SEAL) | | | |
|----|---|----------|----------|------------------------|
| 70 | Supplemental Appendix of Exhibits to Motion to Seal Certain Confidential Trial Exhibits – Volume 16 of 18 (FILED UNDER SEAL) | 12/24/21 | 28 29 | 6738–6817 6818–6854 |
| 71 | Supplemental Appendix of Exhibits to Motion to Seal Certain Confidential Trial Exhibits – Volume 17 of 18 (FILED UNDER SEAL) | 12/24/21 | 29 | 6855-7024 |
| 72 | Supplemental Appendix of Exhibits to Motion to Seal Certain Confidential Trial Exhibits – Volume 18 of 18 (FILED UNDER SEAL) | 12/24/21 | 29 30 | 7025–7067 7068–7160 |
| 82 | Transcript of Hearing Regarding Unsealing Record (FILED UNDER SEAL) | 10/05/22 | 33 | 7825–7845 |
| 75 | Transcript of Proceedings Re: Motions (FILED UNDER SEAL) | 01/12/22 | 31 | 7403–7498 |
| 76 | Transcript of Proceedings Re: Motions (FILED UNDER SEAL) | 01/20/22 | 31 | 7499–7552 |
| 77 | Transcript of Proceedings Re: Motions (FILED UNDER SEAL) | 01/27/22 | 31 | 7553–7563 |
| 79 | Transcript of Proceedings Re: Motions Hearing (FILED UNDER SEAL) | 02/10/22 | 32 | 7575–7695 |
| 80 | Transcript of Proceedings Re: Motions Hearing (FILED UNDER SEAL) | 02/16/22 | 32 | 7696–7789 |
| 83 | Transcript of Status Check (FILED UNDER SEAL) | 10/06/22 | 33 | 7846–7855 |
| 98 | Transcript of Status Check (FILED UNDER SEAL) | 10/11/22 | 46 | 11,150–11,160 |

CERTIFICATE OF SERVICE

I certify that on November 15, 2022, I submitted the foregoing "Petitioners' Appendix" for filing *via* the Court's eFlex electronic filing system. Electronic notification will be sent to the following:

Pat Lundvall Kristen T. Gallagher Amanda M. Perach McDonald Carano Llp 2300 West Sahara Avenue, Suite 1200 Las Vegas, Nevada 89102

Attorneys for Real Parties in Interest

I further certify that I served a copy of this document by mailing a true and correct copy thereof, postage prepaid, at Las Vegas, Nevada, addressed as follows:

The Honorable Nancy L. Allf DISTRICT COURT JUDGE – DEPT. 27 200 Lewis Avenue Las Vegas, Nevada 89155

Respondent

Joseph Y. Ahmad
John Zavitsanos
Jason S. McManis
Michael Killingsworth
Louis Liao
Jane L. Robinson
P. Kevin Leyendecker
AHMAD, ZAVISTANOS, ANAIPAKOS,
ALAVI & MENSING, P.C.
1221 McKinney Street, Suite 2500
Houston, Texas 77010

Justin C. Fineberg
Martin B. Goldberg
Rachel H. LeBlanc
Jonathan E. Feuer
Jonathan E. Siegelaub
David R. Ruffner
Emily L. Pincow
Ashley Singrossi
LASH & GOLDBERG LLP
Weston Corporate Centre I
2500 Weston Road, Suite 220
Fort Lauderdale, Florida 33331

Attorneys for Real Parties in Interest

/s/ Jessie M. Helm

An Employee of Lewis Roca Rothgerber Christie LLP

| 000751 | | |
|--------|--|--|
| | | |
| | | |

| Α | If the clients | bought the progran | n, we charge them the fe | e. |
|---|----------------|--------------------|--|----|
| _ | \A/ II 'C | 1 5 | 1:1: ((((((((((((((((((| |

Q Well, if you apply Data iSight, which is part of OCM, you get a cut, right?

A Yeah. The client signs up for the program and they know there's a fee associated with it.

Q Well, we looked at the AT&T plans, which are as late as 2019. This claim was in 2019. I mean, you didn't follow the plan, right?

- A I don't know if that plan is associated with that claim.
- Q Okay.
- A That SPD is from 2014.
- Q Oh. And by the way, one of the paternalistic reasons that employers put that out-of-network emergency charges be included in their summary plan documents is because they want to protect the member from being balanced billed, right?
- A I don't know the motive of the employers, but the Affordable Care Act outlines very specific rules that you have to follow and that's what that language is trying to emulate.
- Q Sorry. I'm asking -- remember when we looked yesterday, when we were talking about migrating clients off of reasonable and necessary and one of the phrases you all used was that some clients are paternalistic, because they want to protect their members, right?
 - A Understood.
 - Q What we just saw cheated this member out this protection.
 - A I would disagree. I can explain.
 - MR. BLALACK: Object to form. Argumentative.

| 2 |
|----|
| 3 |
| 4 |
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
| 23 |
| 24 |
| 25 |

| | THE COURT: Objection sustained. Rephrase. |
|-------------|---|
| BY MR. ZA | AVITSANOS: |
| Q | What we just saw denied this member the protection called |
| for under | that plan? |
| А | I would disagree. |
| Q | Okay. |
| А | I can explain. It's a very complicated process. |
| Q | So here's the thing. I want to get finished with you today |
| and I know | v you keep saying you want to explain, okay. And I'm look, I |
| promise y | ou're going to get a full opportunity, okay? And I just gotta get |
| through th | nese materials, okay? |
| А | I know your |
| Q | Listen, I'm getting sick of the sound of my own voice up here. |
| | THE COURT: Please don't interrupt. |
| | MR. ZAVITSANOS: Okay. |
| BY MR. ZA | AVITSANOS: |
| Q | So we're going to I'm just going to try to get through this, |
| okay? | |
| А | I understand. It's a complicated process. These are |
| complicat | ed plans I'm trying to explain, so people can understand. |
| Q | Okay. Now, let's go to okay. Let's go to 175. We've talked |
| about this | document a little bit. All right. So page 3 |
| | MR. ZAVITSANOS: Or excuse me, Michelle. Page 2. And |
| will you p | lease pay up the first paragraph with the heading? Landscape |
| and the fir | st paragraph. |

| 1 | | THE WITNESS: Can I just take a quick peek? |
|----|------------|---|
| 2 | BY MR. Z | AVITSANOS: |
| 3 | Q | Sure. So let me know when you're ready. |
| 4 | | MR. ZAVITSANOS: Michelle, can you scroll up just a tiny bit |
| 5 | within tha | at box no, within the box, just scroll up just a little bit so we |
| 6 | can make | sure we got all the words. Thank you, Michelle. |
| 7 | BY MR. Z | AVITSANOS: |
| 8 | Q | Let me know when you're ready. |
| 9 | А | Yeah, just you're just looking at page 2 for now? |
| 10 | Q | Yes, sir. Okay. So again and we covered this, but this is |
| 11 | talking ab | oout |
| 12 | А | Okay, I'm ready. |
| 13 | Q | Yeah. So this is talking about ASO clients like United and it |
| 14 | says that | those clients typically have established a cap on eligible or |
| 15 | allowed. | Now, eligible or allowed means the amount that's being |
| 16 | reimburs | ed to them, right? |
| 17 | А | Yeah. I use allowed amount. |
| 18 | Q | Okay. A cap on eligible or allowed |
| 19 | | MR. ZAVITSANOS: Hold on, Michelle. Not going to highlight |
| 20 | yet. | |
| 21 | BY MR. Z | AVITSANOS: |
| 22 | Q | that is tied to a |
| 23 | | MR. ZAVITSANOS: Right here, Michelle. |
| 24 | BY MR. Z | AVITSANOS: |
| 25 | 0 | that is tied to a usual and customary out-of-network |

| 1 | reimbursement methodology, right? | | | |
|----|-----------------------------------|---|--|--|
| 2 | A That's what that says. | | | |
| 3 | Q | | | |
| | | Okay. So when it says typically | | |
| 4 | | MR. ZAVITSANOS: Circle the word typically. | | |
| 5 | BY MR. ZA | AVITSANOS: | | |
| 6 | Q | typically means usually, most of the time, right? | | |
| 7 | Α | I don't know how you would use it, but | | |
| 8 | Q | That's a typical thing, right? | | |
| 9 | А | Understood. | | |
| 10 | Q | Okay. So this is a charge-based methodology that often | | |
| 11 | exceeds 3 | 00 percent of Medicare, right? | | |
| 12 | А | UNC is what the providers submit for their charges. | | |
| 13 | Q | Okay. Now all right. Let's now move to page 4. | | |
| 14 | | UNIDENTIFIED SPEAKER: Page what? | | |
| 15 | | MR. ZAVITSANOS: Page 4. | | |
| 16 | | THE WITNESS: Can I just take a quick peek? | | |
| 17 | BY MR. ZA | AVITSANOS: | | |
| 18 | Q | Sure. Okay. Now | | |
| 19 | Α | Hold on. | | |
| 20 | Q | Sure. | | |
| 21 | | MR. ZAVITSANOS: Michelle, can you please pull up the | | |
| 22 | bottom se | cond down here and we're going to go through this chart here. | | |
| 23 | | THE WITNESS: Okay. | | |
| 24 | BY MR. ZA | AVITSANOS: | | |
| 25 | Q | Okay. So again, you're try it looks like, according to this | | |

| document, you are trying to migrate your clients, your ASO clients, away |
|--|
| from reasonable and customary to these deeper cuts, right? |

- A We were uncompetitive with our competitors. They're doing something more significant, so we're trying to educate that we can do this, too.
 - Q Is that a yes? You all are trying to --
 - A It doesn't say migrate here.
 - O Okay. So what more can we do? SSPE -- that's this, right?
- A Yes.

- O The one that we're talking about.
- A Yes.
 - On out of network benefits. Okay. This potential opportunity would apply the Data iSight market rates, which are generally deeper than reasonable and customary. If a provider pushes back and wants to balance fill the members, we would adjust to the appropriate reasonable and customary amounts for the claims, right?
 - A That's what that says, yes.
 - Q Are you a poker player?
- 19 A Lam not.
 - Q Okay.
 - A I'm terrible.
 - Q Do you know what bluffing is?
- 23 A Yeah, I know what bluffing is.
 - Q So if a -- if you bluff and the other player calls you, you're going to fold, right? That's kind of what that says.

| _ |
|----|
| 3 |
| 4 |
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
| 23 |
| 24 |
| 25 |

| 1 | Α | No, that's not what that says. These are services where the |
|---|-------------|---|
| 2 | member ha | as a choice. |
| 3 | Q | Okay. |
| 4 | А | These are not ER physician services. |
| 5 | Q | Well, it looks like, according to this document, the way that a |
| 6 | provider ca | n be assured of getting the reasonable and customary |
| 7 | amount is | to balance bill the member, according to that, right? |
| 8 | А | That's not what that says. And these are for non-ER |
| 9 | services, b | y the way. |
| 0 | Q | SSPE is for non-emergency? |
| 1 | А | You're pointing to out of network benefit level in that chart. |
| 2 | Q | That's my question, sir is does SSPE apply to emergency |
| 3 | room charç | ges? |
| 4 | А | I can't see what you're highlighting. Were you highlighting |
| 5 | the | |
| 6 | Q | Forget it. Forget about it. |
| 7 | А | Okay. |
| 8 | Q | Does SSPE apply to emergency room charges? |
| 9 | А | It depends on the benefit plan. |
| 0 | Q | Okay. Now all right, so once again if a provider pushes |
| 1 | back and w | vants to balance bill the member, United would adjust for the |
| 2 | reasonable | and customary amount, right? |
| 3 | А | We will do what the benefit plan tells us to do for the |
| 4 | choice | |
| 5 | Q | I'm just asking, that's what that says, right? |
| | | |

| A That's what that sa | ys. |
|-----------------------|-----|
|-----------------------|-----|

| | Q | Now what if Ruby Crest for the claims at issue in this case, |
|------|--------|--|
| Ruby | Crest | and the other two provider groups do not balance bill the |
| mem | ber? \ | What are their options to get the reasonable and customary |
| amoi | ınt? | |

A I'm not sure if I understand your question. The benefit plan would have to be looked at.

Q No, sir, I'm just going by what's up on the screen. I'm looking at what's up on the screen. And this seems to say if a provider pushes back and wants to balance bill the member, United would adjust to the appropriate, reasonable and customary amount of their claim, right?

A Yeah, but you're looking under a column that's not applicable to ER services.

Q Sir, once again, are you telling us that SSPE does not apply to ER plans?

A I've continuously tried to explain to you it depends on the benefit plan.

Q Well, hold on for a second. An emergency room provider that's out-of-network, if you apply a deep discount like 80 or 85 percent, in the absence of some legal prohibition, they could balance bill the member, right?

A A provider can bill whatever they want. We can't regulate that. They can go after the member, but if we -- if they bill a reasonable amount, there's no reason not to pay that. If they bill a very high amount

| 1 | then that's | s something that we have to help them the member in the |
|----|---------------|--|
| 2 | employer | group with. |
| 3 | Q | My question is a little different. Okay. My question is, an |
| 4 | emergend | ry room provider whose bill has been cut by 80 or 85 percent, in |
| 5 | the absen | ce of a law prohibiting that during this relevant time period, |
| 6 | they could | d balance bill the member, right? |
| 7 | А | Well, I think to be clear, the provider typically doesn't do the |
| 8 | bill, it's th | e staffing company. |
| 9 | Q | That's fine. |
| 10 | А | And if it's that deep of a reduction, it's a very high billed |
| 11 | amount. | And yes, they have the right to take the member to collections |
| 12 | and the er | mployer group to collections. |
| 13 | Q | Okay. And if they have a policy of not balance billing, then |
| 14 | the only re | ecourse is what we're doing here. |
| 15 | Α | No, I believe they also do collection efforts. And I've seen |
| 16 | Q | Listen to my question, sir. If |
| 17 | А | Well, it's not the only recourse. |
| 18 | Q | If the claims at issue in this case, these three provider groups |
| 19 | have a po | licy of not balance billing during this time period, their only |
| 20 | recourse i | s what we're doing here. |
| 21 | Α | I disagree. |
| 22 | Q | Okay. Now let's look at |
| 23 | | MR. ZAVITSANOS: Michelle, close out the pull out, please, |
| 24 | and let's l | ook at this chart. |

| | Ö |
|---|---|
| | 4 |
| | 5 |
| | 6 |
| | 7 |
| | 8 |
| | 9 |
| 1 | 0 |
| 1 | 1 |
| 1 | 2 |
| 1 | 3 |
| 1 | 4 |
| 1 | 5 |
| 1 | 6 |
| 1 | 7 |
| 1 | 8 |
| 1 | 9 |
| 2 | 0 |
| 2 | 1 |
| 2 | 2 |
| 2 | 3 |
| 2 | 4 |
| | |

| 1 | Q | Are you telling the jury that this chart does not apply to | |
|----|--|--|--|
| 2 | emergenc | y room claims? | |
| 3 | А | Which chart? The whole chart? | |
| 4 | Q | Yeah. | |
| 5 | А | ER services are applied at the in-network benefit level. So | |
| 6 | that's not | the out of network benefit level, it's the in-network benefit | |
| 7 | level. | | |
| 8 | Q | Okay. So that's the third column? | |
| 9 | А | Where it says INN benefit level, yes. | |
| 10 | Q | Okay. So let's see how this SSPE works. Okay? So the claim | |
| 11 | comes in. | The claim is received, right? | |
| 12 | А | Yes. | |
| 13 | Q | That's that claim is filed electronically with United, right? | |
| 14 | А | Most likely, yes. | |
| 15 | Q | Okay. And we're going to talk about how this how this | |
| 16 | SSPE worl | ks. So the claim comes in. And if it's at the 80th percentile of | |
| 17 | Fair Health | , and it's over 500 percent of Medicare, then it's going to go | |
| 18 | into this flo | ow chart, right? | |
| 19 | А | Again, as I've said many times, first of all, you've got to look | |
| 20 | at the ben | efit plan and see what they have. | |
| 21 | Q | I'm talking about this one. Forget the benefit plan. I'm | |
| 22 | talking about what is on this document, which you all are proposing. | | |
| 23 | The claim | is received. The VMP of 500 percent of Medicare ceiling, | |
| 24 | starting 4/ | 1/18, right? Right? | |
| 25 | А | Yes, that's what that says. | |

| 000760 | | | |
|--------|--|--|--|
| | | | |
| | | | |
| | | | |

| | Q | Okay. So now we go into our decision tree here. | First we |
|-------|--------|--|-------------|
| look | at the | wrap network to see if that's a deep enough cut ac | ccording to |
| that, | right? | | |

A It's like a waterfall. If the providers agree to a reasonable rate, and it's less than five times Medicare, the largest payer in the country, then we would take that. If the benefit plan has the [indiscernible - Mr. Zavitsanos speaking over the witness]

MR. ZAVITSANOS: Your Honor, the last response, we have a limine issue.

THE COURT: So counsel please approach.

[Sidebar at 10:38 a.m., ending at 10:40 a.m., not transcribed]

THE COURT: Good morning, everybody. We're going to take our morning recess. So during this recess don't talk with each other or anyone else on any subject connected with the trial. Don't read, watch, or listen to any report of or commentary on the trial. Don't discuss this case with anyone connected to it by any medium of information including, without limitation, newspapers, television, radio, radio, internet, cellphones or texting.

Don't conduct any research on your own relating to the case.

Don't consult dictionaries use internet or use reference materials. Don't post on social media, don't talk, text Tweet, Google, or conduct any other type of book or computer research with regard to any issue, party, witness, or attorney involved in the case.

Most importantly, do not form or express any opinion on any subject connected with the trial until the matter is submitted to you.

| | 2 |
|---|---|
| | 3 |
| | 4 |
| | 5 |
| | 6 |
| | 7 |
| | 8 |
| | 9 |
| 1 | 0 |
| 1 | 1 |
| 1 | 2 |
| 1 | 3 |
| 1 | 4 |
| 1 | 5 |
| 1 | 6 |
| 1 | 7 |
| 1 | 8 |
| 1 | 9 |
| 2 | 0 |
| 2 | 1 |
| 2 | 2 |
| 2 | 3 |
| 2 | 4 |
| 2 | F |

We'll go to 10:55, and we'll take a light lunch today. Thank you.

THE MARSHAL: All rise for the jury.

THE COURT: And, Mr. Haben, I'll ask you to step out during the argument.

THE WITNESS: All right. Thank you.

[Jury out at 10:40 a.m.]

[Outside the presence of the jury]

THE COURT: So the room is clear, Mr. Zavitsanos.

MR. ZAVITSANOS: Yes, Your Honor. I will -- I'll get right to the point. I mean I'll spare how we got here. But the Court -- the Court has devoted a considerable amount of time to this interplay between Medicare and the out-of-network rates that we are talking about in this case. And ultimately where the Court came down was issuing the limine ruling following very extensive briefing and arguments. The Court entered its order.

Subsequent to that order, which prohibited the mention of Medicare, I visited with Mr. Blalack. And he and I both recognized that because of the number of times that CMS is mentioned on the documents and the amount of redactions that would need to happen, I would agree to move back a little bit on that by agreement, provided explicitly that two things were not mentioned either explicitly or subtly.

And that is, number one that Medicare is the largest payor in the country, which, of course, conveys the image that this is the way that most doctors receive payment. And therefore if it's good -- if it's good when they receive Medicare, it must be good if they receive just a little

bit above Medicare. That was the first -- and Mr. Blalack agreed that he would avoid that. And frankly, he has been -- he has been a gentleman. He has not violated that. And in opening he did not violate that.

Second, I said that the other thing I said that the other thing we would want to avoid, which is a very close correlator to the first one, is a suggestion, either explicitly or implicitly, that Medicare, itself, is an appropriate rate. And again, Mr. Blalack agreed and again he honored that and did not violate it during the opening statements.

Now Mr. Haben, I asked him a question. The answer that he gave, which violated the limine, respectfully I believe was not responsive. It was a canned speech that he had in his pocket. He pulled it out, and he explicitly, explicitly violated, I believe both of the agreements that I reached with Mr. Blalack and the Court's ruling on the limine.

And so at this point, Your Honor, the only thing I'm going to ask -- I like Mr. Blalack, okay. The only thing that I'm going to ask is that Mr. Blalack admonish Mr. Haben to not do that again. And that he -- that he not mention that it's the largest system in the country, or that it's reasonable, or whatever. I mean for the most part everything else is fair game. But I'd just ask that he be admonished to do that. Because I can't respond to that without opening the door to my agreement. And again his answer, I believe, was not responsive. So it's not like well, I asked him about it and therefore he gave me -- he gave me the answer. I didn't ask him about who the largest payor was in the country.

THE COURT: And your response, please?

MR. BLALACK: Yes, Your Honor. Let me -- let me do the easy part first and then I'll make the record I need to make for the more complex part.

Part one, Mr. Haben has been advised that what he should stay away from is any discussion of Medicare as, you know, the largest payor in the country and all that sort of thing, as well as anything suggesting that Medicare's specific rate, the fee schedule, is the reasonable proper payment for these services. So that has been given. I will absolutely embrace the obligation that has been requested by counsel to advise him of that and reaffirm to him that he just -- he should stay away from that in terms of responding to any other question from counsel. So with that, that part is easy, and I will take it upon myself to do that as soon as we break.

I want to make a broader record, though, on something, Your Honor. One, the order on the motion in limine has not yet been entered. I think we have a proposed order with competing language. But the reason for that, Your Honor, is our view was Medicare -- and this has to come into this case. It's impossible to try the case without it. My client's state of mind, he's been attacked for three days, he's inextricably tied to their view that the rates they pay are reasonable, because they're a multiple of Medicare. And that's the foundation of everything we do.

Our opponents disagree with us, and that's fine. That's an issue of fact for the jury to sort out. But the ability of our clients to defend in good faith and state mind is a function of being able to explain that.

So during the course of this trial, document after document, after document, testimony after testimony comes in discussing Medicare in many different ways. And in fairness to Mr. Haber, given how his entire business operation is set around a multiple of Medicare, I think it's just sometimes hard for him to figure out as a lay person where that line is. I will reaffirm where that line is, so that he knows.

With respect to, you know, going forward, I will make sure that those two areas, he understands are not appropriate. I will make offers of proof on those at a separate time. I do think that the areas that I covered in opening, it sounds like we don't have an agreement. That's the only thing with respect to Medicare that's not just referring to a document that's important to us, which is to be able to at least show what the charges are, and the allowed amounts are, as a reference to Medicare, which we did in opening, and have the Defendant be able to say that the rate that was paid, they believe is a reasonable rate at 160 or whatever it was percent of Medicare, but will not testify that the Medicare rate is the reasonable rate or describe the breadth and scope of the Medicare program. So with that record, Your Honor, I'll be glad to advise Mr. Haber.

THE COURT: Thank you. And briefly?

MR. ZAVITSANOS: No response, Your Honor.

THE COURT: All right. So there was a request for admonishment. That's not necessary given that fact that Mr. Blalack is willing to counsel with the client during the recess.

So that's the ruling. It's 10:47. See you at 10:55.

| 0 |
|---|
| 0 |
| 0 |
| 7 |
| 0 |
| Ö |
| - |
| |

| 1 | MR. ZAVITSANOS: Oh, Your Honor, just to be clear. Just to |
|----|--|
| 2 | be clear. I did not ask the Court to admonish him. |
| 3 | THE COURT: That's how I heard it. |
| 4 | MR. ZAVITSANOS: Maybe I misspoke it. I'm sorry, Your |
| 5 | Honor. I asked Mr. Blalack to admonish the witness. |
| 6 | THE COURT: But Mr. Blalack need not admonish him. He |
| 7 | merely needs to counsel with him. |
| 8 | MR. ZAVITSANOS: Yes, Your Honor. |
| 9 | THE COURT: Thank you both. |
| 10 | MR. BLALACK: Thank you, Your Honor. |
| 11 | THE COURT: See you at 10:55. |
| 12 | [Recess taken from 10:47 a.m. to 10:57 a.m.] |
| 13 | THE MARSHAL: Courtroom 27 is back in session. |
| 14 | THE COURT: Please remain seated. Let's bring in the jury. |
| 15 | MR. ROBERTS: Thank you, Your Honor. And Lee Roberts |
| 16 | here for the Defendant's, Your Honor. |
| 17 | THE COURT: We did notice you were missing for a while this |
| 18 | morning. |
| 19 | MR. ZAVITSANOS: We had an APB on him. |
| 20 | MR. ROBERTS: I had mediation with Judge Gonzalez this |
| 21 | morning, and I got it started before I headed back since Mr. Blalack had |
| 22 | this witness, but I appreciate the Court's indulgence. |
| 23 | THE COURT: That's some multitasking. |
| 24 | MR. ZAVITSANOS: The room did feel a little out of balance. |
| 25 | Oh, and Your Honor, what just so for budgeting purposes, what time |
| | |

| 1 | are you go | ing to break for lunch? |
|----|------------|---|
| 2 | | THE COURT: Somewhere between 12:10 and 12:15. |
| 3 | | MR. ZAVITSANOS: Got it. |
| 4 | | THE COURT: They seem to tolerate the 75-minute pretty |
| 5 | well. | |
| 6 | | MR. ZAVITSANOS: Okay. |
| 7 | | MR. BLALACK: I agree. |
| 8 | | MR. ZAVITSANOS: Great. |
| 9 | | [Pause] |
| 10 | | THE MARSHAL: All rise for the jury. |
| 11 | | [Jury in at 10:59 a.m.] |
| 12 | | THE COURT: Thank you. Please be seated. Plaintiff, please |
| 13 | continue. | |
| 14 | | MR. ZAVITSANOS: Thank you, Your Honor. May it please |
| 15 | the Court, | counsel? |
| 16 | BY MR. ZA | VITSANOS: |
| 17 | Q | Before we get back to this waterfall that you mentioned, do |
| 18 | you know | where AT&T is based? |
| 19 | А | I don't. |
| 20 | Q | Okay. If I told you, it's in Dallas, Texas, any reason to dispute |
| 21 | that? | |
| 22 | А | No. That would kind of refresh my memory. |
| 23 | Q | Okay, fair enough. Now back to the waterfall. Okay. So |
| 24 | А | Sorry, what page are we on again? |
| 25 | Q | Oh, I'm sorry. |
| | | |

| 00767 | | |
|-------|--|--|
| 7 | | |
| | | |
| | | |
| | | |
| | | |

| I | A | 3? | | | | |
|----|------------|--|--|--|--|--|
| 2 | Q | Mr. Haben, I'm on page 4. So we're looking at we're | | | | |
| 3 | talking ab | talking about the SSPE program. So the claim comes in. Now this wrap | | | | |
| 4 | network tl | nat's in the waterfall, that's a wrap network that United had | | | | |
| 5 | signed wi | th MultiPlan, right? | | | | |
| 6 | А | United has a contract with MultiPlan to access their wrap | | | | |
| 7 | network. | | | | | |
| 8 | Q | And separate and apart from that, providers sign agreements | | | | |
| 9 | with Multi | Plan for this wrap arrangement, right? | | | | |
| 10 | А | If they're in the wrap, either MultiPlan has the agreement or | | | | |
| 11 | MultiPlan | leases an agreement from another | | | | |
| 12 | Q | Okay. | | | | |
| 13 | А | entity. | | | | |
| 14 | Q | But even though you have signed an agreement with | | | | |
| 15 | MultiPlan | , if it's more than 500 percent of Medicare at this point then | | | | |
| 16 | even thou | gh you signed it, you're going to go to this next step would be | | | | |
| 17 | the fee ne | gotiation if the wrap network is above 500 percent, right? | | | | |
| 18 | According | to this waterfall. | | | | |
| 19 | А | If the client's benefit plan has wrap network and they had | | | | |
| 20 | benchmar | k pricing in their benefit plan, then yes. We would go to the | | | | |
| 21 | next step | if it's greater than 500 percent of Medicare. | | | | |
| 22 | Q | And if this fee negotiation, which is with the provider, right? | | | | |
| 23 | А | Yes. | | | | |
| 24 | Q | And MultiPlan does that negotiation as we said, right? | | | | |
| 25 | А | Yes. | | | | |
| | | | | | | |

| 1 | Q | If that negotiation does not yield an acceptable outcome, |
|----|-------------|---|
| 2 | then you'r | e just going to apply this OCM rate using Data iSight, right? |
| 3 | А | The OCM would kick in, yes. |
| 4 | Q | Data iSight, right? |
| 5 | А | Yes. |
| 6 | Q | And these are the charges that were previously paid at 100 |
| 7 | percent of | billed charges, right? |
| 8 | А | Depends on the benefit plan. |
| 9 | Q | I'm just saying what's on the screen. |
| 10 | А | That's what that says on the screen, yes. |
| 11 | Q | Okay. And going into this OCM, did United know that there |
| 12 | were man | y scenarios where this would be worse for the employer? |
| 13 | А | I'm sorry; can you ask that a different way? |
| 14 | Q | Sure. This document is called, "Enhancing out of network |
| 15 | competitiv | re position", right? |
| 16 | А | Yes. |
| 17 | Q | Okay. Did you do financial projections on what kind of |
| 18 | impact this | s would have on employers? |
| 19 | А | I don't know if there was financial impact, but I'm assuming |
| 20 | so. | |
| 21 | Q | Let's look at page 6. Okay. Now there's a lot going on here |
| 22 | and let's s | ee if we can break it down. |
| 23 | А | Can I just take a quick peek? |
| 24 | Q | Yes, sir. |
| 25 | | MR. ZAVITSANOS: So let's start, Michelle, right here. And |

| 1 | we go from here to here. | | | |
|----|--------------------------|--|--|--|
| 2 | BY MR. ZA | AVITSANOS: | | |
| 3 | Q | Okay. So according to this document | | |
| 4 | А | I just need a few more seconds here. | | |
| 5 | Q | Sure. | | |
| 6 | А | It's really small. | | |
| 7 | | MR. ZAVITSANOS: It's the assumptions part that's showing. | | |
| 8 | That box. | Well, just that box, the assumptions box. | | |
| 9 | | THE WITNESS: Okay. I'll ask questions as we go. | | |
| 10 | BY MR. ZA | AVITSANOS: | | |
| 11 | Q | Yes, sir. So for purposes of these financial projections we're | | |
| 12 | assuming | a bill charge of \$1,000, right? | | |
| 13 | А | Yes. | | |
| 14 | Q | We're assuming that the member deductible has been | | |
| 15 | satisfied, b | out the co-insurance is 60/40, right? | | |
| 16 | А | That's what that says, yes. | | |
| 17 | Q | Meaning that the plan will pay 60 percent, the member pays | | |
| 18 | 40? | | | |
| 19 | А | Yes. I believe that's kind of the ratio | | |
| 20 | Q | Okay. | | |
| 21 | А | we were assuming. | | |
| 22 | Q | And the fee that you all are going to charge on this | | |
| 23 | assumptio | n is 35 percent, right? | | |
| 24 | А | Yes. That's what that says. | | |
| 25 | Q | Okay. So the other assumption you're making here is that | | |

| 2 |
|----|
| 3 |
| 4 |
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
| 23 |
| 24 |
| 25 |

| the assumption | is, this bi | II charge | that the | reasonable | and | custom | ary |
|------------------|-------------|-----------|----------|------------|-----|--------|-----|
| amount is \$600, | right? | | | | | | |

- A Yes. That's an assumption on that benefit plan.
- Q But if you apply this Data iSight methodology it's \$300, right?
- A That is the assumption, yes.
- Q Okay. So these assumptions are going to apply to the scenarios we're going to look at.

MR. ZAVITSANOS: Michelle, close that out. And Michelle, here's what I want you to do now. I want you pull up from here to here. Just this area here.

BY MR. ZAVITSANOS:

Q Okay. And here's what we're doing. We're looking at the effect now on the employer. We looked at earlier on the effect on the employee. Now we're looking at the effect on the employer. So these are the assumptions we just talked about here, right?

MR. ZAVITSANOS: Michelle, can you make that a little bigger?

BY MR. ZAVITSANOS:

- Q Okay. All right. So now the column on the left -- or excuse me, on the right, current, that's under the old regime using reasonable and customary, right?
 - A That's underneath the old program as the example.
- Q Okay. So the allowed amount was \$600. That's the reasonable and customary, right?
 - A Yes.

| 1 | Q | The client, that would be the employer, right? |
|----|------------|---|
| 2 | А | Yes. |
| 3 | Q | They're going to pay \$360, right? |
| 4 | А | That is what that says. |
| 5 | Q | There's the member part, but the client cost is \$360 under the |
| 6 | old regime | e, right? |
| 7 | А | That would be the client responsibility. |
| 8 | Q | And these are projections that looks like you all were making |
| 9 | going into | this program for clients that had not switched over yet, right? |
| 10 | А | It was a simplified example so people can understand it. |
| 11 | Q | Okay. Now let's go to the next one. Let's now look at |
| 12 | proposed | here. |
| 13 | | MR. ZAVITSANOS: Michelle, I need you to pull from here to |
| 14 | here. See | if you can capture all of this. |
| 15 | BY MR. ZA | AVITSANOS: |
| 16 | Q | Okay. So all right. So under the Data iSight methodology |
| 17 | where the | allowed amount is \$300 rather than \$600, do you see that? |
| 18 | А | I do. |
| 19 | Q | So the allowed amount is \$300, right? |
| 20 | А | Yes. |
| 21 | Q | Same assumption? |
| 22 | А | Yeah. |
| 23 | Q | The client now instead of 360 is paying 180, right? |
| 24 | А | Correct. |
| 25 | ο | But they've also got to pay the fee, the 35 percent fee, which |

| 3 |
|----|
| 4 |
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
| 23 |
| 24 |
| |

| 1 | is \$245, ri | ght? | | |
|----|---|--|--|--|
| 2 | А | In that example it is, yes. | | |
| 3 | Q | And so when we get to it the total cost to the employer | | |
| 4 | | MR. ZAVITSANOS: Right here, Michelle. | | |
| 5 | BY MR. Z | AVITSANOS: | | |
| 6 | Q | Is \$425, right? | | |
| 7 | | MR. ZAVITSANOS: You had it, Michelle. | | |
| 8 | | THE WITNESS: Yes. That's what that says. | | |
| 9 | | MR. ZAVITSANOS: Okay. So Michelle, highlight 425. | | |
| 10 | BY MR. Z | AVITSANOS: | | |
| 11 | Q | So under the new plan designed to save money, the | | |
| 12 | employer | s obligation is actually higher than the old plan according to | | |
| 13 | this? | | | |
| 14 | А | They save on medical costs, but they do pay a fee. If they | | |
| 15 | agree | | | |
| 16 | Q | That's not my question. My question is, this OC this is | | |
| 17 | your docu | ment, this is United doing these calculations, right? | | |
| 18 | А | As an example, yes. | | |
| 19 | Q | And so United knows going into this before converting | | |
| 20 | employers | s over, running these assumptions, the employer's going to be | | |
| 21 | worse off | than under reasonable and customary, right? | | |
| 22 | А | I think what they're trying to reflect I didn't write this. | | |
| 23 | They're trying to reflect that they probably are going to have to negotiate | | | |
| 24 | with the client on a lower fee. | | | |
| 25 | Q | Sir, I'm not asking you to speculate for someone. I just want | | |

| 000773 | | |
|--------|--|--|
| | | |
| | | |

| to know what's on | this document. | Going into this, thi | s chart, the |
|-------------------|-----------------|----------------------|--------------|
| employer cost num | ber is higher w | ith SSP than withoເ | ut, correct? |

A Let me just get my bearings please. Yes. That's the math.

MR. ZAVITSANOS: You can close it out, Michelle.

BY MR. ZAVITSANOS:

- Q All right. Now I thought you said a couple of times -- oh, I thought you said a couple of times, Mr. Haben, please correct me if I misheard you, okay? I thought you said you were trying to catch up with your competitors.
 - A Yes.
 - O Or words to that effect.
- A That was the understanding through consultants, that we were uncompetitive. Our clients are paying more for services than they should.
 - Q Through consultants?
- A Yes.
 - Q Who -- what consultants?
 - A There's consultants that work with employer groups, Willis Towers Watson, Aon, other entities.
 - Q Aon, that's an insurance company too, right?
 - A I do not know. I know there's Aon Consulting.
 - Q So did the consultants help you come up with these names?
 - A No. They did not. They provided us feedback that we would lose clients if we're not competitive.
 - O Okay, fair enough. Wait a minute, they said what?

| 000774 | | | |
|--------|--|--|--|
| | | | |
| | | | |
| | | | |

| Α | If we're not competitive on medical cost savings we're at risk |
|-------------|--|
| of losing a | client. |

- Q And so you did this to -- let me finish the point first before we get there. Okay. So my question I think started before I veered off, my apologies. The question is, you feel like you all were behind your competitors, right?
 - A That was the feedback we were getting.
- Q Let's go to Exhibit 66, page 1. Now we've seen this document before.
 - A Can I --
 - Q This --
 - A -- go get it please?
- Q Sure. This is the 2017 business plan which I think was put together in 2016. So this would be at the beginning of the program, right?
 - A We've had programs in place since 2003.
- Q Yeah. The five -- excuse me. This would be the beginning -- closer to the beginning of this five-year period that we've talked about, right?
 - A The five-year period you are referring to, yes.
- O Okay. So let's look at page 21 please. "Maintaining our lead."
- MR. ZAVITSANOS: Michelle, can you pull this out and pull out "seizing the opportunity", those three bullets.
 - THE WITNESS: Can I read for a second?

| \subset |) |
|-----------|---|
| \subset |) |
| \subset |) |
| _ | 1 |
| _ | 1 |
| C | 1 |

| 1 | BY MR. ZA | AVITSANOS: | |
|----|--|---|--|
| 2 | Q | Sure. | |
| 3 | А | Is it "seizing the opportunity" is the section? | |
| 4 | Q | Yes. | |
| 5 | А | Okay. | |
| 6 | | MR. ZAVITSANOS: Michelle, highlight the part that says, | |
| 7 | "shared sa | avings". | |
| 8 | BY MR. ZA | AVITSANOS: | |
| 9 | Q | Let me know when you're ready. | |
| 10 | А | I am ready. | |
| 11 | Q | So you told us you were behind your competitors, but | |
| 12 | internally you were leading the pack, right? "Maintaining our lead", | | |
| 13 | that's wha | t that says. | |
| 14 | А | That's just in reference probably not related to how | |
| 15 | competitiv | ve we are with our network. | |
| 16 | Q | I'm sorry. Sir, it just says, "Maintaining our lead", right? | |
| 17 | А | That's what that says, yes. | |
| 18 | Q | Lead means you're ahead, right? | |
| 19 | А | Yes, it does. | |
| 20 | Q | Okay. All right. And if we go to page 2. This business plan I | |
| 21 | think we a | greed was written in 2016, right? Because it's a '17 business | |
| 22 | plan. | | |
| 23 | А | I believe so. | |
| 24 | Q | Okay. All right. | |
| 25 | | MR. ZAVITSANOS: So Michelle, will you please pull up the | |

| 3 | BY MR. ZA | AVITSANOS: |
|----|-------------|---|
| 4 | Q | Okay. "We are in a third year of unprecedented organic |
| 5 | growth wit | th almost one million new fully insured group members added |
| 6 | to our rank | ks since 2015." Here's the part I want to ask you about. |
| 7 | | MR. ZAVITSANOS: Michelle, highlight the next sentence. |
| 8 | BY MR. ZA | VITSANOS: |
| 9 | Q | "We will continue this growth by advancing our already |
| 10 | industry-le | eading gross margins by \$5 PMPM while continuing" blah blah. |
| 11 | Do you see | e that? |
| 12 | А | I do. |
| 13 | Q | Okay. So in 2016, industry-leading margins, and exceeding |
| 14 | you exceed | ded your budget budgetary expectation by \$5 PMPM. |
| 15 | А | I didn't write this, so I don't know what he means. |
| 16 | Q | You don't know what it means, "That we will continue this |
| 17 | growth by | advancing our already industry-leading gross margins by \$5 |
| 18 | PMPM"? | |
| 19 | А | I can read what you read, but I don't |
| 20 | Q | Let me just write it the way it is. Okay? |
| 21 | А | Yep. |
| 22 | Q | All right. That was in '16? |
| 23 | А | Yes. |
| 24 | Q | Okay. Now, the PMPM, that's the base fee that you charge |
| 25 | an ASO cli | ent. We talked about that, right? |
| | I | |

third paragraph where it says, "We are in a third year", that whole

1

2

paragraph, please? Great.

| 1 | А | Um |
|----|----------------|--|
| 2 | Q | Per member per month. |
| 3 | А | When we talked about it, yes. I don't know what he's |
| 4 | referring to | o. I didn't write it. |
| 5 | Q | Okay. And typically, the PMPM fee does not include 35 |
| 6 | percent? | |
| 7 | А | Typically, no. |
| 8 | Q | Okay. All right, now |
| 9 | | [Counsel confer] |
| 10 | BY MR. ZA | VITSANOS: |
| 11 | Q | Okay. Now, as you began implementing this SSPE program, |
| 12 | with the H | ealth and MultiPlan. Let's go to 343. As you were doing that |
| 13 | | [Counsel confer] |
| 14 | | MR. ZAVITSANOS: 342, Michelle. |
| 15 | BY MR. ZA | VITSANOS: |
| 16 | Q | As you were doing that, what happened was because of the |
| 17 | amount of | money that you were making, you started losing clients. So |
| 18 | instead of | well, let me know, I'm going to keep on going. Is it correct |
| 19 | that as SS | PE was getting implemented, you began losing clients? |
| 20 | А | I don't know for sure. |
| 21 | Q | Okay. So this is something called Project Airstream MVP |
| 22 | Overview. | And by the way, since we're on this, we're going to get to this |
| 23 | a little bit l | ater, but let me just for clarification, see if we can agree. So |
| 24 | remember | , we talked about that NewCo, New Company? |
| 25 | А | Yeah. |

| \circ | |
|----------------|--|
| ŏ | |
| ŏ | |
| \overline{A} | |
| 7 | |
| ∞ | |

| 1 | Q | That is also referred to as Project Airstream sometimes, |
|----|------------|--|
| 2 | right? | |
| 3 | А | Yes. |
| 4 | Q | Okay. And Project Airstream today, is now the government? |
| 5 | А | Yes. |
| 6 | Q | All right. All right. Now, we'll get to that later. |
| 7 | | But let's go we're on this, Exhibit 342. Let's go to page 26. |
| 8 | | MR. ZAVITSANOS: And Michelle, can you pull up that wrap? |
| 9 | The whole | the whole thing, please. |
| 10 | BY MR. ZA | AVITSANOS: |
| 11 | Q | All right. The green line is the number of ASO clients, right? |
| 12 | А | No, it's membership. |
| 13 | Q | Membership, excuse me. It's the number of membership, |
| 14 | right? | |
| 15 | А | Correct. |
| 16 | Q | And that's dropping pretty significantly, right? |
| 17 | А | That's what that looks like, yes. |
| 18 | Q | And it's dropping at the same time as your shared savings |
| 19 | revenue is | going up, right? |
| 20 | А | That is correct. |
| 21 | Q | So you're getting a 27 percent increase in shared savings |
| 22 | revenue, v | which includes SSPE, from 647 million to 819 million, but |
| 23 | members | are dropping off along the way, right? |
| 24 | А | That's what that reflects, yes. |
| 25 | Q | But members wanted or clients wanted SSPE, that's your |

| | 3 |
|---|---|
| | 4 |
| | 5 |
| | 6 |
| | 7 |
| | 8 |
| | 9 |
| 1 | 0 |
| 1 | 1 |
| 1 | 2 |
| 1 | 3 |
| 1 | 4 |
| 1 | 5 |
| 1 | 6 |
| 1 | 7 |
| 1 | 8 |
| 1 | 9 |
| 2 | 0 |
| 2 | 1 |
| 2 | 2 |
| 2 | 3 |
| 2 | 4 |
| | |

| 1 | testimony, | right? |
|----|-------------|---|
| 2 | А | Clients were looking for us to help address high medical |
| 3 | expense. | |
| 4 | Q | Yeah. Was it these clients, the ones on the graph going |
| 5 | down? Wa | as it those clients? |
| 6 | А | I don't know who's in that count. |
| 7 | Q | All right. Now |
| 8 | | [Counsel confer] |
| 9 | | MR. ZAVITSANOS: Your Honor, may I ask counsel if he has |
| 10 | any object | ion to Exhibit 96? And I would direct counsel to page 1, at the |
| 11 | top. | |
| 12 | | MR. BLALACK: If I could counsel, did you plan to provide |
| 13 | the attachr | ment too or just the exhibit? |
| 14 | | MR. ZAVITSANOS: Yes, we did. |
| 15 | | MR. BLALACK: Okay. No objection if both are coming in. |
| 16 | | THE COURT: Exhibit 96 will be admitted. |
| 17 | | [Plaintiffs' Exhibit 95 is admitted in evidence] |
| 18 | BY MR. ZA | VITSANOS: |
| 19 | Q | Before I do that, Mr. Haben, I just I'm sorry, I just need to |
| 20 | button up | one last point. On Exhibit |
| 21 | | MR. ZAVITSANOS: Is 126 in, Michael? |
| 22 | | [Counsel confer] |
| 23 | | MR. ZAVITSANOS: All right. Let's Michelle, please pull up |
| 24 | 96. Okay. | So first of all, let's see who this is from and who this is to. All |
| 25 | the way do | own, Michelle. Let's get the whole email, please. All right. |

| , | _ | | |
|---|---|---|--|
| ? | = | 1 | |
| ? | = | ί | |
| - | _ | ĺ | |
| C | χ |) | |
| • | _ | • | |

| 1 | BY MR. ZA | VITSANUS: |
|----|--------------|--|
| 2 | Q | Okay. So it's from John Haben to a bunch of folks here, |
| 3 | right? | |
| 4 | А | Yes. |
| 5 | Q | And the subject is OCM, that's outlier cost management, |
| 6 | right? | |
| 7 | Α | Yes. |
| 8 | Q | And that's the same as SSPE, right? |
| 9 | Α | It's a component inside SSPE. |
| 10 | Q | Yes, sir. And okay. And it looks like basically, it looks |
| 11 | like you all | were getting together with MultiPlan to talk about to |
| 12 | discuss po | tential opportunity to improve planned outlier cost |
| 13 | manageme | ent by 900 million dollars, right? |
| 14 | А | Can I just read this for a second? |
| 15 | Q | Okay. So you were going to |
| 16 | | THE COURT: Well, he just asked to |
| 17 | | THE WITNESS: Can |
| 18 | | THE COURT: for a chance to read it. |
| 19 | | MR. ZAVITSANOS: Oh, I'm sorry, Your Honor. My |
| 20 | apologies. | I didn't hear him. |
| 21 | | THE WITNESS: Yeah. You can keep going. I'll apology if |
| 22 | any questi | ons. |
| 23 | | MR. ZAVITSANOS: Okay, sir. |
| 24 | BY MR. ZA | VITSANOS: |
| 25 | Q | So according to this email, UnitedHealthcare and MultiPlan |
| | | |

| 1 | were going to meet at some conference so that they could coordinate | | |
|----|---|--|--|
| 2 | how this _l | orogram could cause even deeper cuts, right, by \$900 million, | |
| 3 | right? | | |
| 4 | | MR. BLALACK: Object to form. | |
| 5 | | THE COURT: Overruled. | |
| 6 | | THE WITNESS: That's not what that says. | |
| 7 | BY MR. Z | AVITSANOS: | |
| 8 | Q | Okay. We want to get together with Dale from MultiPlan this | |
| 9 | morning. | What is HEAC? | |
| 10 | А | HEAC, hospital executive advisory committee. | |
| 11 | Q | To discuss potential opportunity to improve planned outlier | |
| 12 | cost mana | agement by \$900 million. Do you see that? | |
| 13 | А | Yes. | |
| 14 | Q | Is that does that cover emergency room physicians or is | |
| 15 | this just tl | ne facilities? | |
| 16 | А | I don't know for sure. | |
| 17 | Q | Okay. All right. Fair enough. Let's go to let's now go to | |
| 18 | and you p | repared this PowerPoint, right, page 2? | |
| 19 | А | On page 2, I believe so. | |
| 20 | Q | Okay. Now, this is page 2, please. Okay. April 2017? | |
| 21 | А | Correct. | |
| 22 | Q | Right? | |
| 23 | А | Correct. | |
| 24 | Q | Okay. And we're going to go now to, please, page 3. And | |
| 25 | okay. So | this is a document you prepared. | |

| 000782 | | | |
|--------|--|--|--|
| | | | |
| | | | |
| | | | |
| | | | |

| | MR. ZAVITSANOS: | And Michelle, | can we pull th | nis part up, |
|-----------|-----------------|---------------|----------------|--------------|
| please? | | | | |
| BY MR. ZA | VITSANOS: | | | |

- Q And it looks like what you are doing is you're making a recommendation on something called layering benchmark pricing over the shared savings programs when OCM is implemented in July of 2017, right?
 - A Correct. That's what that says.
- Q All right. And so here, step 1, the waterfall, is the wrap network rate will only be accepted if the threshold is achieved. Meaning less than 350 percent of Medicare, right?
 - A Or 350 percent, 350 or less.
- Q Or less, right. And then, fee negotiation. The negotiated amount will be accepted only if the threshold is achieved, the 350 percent, right?
 - A Correct. That's what that says.
 - O Third-party network, is that the wrap agreement?
- A No.
- Q Oh. Okay. Never mind. All right. Let's go to the bottom one, Data iSight. If the solutions above do not meet the threshold, the plan will reprice using Data iSight, i.e., which stands for in other words, 350 percent of CMS, right?
- A Yes, that's what that says.
 - Q All right. So if the bill comes in and it's above the wrap agreement you agreed to, you're going to cut it down to 350 percent of

| CMS | using | Data | iSight? |
|-----|-------|------|---------|
|-----|-------|------|---------|

A That's not exactly what that says, and I could -- I'm glad to walk through the waterfall, how it works.

Q Well, no. I'm just talking about what's written on the screen. I mean, the final step is if the solutions above, meaning if the doctor doesn't agree to accept less, then you're just going to pay him 350 percent of Medicare, right?

A Yeah. We're looking for reimbursement amounts that are accepted to keep the member out of the middle, to hold them harmless.

- Q Yeah. My question is --
- A If it doesn't achieve that, then yes, we will pay 350.
- Q That's my question. Okay. So --
- A That's for benefit plans, if the client adopts it, yes.
- Q Right. And by the way, on the fully insured side, the same thing would be true, right?
 - A Not 100 percent, no.
- Q Mostly. I mean, you'd have this 350 percent benchmark applied on the fully insured side as well, right?
- A It all depends on the benefit plan of what's filed and approved in the state.
 - Q Sir --
 - A It's not a general comment.
- Q -- on the fully insured side, were there plans that are not ASO plans, where United is the -- taking the risk, were you applying this 350 percent?

| \subset |) |
|----------------|----|
| \subseteq | 7 |
| \subseteq | ٠. |
| $\hat{\alpha}$ | 1 |
| \tilde{a} | |

| 1 | А | There's different mechanisms for the 350, so there's an |
|----|--------------|--|
| 2 | egregious | biller mechanism, there's a benchmark pricing mechanism. |
| 3 | And there | s kind of a cratered out floor. So that you're I if you want |
| 4 | to show m | e something specific, I can look at it and tell you. But there |
| 5 | the plans - | - |
| 6 | Q | You don't remember if the 350 percent applied to any part of |
| 7 | the fully in | sured side of your business? |
| 8 | А | You would have to show me a benefit plan, and I could look |
| 9 | at it. | |
| 10 | Q | But you don't remember, sitting there as the head of the |
| 11 | bottom ne | twork, the guy who wrote this memo with the |
| 12 | recommer | ndation, you don't remember if the fully insured side included |
| 13 | 350 percer | nt? |
| 14 | А | It depends on the type of program. It could have. There's |
| 15 | multiple | |
| 16 | Q | And then and then, that 350 percent was later cut to 250 |
| 17 | percent, ri | ght? |
| 18 | А | Explain what you're asking. |
| 19 | Q | Did the 350 percent that you were talking about in this |
| 20 | document | here, did that subsequently get cut to 250 percent? |
| 21 | А | In terms of the benchmarking? |
| 22 | Q | Yeah. |
| 23 | А | Yeah. We make a recommendation to reduce that to 250. |
| 24 | Q | You made a recommendation to who? |
| 25 | А | If the clients wanted to adopt that, they could. |

| _ | |
|---------------|---|
| C |) |
| C |) |
| C |) |
| _ | 1 |
| α |) |
| \mathcal{O} | 1 |

| 1 | U | How about on the fully insured side, did you reduce that to | | |
|----|--|---|--|--|
| 2 | 250 percent on any benefit plan on the fully insured side? | | | |
| 3 | А | I don't remember. | | |
| 4 | Q | Okay. Okay. Page 4 of Exhibit 96. Now, this is your | | |
| 5 | PowerPoir | nt, and right? This is your PowerPoint, right? | | |
| 6 | А | Yes. | | |
| 7 | Q | And our competition and the next steps. And remember, I | | |
| 8 | know I've | asked you this before. But remember, you told me you all | | |
| 9 | were behir | nd the competition, right? | | |
| 10 | А | Correct. | | |
| 11 | | MR. ZAVITSANOS: Michelle, highlight the last bullet point. | | |
| 12 | BY MR. ZA | AVITSANOS: | | |
| 13 | Q | It looks like, according to the document you prepared, United | | |
| 14 | would be I | eading the pack by cutting the threshold to 350 percent? | | |
| 15 | А | We would be in line with another competitor, yes. | | |
| 16 | | MR. ZAVITSANOS: Whoa, whoa, whoa, whoa. Hold it. | | |
| 17 | Michelle, h | nold on to that. | | |
| 18 | BY MR. ZA | AVITSANOS: | | |
| 19 | Q | No. My question was | | |
| 20 | | MR. ZAVITSANOS: Just highlight the whole page, Michelle. | | |
| 21 | BY MR. ZA | AVITSANOS: | | |
| 22 | Q | United would be leading the pack, right? | | |
| 23 | А | Along with another competitor. That's what that says. | | |
| 24 | Q | Along with another competitor. Okay. All right. So there's | | |
| 25 | two of the | main insurance companies in the country are doing this, | | |
| | | | | |

| C | |) |
|---|---|---|
| C | |) |
| C | _ |) |
| - | _ | 1 |
| C | χ |) |
| • | 7 | ١ |

| 1 | right? | |
|----|-------------|---|
| 2 | А | There could be more. I'm not aware of exactly who else is |
| 3 | out there. | |
| 4 | Q | And United is a public company, right? |
| 5 | А | Yes, we are. |
| 6 | Q | Meaning you're you have quantitative financials that are |
| 7 | available t | o the public, right? |
| 8 | А | Yes. Unlike a private entity, yes. |
| 9 | Q | Sure. And if a competitor sees what you are doing and |
| 10 | you're lead | ding the pack, well, the pack is going to move with the leader, |
| 11 | right? | |
| 12 | Α | In the audited financials, the competitors don't see what your |
| 13 | proprietary | y programs are. |
| 14 | Q | I know we talked about this. Well, first of all, you it looks |
| 15 | like that U | nited, you know what the other insurance companies are doing |
| 16 | because yo | ou mention it in your bullet point there, right? |
| 17 | Α | Yes. Consultants have informed us we're uncompetitive. |
| 18 | Q | Yeah. And you're not the only company that uses |
| 19 | consultant | s, right? |
| 20 | Α | No. |
| 21 | Q | Okay. And so again, my question is if you cut the benchmark |
| 22 | and you sa | ay we're never going to pay above 350, the competition is |
| 23 | going to fo | ollow right behind, right? |
| 24 | А | Depends on what the employer groups want. |
| 25 | | MR. ZAVITSANOS: All right. So Michelle, you can take that |

| 1 | down, ple | ase. Michael, is 126 in? |
|----|------------|---|
| 2 | | MR. KILLINGSWORTH: I think it's in. |
| 3 | | MR. ZAVITSANOS: All right. |
| 4 | BY MR. Z | AVITSANOS: |
| 5 | Q | Mr. Haben, would you be so kind as to be at Exhibit 126? |
| 6 | А | I don't know what this is. Can I just take a peek? |
| 7 | Q | Yes, sir. And I would like you to look at specifically pages 3 |
| 8 | and page | 36. |
| 9 | А | Three and thirty-six? |
| 10 | Q | Yes. |
| 11 | А | Give me just a minute. |
| 12 | Q | Sure. |
| 13 | | [Witness reviews document] |
| 14 | А | Sorry I'm not familiar, but I need just a little bit more time. |
| 15 | Q | Okay. |
| 16 | | [Witness reviews document] |
| 17 | А | Okay. You can start, and I'll tell you if I have questions. |
| 18 | Q | Okay. Does page 36 deal with shared savings? |
| 19 | А | Can I have a I didn't write this. I'm not part of this group. |
| 20 | Q | Actually, let me do this. You can put that up. Let me do it |
| 21 | this way. | Would you agree with me that as you were rolling out SSPD, |
| 22 | there was | concern from a lot of the ASO clients and there was a lot of |
| 23 | pressure f | from those clients to reduce your fee revenue from these out of |
| 24 | network p | rograms, sir? |
| 25 | Α | There's always pressure on fees for clients. |

| c | _ |) | |
|---|---|---|--|
| | |) | |
| C | ž | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| 1 | Q | Well, that's not my question. As you were rolling out SSPD, | |
|----|---|---|--|
| 2 | at that time, was there a concern within the company that there was a lot | | |
| 3 | of pressure from clients about your fee revenue from these out of | | |
| 4 | network p | rograms, like SSPD? | |
| 5 | А | Yes. There's always pressure on those fee programs. | |
| 6 | Q | And so initially, you let's go to Exhibit 67, please. | |
| 7 | А | May I put this one away? | |
| 8 | Q | Yes, sir. So if we go to page 3 of Exhibit 67. | |
| 9 | А | Okay. Let me get that up here. | |
| 10 | | MR. ZAVITSANOS: Yeah. And Michelle, pull this off, please. | |
| 11 | BY MR. ZAVITSANOS: | | |
| 12 | Q | Okay. So as you're rolling out SSPD, we've looked at this | |
| 13 | once before, you came up with the talking points that notwithstanding | | |
| 14 | these additional fees, why it was good for these ASO clients to adopt | | |
| 15 | SSPD, righ | nt? | |
| 16 | А | Can I'm sorry, I couldn't see where you're pointing. | |
| 17 | Q | Well, just these paragraphs here that we talked about before. | |
| 18 | I'm not go | ing to bother repeating it again. So for example | |
| 19 | | MR. ZAVITSANOS: Highlight the last paragraph, Michelle. | |
| 20 | BY MR. ZA | AVITSANOS: | |
| 21 | Q | When you were trying to sell SSPD to your clients, right? | |
| 22 | А | Yes. The clients are asking for help on their medical costs. | |
| 23 | Q | Did you share with any of your clients the scenario that if | |
| 24 | they imple | emented SSPD, there would be situations where it would | |

actually cost them more, like you did internally?

| 000789 | | | |
|--------|--|--|--|
| 789 | | | |
| | | | |
| | | | |
| | | | |

| Α | I don't know. |
|-------------|---|
| | MR. ZAVITSANOS: Counsel may I ask Counsel if he has an |
| objection t | o Exhibit 8? |
| | MR. BLALACK: We have no objection, Your Honor. |
| | THE COURT: Exhibit 8 will be admitted. |
| | [Plaintiffs' Exhibit 8 admitted into evidence] |
| | MR. ZAVITSANOS: Okay. Michelle, go to page 2. |
| BY MR. ZA | VITSANOS: |
| Q | All right. So this is the agreement between United and |
| MultiPlan, | right? |
| А | Yeah. I believe so. |
| Q | Yeah. |
| | MR. BLALACK: Your Honor, can we approach real |
| | THE COURT: You may. |
| | MR. BLALACK: for just a moment. |
| | MR. ZAVITSANOS: Take that down, Michelle. |
| [5 | Sidebar at 11:42 a.m., ending at 11:44 a.m., not transcribed] |
| | THE COURT: Thank you. Go ahead, please. |
| | MR. ZAVITSANOS: Okay. May I proceed, Your Honor? |
| | THE COURT: Please. |
| | MR. ZAVITSANOS: Thank you. Okay. So Michelle, will you |
| please pull | up Exhibit 8, page 2, first paragraph. |
| BY MR. ZA | VITSANOS: |
| Q | Okay. This is a really long document, and I'm only going to |
| cover one | tiny little part of it. This is the agreement between |

| | 3 |
|---|--------|
| | 4 |
| | 5 |
| | 6 |
| | 7 |
| | 8 |
| | 9 |
| 1 | 0 |
| 1 | 1 |
| 1 | 2 |
| 1 | 3 |
| 1 | 4 |
| 1 | 5 |
| 1 | 6 |
| 1 | 7 |
| 1 | 8 |
| | 9 |
| | 0 |
| 2 | 1 |
| | 2 |
| | 3 |
| | 4 |
| | т 5 |
| _ | J |

pre-price claims.

| 1 | UnitedHea | ilthcare and MultiPlan, right? |
|----|-------------|--|
| 2 | А | Yes. |
| 3 | Q | And I think if the jury goes through this, they'll see that it was |
| 4 | amended a | a bunch of times, right? I mean, this one is in 2013, right? |
| 5 | А | Yes. |
| 6 | Q | You see that? |
| 7 | А | I believe it's it has been amended quite a bit. |
| 8 | Q | Yeah. And Mr. Haben, I believe |
| 9 | | MR. ZAVITSANOS: Ah, yes. Page 6, Michelle. |
| 10 | BY MR. ZA | AVITSANOS: |
| 11 | Q | And it looks like let's pull this all up. It looks like the persor |
| 12 | who signe | d on behalf of United was you. |
| 13 | А | That's correct. |
| 14 | Q | Minnetonka, I love the name of that town. All right. That's |
| 15 | А | Tonka Toys. |
| 16 | Q | That's right. Okay. So you signed on behalf of United, right? |
| 17 | А | Correct. |
| 18 | Q | Okay. And then, like we said, this was amended a number of |
| 19 | times, righ | nt? |
| 20 | А | I believe so. |
| 21 | Q | Okay. Now okay. And MultiPlan let's just very briefly |
| 22 | remind ou | rselves who MultiPlan is. They are the objective third party |
| 23 | that evalua | ates what a fair reimbursement rate is, right? |
| 24 | А | They're a vendor that provides us tools and resources to |

| 1 | Q | And you consider that to be objective, not biased? |
|----|--------------|---|
| 2 | А | Yes. |
| 3 | Q | Let's go to Exhibit 239, page 13. |
| 4 | А | Can I get that, please? |
| 5 | Q | Yes, sir. And while you're doing that, I'm going to have |
| 6 | Michelle p | ull up this part of it. |
| 7 | | MR. ZAVITSANOS: Michelle, can you do you have those |
| 8 | little arrow | s that you can do? Can you do an arrow on the second bullet |
| 9 | point, pleas | se? |
| 10 | | THE WITNESS: Can I just take a quick peek? |
| 11 | | MR. ZAVITSANOS: Yes, sir. No, the other way. I'm going to |
| 12 | have to sta | nd on my head, you keep doing that. All right. There we go. |
| 13 | Can you m | ove that a little bit? Not that one; the one above it. This one |
| 14 | right here. | Number two. That's good. Don't worry about it. It's fine. |
| 15 | | THE WITNESS: Which page number? |
| 16 | | MR. ZAVITSANOS: Number two, Michelle. You got it at |
| 17 | number th | ree. I'm on page 13, sir. |
| 18 | | THE WITNESS: Okay. Let me read this, please. |
| 19 | | MR. ZAVITSANOS: Yes, sir. There you go. Great. |
| 20 | | [Witness reviews document] |
| 21 | | THE WITNESS: Okay. |
| 22 | BY MR. ZA | VITSANOS: |
| 23 | Q | Okay. So this is a UnitedHealthcare document, right? |
| 24 | А | Yes. I believe it's a draft. |
| 25 | Ω | Yeah. And I think the title of this document is Project |

| $\overline{}$ | |
|---------------|--|
| \asymp | |
| \approx | |
| \preceq | |
| တွဲ | |
| \sim | |
| | |

| 1 | Airstream, | right? Which is |
|----|-------------|--|
| 2 | А | No, it's not. |
| 3 | Q | Project Airstream MVP oh, I'm sorry. You're right, sir. My |
| 4 | apologies. | Excuse me. Out-of-network, change the narrative, change |
| 5 | performan | ce, right? |
| 6 | А | That's what that says, yes. |
| 7 | Q | Yes, sir. Okay. Now, let's first of all, let's look at what |
| 8 | MultiPlan i | s. Internally, you all knew that one out of every five dollars |
| 9 | that MultiF | Plan received came from United, right? |
| 10 | А | That's what we understood. |
| 11 | Q | Okay. That is a huge component for MultiPlan, right, 20 |
| 12 | percent? | |
| 13 | А | You would ask need to ask them. |
| 14 | Q | Well, does United have any single client that represents 20 |
| 15 | percent of | their revenue? |
| 16 | А | I don't know. |
| 17 | Q | Okay. Out of any of them. |
| 18 | А | I don't know. |
| 19 | Q | Twenty percent is a very significant amount, would you |
| 20 | agree? | |
| 21 | А | I you would need to ask MultiPlan. |
| 22 | Q | You don't know if 20 percent is a significant amount? |
| 23 | А | Depends on the situation. |
| 24 | Q | If 20 percent of their revenue is coming from United |
| 25 | Healthcare | , do you still think they're unbiased and objective? |

| 000793 | | | |
|--------|--|--|--|

| 1 | А | Yes. |
|----|-------------|--|
| 2 | Q | Okay. And by the way, we heard a lot in opening statement |
| 3 | about priva | ate equity. Is MultiPlan owned by private equity? |
| 4 | А | No, they're not. |
| 5 | Q | Well, were they at this time? Look at the last bullet. |
| 6 | А | Yes, they were. |
| 7 | Q | Okay. Okay. Now, looking at this document, sir, first page, |
| 8 | the reason | that that discussion about MultiPlan was in there is because |
| 9 | by 2018, as | s these programs were underway, you all started discussing |
| 10 | creating th | is new co, Project Airstream, that would replace MultiPlan, |
| 11 | right? | |
| 12 | А | That's not a hundred percent true. |
| 13 | Q | Let's look on the second page. |
| 14 | | MR. ZAVITSANOS: Michelle, pull out the executive summary |
| 15 | for the yea | r. Okay. |
| 16 | BY MR. ZA | VITSANOS: |
| 17 | Q | So we see that the primary out of network vendor, MultiPlan, |
| 18 | has a \$300 | million a year vendor fee, right? |
| 19 | А | That's what we pay MultiPlan, yes. |
| 20 | Q | Right. And so action with urgency and acceleration |
| 21 | А | I'm sorry. Where were you pointing? |
| 22 | Q | Action with urgency and acceleration, same |
| 23 | А | I see it. |
| 24 | Q | Same box. |
| 25 | А | Yeah. |
| | | |

| 2 |
|----|
| 3 |
| 4 |
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
| 23 |
| 24 |
| 25 |

| _ | | |
|----|--------------|---|
| 1 | Q | "Improve out of network program reimbursement levels to 80 |
| 2 | percent o | f par rates." Do you see that? |
| 3 | А | Yes, I do. |
| 4 | Q | We're talking about now even deeper cuts, right? |
| 5 | А | I would disagree. |
| 6 | Q | Okay. Let's keep going. Next page, please. And what you all |
| 7 | did is bec | ause you were losing clients on this ASO model, what you |
| 8 | were goin | g to do was you were just going to change the name and |
| 9 | repackage | e the fee as something else, right? |
| 10 | А | I disagree. We were building |
| 11 | Q | You were going I'm sorry. Sorry. I didn't mean to cut you |
| 12 | off. | |
| 13 | А | We were building a member advocacy program. Something |
| 14 | that Multi | Plan does not do. |
| 15 | Q | You were going to redesign shared savings and call it |
| 16 | somethin | g else, right? |
| 17 | А | We were adding a new enhancement to the out-of-network |
| 18 | programs | to help advocacy. |
| 19 | Q | You were going to redesign shared savings and call it |
| 20 | somethin | g else because of the pressure you were getting from these |
| 21 | clients, rig | ght? |
| 22 | А | That's incorrect. We were building an advocacy program for |
| 23 | the | |
| 24 | | MR. ZAVITSANOS: Michelle, highlight this, redesign shared |
| 25 | savings re | evenue model to TCOC focus. |

| , | _ | | |
|---|---|---|--|
| ì | = | • | |
| ì | Ξ | • | |
| - | _ | í | |
| C | C | 5 | |
| Č | 3 | ì | |

| 1 | BY MR. ZAVITSANOS: | |
|----|--|---|
| 2 | Q | It doesn't say eliminate shared savings revenue. It says |
| 3 | redesign. | |
| 4 | | MR. ZAVITSANOS: Can we highlight this, Michelle, right |
| 5 | here? | |
| 6 | BY MR. ZA | AVITSANOS: |
| 7 | Q | Right? |
| 8 | А | Yes, it does. |
| 9 | Q | Okay. So the 35 percent is now called total cost of care. And |
| 10 | you're going to come up with some fancy sounding new terms to make | |
| 11 | sound differently, right? | |
| 12 | А | That's incorrect. I can explain. |
| 13 | Q | No, sir. You were going to redesign this program to this, |
| 14 | right? | |
| 15 | А | We were |
| 16 | | MR. BLALACK: Object to form. Asked and answered. |
| 17 | | THE COURT: Overruled. |
| 18 | BY MR. ZA | AVITSANOS: |
| 19 | Q | Just last last question. You were going to redesign shared |
| 20 | savings, the percentage, for what you call a TCOC focus | |
| 21 | А | That |
| 22 | Q | total cost of care focus? |
| 23 | А | That's not what that says. |
| 24 | Q | That's not what that says? |
| 25 | А | You said the percentage. It doesn't say the percentage. |

| 1 | Q | Then, we go on to page 5, moving from strategy to |
|----|------------|---|
| 2 | execution. | |
| 3 | | MR. ZAVITSANOS: Michelle, follow me right here. Thank |
| 4 | you. | |
| 5 | BY MR. ZA | VITSANOS: |
| 6 | | |
| 7 | | |
| 8 | | |
| 9 | | |
| 10 | | |
| 11 | | |
| 12 | | |
| 13 | | |
| 14 | | |
| 15 | | |
| 16 | | |
| 17 | | |
| 18 | | |
| 19 | | |
| 20 | | |
| 21 | | |
| 22 | | |
| 23 | | |
| 24 | | |
| 25 | | |
| | | 00 |

| 1 | | |
|----|--|--|
| 2 | | |
| 3 | | |
| 4 | | |
| 5 | | |
| 6 | | |
| 7 | | |
| 8 | | MR. ZAVITSANOS: What exhibit, Michael? |
| 9 | | MR. KILLINGSWORTH: It's 266, page 4. |
| 10 | BY MR. ZA | AVITSANOS: |
| 11 | Q | Let's pull up Exhibit 266. |
| 12 | А | I need to go get it. |
| 13 | Q | Yes, sir. |
| 14 | А | What page, please? |
| 15 | Q | Okay. So we are going to page first of all, let's identify |
| 16 | what this is. Okay. This is the 2019 business plan, right? | |
| 17 | А | Yeah. That's what that says. |
| 18 | Q | And if we go to page give me one second, sir. |
| 19 | А | Uh-huh. Take your time. |
| 20 | Q | Okay. Let's go to when did you start doing Total Cost of |
| 21 | Care, sir, when you started using that concept | |
| 22 | А | I don't know that |
| 23 | Q | with your clients? |
| 24 | А | I don't know. That was part of the clinical team. Not my |
| 25 | team. | |

| 2 |
|----|
| 3 |
| 4 |
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
| 23 |
| 24 |
| 25 |

| 1 | Q | Okay. Well, let's go to page 17, please. |
|---|--------------|---|
| 2 | | MR. ZAVITSANOS: Right here, Michelle. Pull that up. |
| 3 | BY MR. ZA | VITSANOS: |
| 4 | Q | Gross margin in 2019, is higher than it's ever been, right? |
| 5 | А | I didn't write this, so I don't know what that means. |
| 6 | Q | You don't know? |
| 7 | А | It says, "historically high." |
| 3 | Q | You didn't write this? |
| 9 | А | I did not. |
| 0 | Q | Okay. So let's look at page 24, please. Okay. So we see that |
| 1 | even thou | gh the ASO growth is shrinking, the gross margin on the |
| 2 | PMPM is ir | ncreasing, right? Less members, more money, right? |
| 3 | А | That's not what that says. |
| 4 | Q | "We stayed at gross margin, PMPM, \$93.85 by 2019, right? |
| 5 | А | Yes. That's what that says. |
| 6 | Q | All right. |
| 7 | А | I think that's the projection. |
| 3 | Q | Yes. And that's because of this we design, where you were |
| 9 | going to pa | ay someone for pinning up cat fees so the clients wouldn't be |
| 0 | starting a 3 | 35 percent, right? |
| 1 | А | That's incorrect. The PMPM is driven by many other |
| 2 | administra | tive services other than the out-of-network programs. |
| 3 | Q | Okay. Now, let's go back to Exhibit 8. And we started talking |
| 4 | about that | this morning. And we're going to go to page 121. And Mr. |
| 5 | Haben, I'm | just going to show this. Let's not |

| 1 | | MR. ZAVITSANOS: Actually, page 120, please, Michelle. |
|----|--|---|
| 2 | BY MR. Z | AVITSANOS: |
| 3 | Q | Okay. So form the slots in the headings, you see what we're |
| 4 | talking ab | out? This is |
| 5 | А | What page? 120? |
| 6 | Q | Yes. This is the agreement between MultiPlan and United. |
| 7 | And these | e are the fees that United will pay to MultiPlan, right? |
| 8 | А | All right. Let me just take a quick peek. |
| 9 | Q | Yes, sir. |
| 10 | А | Yes. Those are the fees for the programs. |
| 11 | | MR. ZAVITSANOS: Michelle, let's go to page 121, which is |
| 12 | the very n | ext page. And Michelle, pull out this box here, just the box, |
| 13 | please. A | nd Michelle, will you highlight this part here? Highlight and |
| 14 | circle this, please. Okay. And then circle the bottom one, please. | |
| 15 | BY MR. ZAVITSANOS: | |
| 16 | Q | Okay. So those are the percentages up on the screen, Mr. |
| 17 | Haben, or | page 121, that MultiPlan would receive when using Data |
| 18 | iSight to pre-price the claims, right? | |
| 19 | А | Yes. |
| 20 | Q | And you maintain to this jury, MultiPlan is objective, right? |
| 21 | Α | Yes, of course. |
| 22 | | MR. ZAVITSANOS: Okay. Thank you, sir. Okay. Take that |
| 23 | down, Mi | chelle. May I ask counsel if they have an objection to 34, Your |
| 24 | Honor? | |
| 25 | | THE WITNESS: What was that number again, Your Honor? |

| 3 |
|----|
| 4 |
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
| 23 |
| 24 |

1

2

MR. BLALACK: Object to the foundation of this document, Your Honor.

THE COURT: There is no stipulation.

MR. ZAVITSANOS: Yes. Okay.

BY MR. ZAVITSANOS:

- Q Mr. Haben, would you describe as best as you can -- if you want to cheat so you can refresh your memory, you're -- you are free to look at Exhibit 24, if you'd like. But you don't have to do them all, correct? And my question is, can you describe to the jury generally, what is Data iSight? What's your understanding of it?
 - A At a high level, without looking at the document?
 - Q Yeah. A high level.
- A Data iSight is a tool that MultiPlan has that's available to do what they call a cost plus a reasonable margin application. So they get to a reasonable reimbursement rate for the providers. It also will incorporate other components that a payor like United would want. So it's an engine that reprices claims and will send back to United.
 - Q Let's pull up 471. Now --
 - A Can I get it?
- Q Actually, hold on. Let's measure it to stay awesome. Okay. So what -- when you say it's a tool, what does that mean?
- A United, when they get an out-of-network claim, they send the claim out to MultiPlan if that claim's eligible for the out-of-network program. It will go in -- if the client has outlier cost management, it goes

| _ | |
|----------|--|
| 0 | |
| 0 | |
| Ō | |
|)0080 | |
| \simeq | |
| \circ | |
| _ | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

| 1 | into Data | iSight. Data iSight has pricing methodology, along with our |
|----|-------------------------------|---|
| 2 | criteria, if | we define that. They'll reprice that claim using their logic, and |
| 3 | they will s | send it back to United. So you can think about it as a claims |
| 4 | repricing | engine. I call it a tool just to be simple. |
| 5 | Q | Okay. So you've seen the Wizard of Oz? |
| 6 | А | I love it. My mom's favorite movie. |
| 7 | Q | Yes, sir. My kid's favorite movie, as well. Okay. So in |
| 8 | Wizard of | Oz, the impression is that there's this almost deity kind of |
| 9 | figure call | ed Wizard of Oz, who employs this kind of black fox magic to |
| 10 | grant people's wishes, right? | |
| 11 | А | I understand. Yup. |
| 12 | Q | But it ends up being this kind of insecure little man who |
| 13 | really is th | ne opposite of what people thought the Wizard of Oz was, |
| 14 | right? | |
| 15 | А | Understood. |
| 16 | Q | Okay. And Data iSight is the Wizard of Oz, would you agree? |
| 17 | | MR. BLALACK: Object to form. Argumentative. |
| 18 | | THE COURT: Sustained. |
| 19 | BY MR. ZAVITSANOS: | |
| 20 | Q | Data iSight is just a front for United to have an independent |
| 21 | source to | use this sophisticated title to reprice claims at whatever |
| 22 | amount U | nited says, would you agree? |
| 23 | А | I disagree. I can explain it and walk through how the |
| 24 | programs work. | |
| 25 | Q | No. We're going to move on. |

| _ |
|---|
| 0 |
| 0 |
| 0 |
| ŏ |
| Õ |
| Ñ |
| |
| |
| |
| |
| |
| |

| 1 | А | Okay. |
|----|--------------|---|
| 2 | | MR. ZAVITSANOS: Your Honor, what would be a good time |
| 3 | to start? | |
| 4 | | THE COURT: Let's go through it right after lunch. |
| 5 | | All right. So everybody, let's take our lunch break. During |
| 6 | the recess, | don't talk with each other or anyone else on any subject or |
| 7 | issue conn | ected with the trial. Don't read, watch, or listen to any report |
| 8 | of or comm | nentary on the trial. Don't discuss this case with anyone |
| 9 | connected | to it or by any medium of information, including without |
| 10 | limitation, | newspapers, television, radio, internet, cell phones, or texting. |
| 11 | | Do not conduct any research on your own relating to the |
| 12 | case. You | can't consult dictionaries, use the internet, or use reference |
| 13 | materials. | Don't talk, do social media, text, Tweet, Google issues, or |
| 14 | conduct an | y other type of book or computer research with regard to any |
| 15 | issue, party | , witness, or attorney involved in the case. |
| 16 | | Most importantly, do not form or express any opinion on any |
| 17 | subject cor | nnected with the trial until the matter is submitted to you. |
| 18 | Thank you | for another great morning. Have a good lunch. And be back, |
| 19 | please, at 1 | 2:45. |
| 20 | | THE MARSHAL: All rise for the jury. |
| 21 | | [Jury out at 12:09 p.m.] |
| 22 | | THE COURT: Mr. Haber, you may step down. |
| 23 | | THE WITNESS: Thank you. |
| 24 | | [Recess taken from 12:09 p.m. to 12:51 p.m.] |
| 25 | | [Outside the presence of the jury] |
| | | |

| ç | 2 | |
|---|----|--|
| | 38 | |
| č | ນ | |
| | | |
| | | |
| | | |

| 1 | | THE COURT: Thanks, everyone. Please be seated. All right. |
|----|--------------|---|
| 2 | I am told th | nat we have 156 people on Blue Jeans. So if anyone is joining |
| 3 | us remotel | y, please be sure to mute yourself. |
| 4 | | Calling the case of Freemont v. United. Note the presence of |
| 5 | counsel an | d their clients. Are we ready to bring in the jury? |
| 6 | | MR. ZAVITSANOS: Yes, Your Honor, from the Plaintiff. |
| 7 | | MR. BLALACK: We are, Your Honor. And I can bring Mr. |
| 8 | Haben in if | you'd like. |
| 9 | | THE COURT: Please. |
| 10 | | [Pause] |
| 11 | | THE MARSHAL: All rise for the jury. |
| 12 | | [Jury in at 12:53 p.m.] |
| 13 | | THE COURT: Thank you. Please be seat. All right. The |
| 14 | Court is in | order. We have a number of people who are watching the TV |
| 15 | remotely d | uring this trial. And unfortunately, right now the video is not |
| 16 | working fo | r you. We're working to get that fixed. |
| 17 | | Plaintiff, please continue. |
| 18 | | MR. ZAVITSANOS: Thank you, Your Honor. And may it |
| 19 | please the | Court, counsel. |
| 20 | BY MR. ZA | VITSANOS: |
| 21 | Q | Okay, Mr. Haben. I think we left off on the Wizard of Oz, |
| 22 | right? | |
| 23 | А | I believe so. |
| 24 | Q | Okay. So Data iSight. First of all, Data iSight, that sounds |
| 25 | like an opp | ressive sounding name. Do you agree? |
| | Ī | |

| • | |
|----|------------|
| 2 | Q |
| 3 | [indiscer |
| 4 | |
| 5 | |
| 6 | |
| 7 | section. |
| 8 | BY MR. 2 |
| 9 | Q |
| 10 | ago. An |
| 11 | that it is |
| 12 | А |
| 13 | Q |
| 14 | excuse n |
| 15 | А |
| 16 | Q |
| 17 | deposition |
| 18 | А |
| 19 | Q |
| 20 | А |
| 21 | Q |
| 22 | started u |
| 23 | benefits |

25

| Α | I'm not a marketing guy. | I wouldn't know. |
|---|--------------------------|------------------|
|---|--------------------------|------------------|

Q Okay. Give me one second. Let's go back to Exhibit 43. [indiscernible] this Data iSight.

MR. ZAVITSANOS: You got it, Michelle? Is the TV off?

[Pause]

MR. ZAVITSANOS: Okay. So please pull out the background section.

BY MR. ZAVITSANOS:

- Q Okay. So this is in July 2016. We looked at it a little while ago. And in describing Data iSight internally within United, you all said that it is a legally sound process. See that?
 - A I do see that.
- Q Okay. As opposed to this random calculated amounts -- or excuse me. As opposed to our random calculated amounts, right?
 - A I see that.
- Q Okay. You remember reviewing with Mr. Fineberg, in your deposition, some materials on Data iSight?
 - A You'd have to refresh my memory.
 - Q Would you please get the binder with Exhibit 413?
 - A Just a minute.
- Q And while you're getting that, Mr. Haben, before United started using Data iSight, it received materials from MultiPlan about the benefits of Data iSight, correct?
 - A Yes, I believe so.
 - Q And you were one of the people that participated in the

| 000805 | | | |
|--------|--|--|--|
| | | | |
| | | | |
| | | | |

| 1 | decision to | use Data iSight? |
|----|--------------|--|
| 2 | А | Yes, I was. |
| 3 | Q | Okay. And this Exhibit 413 is one of the type or materials |
| 4 | that Data is | Sight would provide about how it works, right? |
| 5 | А | I don't recognize this. |
| 6 | Q | Do you remember discussing this at your deposition? |
| 7 | А | Are we looking at the same document? |
| 8 | Q | Yes, sir. There's a Data iSight logo on the front page. |
| 9 | Α | Okay. I was getting confused as to what was on the screen. I |
| 10 | don't reme | ember looking at this document, but you can refresh my |
| 11 | memory. | |
| 12 | Q | Well, look on page 3, please. Do you remember Mr. Fineberg |
| 13 | going thro | ugh this with you? |
| 14 | А | I don't remember. I'm not trying to be difficult. I just don't |
| 15 | remember | |
| 16 | Q | So and do you have your deposition up there? |
| 17 | А | Yes, I do. |
| 18 | Q | Are the exhibits attached to your deposition? |
| 19 | Α | I don't know how this works. So |
| 20 | Q | Here you go. |
| 21 | | MR. ZAVITSANOS: May I approach, Your Honor? |
| 22 | | THE COURT: You may. |
| 23 | BY MR. ZA | VITSANOS: |
| 24 | Q | The part there that the tab 5. And just see if that refreshes |
| 25 | your recoll | ection about this document. |

| 1 | А | I see that it's in there. I don't did he ask me a question |
|----|------------|---|
| 2 | about it? | |
| 3 | Q | I believe he did. But I just wanted to see if it would refresh |
| 4 | your recol | lection that this was addressed during the deposition. |
| 5 | А | If there's a question in there, I'd be glad to look at it. Sorry. I |
| 6 | don't rem | ember that far back. |
| 7 | Q | Right. Okay. And take a look for a second. Does this appear |
| 8 | to be cons | sistent, this document, with the kind of statement that United |
| 9 | was discu | ssing internally about how Data iSight works? Specifically, |
| 10 | look on pa | ages 2 and 3, please. |
| 11 | А | Can I read it? |
| 12 | Q | Sure. |
| 13 | | [Witness reviews document] |
| 14 | Q | Let me know when you're ready. |
| 15 | А | I'm ready. |
| 16 | Q | Okay. So does this appear to contain the same type of |
| 17 | general di | scussion regarding what how Data iSight operates and |
| 18 | works? | |
| 19 | А | It create it contains a description of how they determine the |
| 20 | reimburse | ement amount. |
| 21 | Q | And this is the tool that United used to administer some of |
| 22 | the claims | at issue in this case, right? |
| 23 | А | I believe so. |
| 24 | Q | Okay. |
| 25 | | MR. ZAVITSANOS: Your Honor, we move for the admission |
| | 1 | |

of Plaintiffs' 413.

MR. BLALACK: Your Honor, object to the foundation. The witness didn't write it and did not create it. And it was not produced by any Defendant in this case.

THE COURT: Any response, please?

MR. ZAVITSANOS: Your Honor, this is the tool that they used, and he said that the representations in here are consistent with what United was discussing internally.

THE COURT: Objection is overruled. Exhibit 413 will be admitted.

[Plaintiffs' Exhibit 413 admitted into evidence]
BY MR. ZAVITSANOS:

- Q Okay. So now in fairness to you, Mr. Haben, this is a Data iSight document. You see the logo up there?
 - A I do.
- O All right. Now let's go through this. Page 2. This is what Data iSight is telling the public about what it does. It says to determine the Data iSight reimbursement amount, the first step is to gather some information about your client. The healthcare provider sends the information on a bill to your health plan. Data iSight uses it to build a comparison group or a benchmark group of claims data. This enables us to compare the charges on your claim against other claims in a manner the provider would find to be fair. You see that?
 - A I do.
 - Q And the provider's name here is Ruby Crest Emergency

| Med | licine, | rig | ht? |
|-----|---------|-----|-----|
| | | | |

- A I see that.
- Q And this whole thing that I just read is fiction because the Data iSight amount always works out, always, always, always, always works out to the amount that United wants to pay.

MR. BLALACK: Object to the form of the question.

BY MR. ZAVITSANOS:

Q Right?

MR. BLALACK: Argumentative.

THE COURT: Objection sustained.

MR. ZAVITSANOS: Let me rephrase.

BY MR. ZAVITSANOS:

- Q Is it correct that the Data iSight amount always works out to either 350 percent when that was in effect or when you dropped it to 250 percent it works out to 250 percent every single time?
 - A I don't know if that's true or not.
- Q Okay. Let's go to the first page. Determining the Data iSight reimbursement amount. And this is a representation of how a -- how Data iSight does this, right?
- A I don't know this document. So I don't know what it's representing.
- Q Well, it says the Data iSight reimbursement amount determined for your claim was \$609.28. You see that?
 - A I do.
 - Q Now this column in the far right-hand side, how much is

| c | _ | 5 |
|---|----------|---|
| Č | Ξ | 5 |
| S | _ | • |
| ۲ | <u> </u> | - |
| > | 7 | < |

| 1 | that? | |
|----|-------------|--|
| 2 | А | It says \$174.08. |
| 3 | Q | Okay. Now hold on now. Let's take a look at what's going |
| 4 | on here. S | So this is a claim. |
| 5 | | MR. ZAVITSANOS: Close this out, Michelle, that one page, |
| 6 | page 2. Pu | ıll this out. |
| 7 | BY MR. ZA | AVITSANOS: |
| 8 | Q | This is a claim for Ruby Crest during the relevant time period, |
| 9 | one of the | claims in this case, right? |
| 10 | А | I don't know if it's a claim for this case or not. |
| 11 | Q | Okay. Let me rephrase. It's during the claim period of this |
| 12 | case, right | ? |
| 13 | А | I believe so. |
| 14 | Q | Okay. Let's go to the next page. And the way the waterfall |
| 15 | worked wa | as the 350 percent you get, according to you, the greater of 350 |
| 16 | percent or | the Data iSight amount, right? |
| 17 | А | It would be either the 350 percent of Medicare or the Data |
| 18 | iSight amo | ount, whichever is greater. |
| 19 | Q | Okay. So according to this claim form, which is for Ruby |
| 20 | Crest, Data | a the Data iSight reimbursement amount determined for |
| 21 | your claim | was 609.28. You see that? |
| 22 | А | I do. |
| 23 | Q | So Data iSight ran its methodology, what's laid here on the |
| 24 | second pa | ragraph, and came up with the 609.28, right? |
| 25 | А | If that's what you're representing they did. They repriced |

| 1 | that claim at 609. | | | |
|----|--|---|--|--|
| 2 | Q | Well, the this amount was determined by and then it list | | |
| 3 | a bunch of thing, right, which is their little methodology, right? | | | |
| 4 | А | Hold on. Yes. | | |
| 5 | Q | Okay. So according to this Exhibit 413, what's the Medicare | | |
| 6 | rate? | | | |
| 7 | А | 174.08. | | |
| 8 | Q | If we multiple that by 350 percent the 350 percent, that | | |
| 9 | benchmar | k, comes from United not from Data iSight, right? | | |
| 10 | А | Yes. It's guidance, and I can explain why that is. | | |
| 11 | Q | That's okay. If we multiply 174.08 by the amount that you | | |
| 12 | want to pa | ay, what does it work out to? | | |
| 13 | А | I don't have my calculator. I don't know. | | |
| 14 | | MR. ZAVITSANOS: Michael, you got your calculator. | | |
| 15 | BY MR. Z | AVITSANOS: | | |
| 16 | Q | Will you take his word for it? He's got a trusting face. | | |
| 17 | | MR. BLALACK: I'll check it. | | |
| 18 | | MR. ZAVITSANOS: He's got an even more trusting face. | | |
| 19 | BY MR. Z | AVITSANOS: | | |
| 20 | Q | So let's multiply | | |
| 21 | | MR. BLALACK: Don't worry about it. Go with it, Mr. Haben. | | |
| 22 | Okay. | | | |
| 23 | BY MR. Z | AVITSANOS: | | |
| 24 | Q | Okay. Let's multiply 174.08 times 350 percent. What does | | |
| 25 | that work | out to? | | |

| 1 | А | Is that what the number is? |
|----|-------------|---|
| 2 | Q | Hold on. |
| 3 | | MR. KILLINGSWORTH: Yeah, 609.28. |
| 4 | BY MR. ZA | AVITSANOS: |
| 5 | Q | 609.28. Wow. What a coincidence, right, Mr. Haben? It just |
| 6 | happens to | o be exactly what the Wizard of Oz says it comes out to. |
| 7 | | MR. BLALACK: Object to the form. Argumentative. |
| 8 | | MR. ZAVITSANOS: Let me rephrase. |
| 9 | BY MR. ZA | AVITSANOS: |
| 10 | Q | It just happens to be exactly what United wants to pay, right? |
| 11 | А | It paid per the 350 percent floor. |
| 12 | Q | Well, sir, internally, you all decided you don't want to pay |
| 13 | more than | 350. But to be fair, you're going to let Data iSight run these |
| 14 | sophistica | ted calculations and whichever is higher, 350 or Data iSight, |
| 15 | that's wha | t you're going to go with, right? |
| 16 | А | Yeah. There's I can explain why. |
| 17 | Q | No, sir. Is it a coincidence that every single claim in this case |
| 18 | that Data i | Sight has run works out to exactly 350 or 250? |
| 19 | | MR. BLALACK: Object to the foundation of the question. The |
| 20 | witness do | pesn't know what claims are at issue in the case. |
| 21 | | THE COURT: Overruled. |
| 22 | BY MR. ZA | AVITSANOS: |
| 23 | Q | Is it a coincidence, sir, that every single claim in this case that |
| 24 | Data iSigh | t used this proprietary methodology comes out to exactly what |
| 25 | United wa | nted to pay? |
| | i | |

| 1 | Α | I don't know all the claims. I haven't looked at all of them, s | | | |
|----|---------------|---|--|--|--|
| 2 | I don't know. | | | | |
| 3 | Q | Well, this one works out to exactly what United wanted to | | | |
| 4 | pay, right? | | | | |
| 5 | А | It works out to 350 percent of Medicare. | | | |
| 6 | Q | And you don't have an explanation of why, I mean, down to | | | |
| 7 | the penny | it works out to exactly 350 percent? You don't | | | |
| 8 | А | I | | | |
| 9 | Q | You don't have an explanation for that? | | | |
| 10 | А | I think I can try to explain. | | | |
| 11 | Q | No, sir. Do you have any documents that we can look at | | | |
| 12 | about why | this coincidence took place? | | | |
| 13 | А | I wouldn't characterize it as a coincidence. And I can explain | | | |
| 14 | why. | | | | |
| 15 | Q | By the way, if we go to page 5 of this same document oh, | | | |
| 16 | and by the | way, on that discount from the bill charge down to this | | | |
| 17 | patented, o | computerized, proprietary methodology, Data iSight, MultiPlan | | | |
| 18 | got somew | here between 7 to 10 percent of that differential, right? | | | |
| 19 | А | We have to pay them a fee for repricing the claim. | | | |
| 20 | Q | Okay. So here, part of the same document, Ruby Crest | | | |
| 21 | | MR. ZAVITSANOS: Right down here, Michelle. Will you | | | |
| 22 | highlight tl | nat column across the way? | | | |
| 23 | BY MR. ZA | VITSANOS: | | | |
| 24 | Q | Remember we started your examination by saying these CPT | | | |
| 25 | codes for e | emergency room doctors, there's only five of them and the | | | |

| C | ⊃ | |
|---|-----------|--|
| C | \supset | |
| č | ぅ | |
| 3 | ಹ | |
| • | ٠ | |
| _ | ∹ | |
| ζ | w | |

| 1 | most serio | ous one is 99285, right? |
|----|--------------|--|
| 2 | А | There's only five codes there, yes. |
| 3 | Q | Yeah. And this one, using this patented methodology for |
| 4 | 99285, the | most serious code, Data iSight, MultiPlan, when they get 20 |
| 5 | percent or | 20 percent of the revenues you guys get, they cut it to exactly |
| 6 | what you | wanted to pay, right? |
| 7 | А | They repriced it at 350 percent of Medicare. |
| 8 | Q | Running their sophisticated technology, it just coincidentally |
| 9 | matched v | vhat you wanted to pay? |
| 10 | А | It's not a coincidence. I can explain why. |
| 11 | Q | No, sir. And by the way, in your deposition when you were |
| 12 | asked whe | ther you had an explanation for this, your answer was no, you |
| 13 | did not, riç | ght? But now you have an explanation? |
| 14 | А | Well, you asked me I don't know the specific claim, but you |
| 15 | asked me | in general why I thought it paid 350, and I can try to explain |
| 16 | that. | |
| 17 | Q | No, sir. Okay. Now, the whole reason we were doing this |
| 18 | let's go to | 471, please. I think one of the places we started, Mr. Haben, is |
| 19 | allegedly t | he whole impetus for United doing this is so that you could |
| 20 | control pre | emiums |
| 21 | Α | Can I get |
| 22 | Q | and bring them in check? |
| 23 | Α | Can I get the document? |
| 24 | Q | Yes, sir. I'm sorry. My fault. |
| 25 | А | Okay. |
| | 1 | |

| 1 |
|----|
| 2 |
| 3 |
| 4 |
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
| 23 |
| 24 |
| 25 |

| | Q | Okay. | This docur | ment is so | mething | called | comme | ercial |
|-----|---------|---------|------------|------------|---------|--------|-------|--------|
| com | petitor | financi | al review, | right? | | | | |

- A Yes.
- Q Okay.

MR. ZAVITSANOS: Go to page 3, please. And let's pull out the top paragraph. Michelle, right here. From here to here.

THE WITNESS: Can I just take a peek?

MR. ZAVITSANOS: Sure.

THE WITNESS: Page 8?

MR. ZAVITSANOS: Michelle, highlight here to here.

THE WITNESS: Is that page 3 or page 8?

MR. ZAVITSANOS: Excuse me. I'm sorry, sir. It's page 3.

THE WITNESS: Let me take a look. Okay.

BY MR. ZAVITSANOS:

Q So while United is leading the pack to try and control healthcare costs by eliminating egregious charges like the one we just saw for 99285, at the same time it is cutting rates by significant amounts. Premiums are going up at a high rate increase, right?

A I didn't write this document. I don't know the foundation of it. So I don't know if it's correlated.

Q You're charging more, and you're paying less. You're benefiting on both ends, right?

A I would disagree.

Q Mr. Haben, wouldn't you agree with me that the impetus for this was the concern for members who were paying premiums that were

| 1 | too high? | That was one of the alleged concerns that United had, right? |
|----|-------------|---|
| 2 | А | I'm not sure if I'm following your question. |
| 3 | Q | At the beginning of this five year period, Mr. Haben, I |
| 4 | thought y | ou told us that healthcare costs with these egregious billers |
| 5 | were caus | ing premiums to go up, right? |
| 6 | А | Healthcare costs affect premiums. |
| 7 | Q | So you started substantially cutting reimbursements for out- |
| 8 | of-networ | k providers, right? |
| 9 | А | We started offering programs to our clients to address high |
| 10 | medical co | osts. |
| 11 | Q | And at the same time you're doing that, and you're paying |
| 12 | less and re | eigning in healthcare costs, you're jacking up premiums, right? |
| 13 | А | I don't think it says that. |
| 14 | Q | Okay. Will you please look at Exhibit 273, please? Take a |
| 15 | moment t | o review it, please. |
| 16 | А | There's 190 pages. Is there a page you want me to look at? |
| 17 | Q | Is this a presentation for the ENI, employer and individual |
| 18 | part of the | e company? |
| 19 | А | I'm not familiar with this document, so I don't know what it |
| 20 | is. | |
| 21 | Q | Does it have the United logo on it? |
| 22 | А | It does. |
| 23 | Q | If you will please turn to page 56? |
| 24 | А | Can I take a peek? |
| 25 | Q | Sure. Let me know when you're ready, sir. |
| | I | |

| 2 |
|----|
| 3 |
| 4 |
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
| 23 |
| 24 |
| 25 |

| А | Okay. |
|----------|--|
| Q | Does that page deal with the time period we have been |
| discuss | ing, this 2014 through part of 2019? |
| А | Again, I don't know what the document is. I didn't write it. It |
| does ha | ave a range in the upper left of 2014 to 2018. |
| Q | Does this address premiums during that time? |
| А | I don't know if it does. |
| 0 | Does it have a percentage increase of premiums during that |
| time? | |
| А | It does have a percentage of increase in the premiums. |
| Q | And premiums are one of the things that you and I discussed |
| during | your testimony a few days ago, correct, sir? |
| А | I said that premiums are affected by medical costs. |
| | MR. ZAVITSANOS: Your Honor, we move for the admission |
| of Plain | tiffs' 273. |
| | MR. BLALACK: Object to the foundation, Your Honor. The |
| witness | didn't write it, receive it, and is not involved in its preparation. |
| | THE COURT: And did you say 271? |
| | MR. ZAVITSANOS: Excuse me, Your Honor. 273 and it is to |
| rebut th | ne statement that Mr. Haben offered while under oath. |
| | THE COURT: Objection is overruled. Exhibit 273 will be |
| admitte | ed. |
| | [Plaintiffs' Exhibit 273 admitted into evidence] |
| BY MR. | ZAVITSANOS: |
| Q | Okay. So Mr. Haben, 273 page 56. |

| 2 |
|----|
| 3 |
| 4 |
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
| 23 |
| 24 |
| 25 |

| | | MR. ZA | VITS | ANOS: | Right he | re, Mic | helle. | Just | this. | Kee | p |
|---------|------|----------|------|--------|----------|---------|--------|-------|-------|--------|-----|
| going. | No, | no, no. | Up. | I want | the whol | e thing | right | here. | No, | no, jı | ust |
| the pre | miuı | m increa | ase. | | | | | | | | |

BY MR. ZAVITSANOS:

- Q Mr. Haben, while you're cutting us by up to 85 percent during this time, you're charging members 62 percent higher during that time.

 You're going up and we're going down, right?
 - A I didn't write the document. I don't know what this means.
- Q In your opinion, Mr. Haben, which one is more egregious, this or this?
 - A I don't think they're related.
 - Q Which one is more egregious, sir?

MR. BLALACK: Objection. Asked and answered.

THE COURT: Sustained.

MR. ZAVITSANOS: You can close it, Michelle.

BY MR. ZAVITSANOS:

- Q By the first quarter of 2019, Mr. Haben, the rate for emergency room doctors under this proprietary methodology, Data iSight, it had dropped to 250 percent, right, sir?
 - A Sorry. Can you ask it again, please?
- Q By the first quarter of 2019, the rate for emergency room doctors, under this OCM, Data iSight, SSPE, shared savings, benchmark, yada yada, it had dropped to 250 percent of Medicare, right, which is a 60 to 70 percent reduction off of our billed charges, right?
 - A You're confusing me a little bit with all the programs you

| 1 | threw in th | nere. |
|----|-------------|---|
| 2 | Q | You got your deposition there? |
| 3 | А | Yeah, which page? |
| 4 | Q | Go to page 121. Line 19. |
| 5 | А | Okay. Let me get there. |
| 6 | Q | Yes, sir. 121, line 19. |
| 7 | "Q | Does that refresh your recollection that in the Q1 of 2019 that |
| 8 | United red | uced the OCM emergency room rate to 250 percent of |
| 9 | Medicare? | |
| 10 | "A | Yes, it does." |
| 11 | Did I | read that correctly? |
| 12 | А | You did. |
| 13 | Q | Why did you do that? |
| 14 | А | Why did we drop it down to 250, the benchmark? |
| 15 | Q | Yeah. Yeah, why did you do that? |
| 16 | А | Because that was still a premium above Medicare rate. It |
| 17 | was more | in line with the market and what our clients wanted. |
| 18 | Q | And remember we looked at Exhibit 43 |
| 19 | | MR. ZAVITSANOS: Pull that up, please. First paragraph. |
| 20 | Right there | e, Michelle. |
| 21 | BY MR. ZA | AVITSANOS: |
| 22 | Q | We talked about this, Mr. Haben? |
| 23 | А | Yeah, can I |
| 24 | Q | Yeah, yeah. Sure. Absolutely. Please take your time. |
| 25 | | MR. ZAVITSANOS: Yep. And Michelle, you got a line thing |

| ı |
|----|
| 2 |
| 3 |
| 4 |
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
| 23 |
| 24 |
| 25 |

| 1 | going on. | Okay. All right. |
|---|-------------|--|
| 2 | BY MR. ZA | AVITSANOS: |
| 3 | Q | So before Data iSight, the cuts were random, populated |
| 4 | amounts, | right? |
| 5 | А | That's incorrect. |
| 6 | Q | But if Data iSight is doing whatever you want to do, and it's |
| 7 | coming ou | it to exactly 350 or later, 250, does that tell you, Mr. Haben, |
| 3 | that you're | e really not doing this, the legally sound process, you're still |
| 9 | doing this | random, calculated amounts just because you can? |
| 0 | А | I would disagree, and I can explain why. |
| 1 | Q | No, sir. Now, let's please go to Exhibit 229 and take a |
| 2 | moment to | o look at this, please? |
| 3 | | MR. ZAVITSANOS: Is that in, please? |
| 4 | | MR. KILLINGSWORTH: It's in. |
| 5 | | MR. ZAVITSANOS: Okay. That's in. Let's go to page 3. |
| 6 | Okay. She | e's going to pull it up while you're getting there. Right here, |
| 7 | Michelle, | circle a lot faster right here to here. And this is oh, I'm |
| 3 | sorry, Mic | helle, I need the date. Can we get the top in? Okay. Right |
| 9 | there. A li | ttle further down. Perfect. And Michelle, right here, can you |
| C | highlight t | his one fully? |
| 1 | | THE WITNESS: Which page, please? |
| 2 | | MR. ZAVITSANOS: It's page 3. |
| 3 | BY MR. ZA | AVITSANOS: |
| 4 | Q | Okay. So here you are, here you all are, internally saying |
| 5 | you're goi | ng to drop it from 350 to 250. And it's going to be 250 of |

| 3 |
|----|
| 4 |
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |

| 1 | Medicare o | or Data iSight, whichever is greater, right? |
|----|--------------|---|
| 2 | А | That's correct. It's the floor. |
| 3 | Q | Mr. Haben, are you aware of even one document anywhere |
| 4 | where the | Data iSight rate exceeded these two numbers? Did that ever |
| 5 | happen? | |
| 6 | А | The |
| 7 | Q | For the claims at issue in this case, or otherwise? |
| 8 | А | I don't know if I can answer that question. |
| 9 | Q | Well, we looked at one example, where it worked out to |
| 10 | exactly 350 |), right? |
| 11 | А | The example you had was 350. |
| 12 | Q | Yeah. Okay. So if we go to page 8, of the same document, |
| 13 | right here. | Who's Jacqueline, is it Buccini? |
| 14 | А | I believe that's how you pronounce her name. |
| 15 | Q | Okay. Out-of-network strategy and affordability, right, she's |
| 16 | the manag | er of that? |
| 17 | А | Correct. |
| 18 | Q | Well, okay, "Hi Mark, we're thinking we would like the lower |
| 19 | OCM paid | amounts for professional emergency services from 350 to |
| 20 | 250," right? | |
| 21 | А | That's what that says. |
| 22 | Q | Who is she writing to? |
| 23 | А | I believe it's Mark Edwards at MultiPlan. |
| 24 | Q | But, I thought MultiPlan is the umpire. I thought they were |
| 25 | supposed t | to be objective? Say what? They're supposed to be objective, |
| | I | |

| | | 1 |
|--------|--|---|
| | | 1 |
| 0 | | 1 |
| 000821 | | 1 |
| _ | | 1 |
| | | 1 |
| | | 1 |
| | | 1 |
| | | _ |

| 1 | right? | |
|----|-------------|--|
| 2 | | MR. BLALACK: Object to the form. Argumentative. |
| 3 | | THE COURT: Overruled. |
| 4 | BY MR. ZA | AVITSANOS: |
| 5 | Q | They're supposed to be objective, right? |
| 6 | А | MultiPlan is the administrator of the repricing engine for us. |
| 7 | Q | Yeah. So this, Mr. Haben, is a wink-wink. We set your Data |
| 8 | iSight eng | ine to come out to 250. That's what this is, right? |
| 9 | А | I disagree, and I can explain why. |
| 10 | Q | No, sir. You all are writing to MultiPlan, and you're telling |
| 11 | them that | you want to lower the amount, right? |
| 12 | А | We're asking them to adjust the repricing engine. |
| 13 | Q | To what? |
| 14 | А | Instead of the 250 |
| 15 | Q | Adjust the repricing engine? Is that what you just said? |
| 16 | А | Yeah, and I can explain why. |
| 17 | Q | The engine is Data iSight? |
| 18 | А | No, because we have criteria we need to meet for the |
| 19 | Affordable | e Care Act. |
| 20 | Q | Data iSight is sometimes referred to as the Data Pricing |
| 21 | Engine, riç | ght? |
| 22 | А | It's a machine. |
| 23 | Q | Do you know what a Freudian slip is? |
| 24 | А | I believe so, yeah. |
| 25 | Q | Did you just do one of those, a Freudian slip? |
| | I | |

| 000822 | | | |
|--------|--|--|--|
| | | | |
| | | | |

| | Α | No, it's a Data iSight is a repricing engine. |
|-----|------------|---|
| | Q | Okay. And by the way, when you did this, dropping it from |
| | 350 to 250 | , you as the head of out-of-network, you have no idea what |
| | analysis U | nited did before using this out-of-network rate for emergency |
| | room doct | ors under OCM to 250 percent, correct? |
| | А | I don't know what you're asking. |
| -11 | | |

- Q You have no idea what type of analysis, if there was any,
 United did, before doing what we're looking at up on the screen? They
 just did it, right?
 - A That's a mischaracterization.
 - Open your deposition, page 138. 138, line 17.
- "Q Okay. So let's talk about that change. What analysis did United conduct prior to reducing the OCM rate from 350 percent of Medicare to 250 percent of Medicare?
- "A I don't know specifically, but I believe we looked at the par median rates and determined the par median and the aggregate, which was less than 200. So we could safely move from 350 to 250 and still be in compliance with PPAC.
- "Q Did you conduct any other analysis, other than looking at the par median rates?
 - "A I don't know if we did."
- 22 Did I read that right?
- 23 A Yes, you did.
 - Q Okay. You began the answer with you don't know specifically what was done, right?

| 1 | A | Right. I did not conduct the analytics. |
|----|------------|--|
| 2 | Q | But this was your program. OCM was your program. |
| 3 | А | OCM was an out-of-network program, yes. And I didn't do |
| 4 | the analyt | ics. |
| 5 | Q | And I mean you don't even know if there was a written |
| 6 | analysis d | one, right? |
| 7 | А | I don't know. |
| 8 | Q | Yeah, you don't know specifically if there was or was not a |
| 9 | written an | alysis done, even though you were the guy in charge, right? |
| 10 | А | Correct. I trust my group. |
| 11 | Q | Thank you, sir. And you don't know if a written analysis was |
| 12 | done, but | if we go to page is 418 in? |
| 13 | | THE COURT: I show that it is. |
| 14 | | MR. ZAVITSANOS: Okay. |
| 15 | | THE COURT: Defendant do you show 418 is admitted? |
| 16 | | MR. BLALACK: Your Honor, I think that's a conditional, I |
| 17 | thought. | |
| 18 | | MR. ZAVITSANOS: No, I thought it was |
| 19 | | MR. BLALACK: Oh, it's in. My apologies. It is in, Your |
| 20 | Honor. | |
| 21 | | MR. ZAVITSANOS: 418. |
| 22 | | THE COURT: Just a minute. |
| 23 | | THE WITNESS: Can I get it? |
| 24 | | MR. ZAVITSANOS: Sure. And Michelle while Mr. Haben is |
| 25 | doing that | , can we from here to here, please? And Michelle, follow me |

| 1 | here Hia | hlight this, and highlight this, and then highlight attachments. |
|----|------------|--|
| 2 | Okay. | inight and, and inginight and, and then inginight attachments. |
| 3 | Okay. | THE WITNESS: Can I just |
| | DV MD 7 | AVITSANOS: |
| 4 | _ | |
| 5 | Q | So this is |
| 6 | А | Can I take a look please? |
| 7 | Q | Sure. Take your time. |
| 8 | | [Witness reviews document] |
| 9 | А | Okay. I can I'll ask questions if I need to. |
| 10 | Q | So this is Ms. Paradise writing to you with an attachment, |
| 11 | right? | |
| 12 | А | I believe so. |
| 13 | Q | And go to the go to page 3, please. Who prepared this |
| 14 | attachmei | nt? |
| 15 | А | I believe I probably did. |
| 16 | Q | Yeah, page 3, Exhibit 1 418, page 3. |
| 17 | | MR. ZAVITSANOS: Pull out the whole thing, Michelle. And |
| 18 | please hig | hlight the name. |
| 19 | BY MR. Z | AVITSANOS: |
| 20 | Q | Is that you? |
| 21 | А | That's my name. |
| 22 | Q | Okay. So this is a privileged and confidential report. Let's go |
| 23 | to the nex | t page, page 4. Okay. This is a little hard to read, Mr. Haben. |
| 24 | А | Yeah, I'm not able to read it. |
| 25 | Ω | Okay. Here's what I'm going to |

| 1 | | MR. ZAVITSANOS: Michelle, can you close this out? And I |
|----|------------|--|
| 2 | want you | to pull out this part right here. See if we can read it a little |
| 3 | easier. Th | e report that Mr. Haben prepared. Okay. |
| 4 | BY MR. ZA | AVITSANOS: |
| 5 | Q | So this is your report, right? |
| 6 | А | Yes. My team helped me put it together. |
| 7 | Q | Thank you. Okay. Okay. So effective March of '19, ASO |
| 8 | Profession | nal now, that's ER doctors that includes ER. doctors, right? |
| 9 | | MR. ZAVITSANOS: Hold on, Michelle. |
| 10 | BY MR. ZA | AVITSANOS: |
| 11 | Q | That includes ER doctors, professional, right? |
| 12 | А | I am not always ERs are not always in the professional |
| 13 | services. | |
| 14 | Q | The doctors, sir. Not the facilities. |
| 15 | А | I'm sorry, but I've got to look at the context. |
| 16 | Q | Anyway, well, let me keep going. |
| 17 | А | Okay. |
| 18 | Q | ASO professional and facility ER reimbursement reduced |
| 19 | from 350 t | to 250 of CMS or Data iSight, whichever is greater, right? |
| 20 | А | Yes, I do see that. |
| 21 | Q | So you prepared the report identifying what's going to |
| 22 | happen, b | ut you don't know what documentation there is to justify that? |
| 23 | А | My team put the report together, and I presented it. |
| 24 | Q | It's got your name on it, sir. |
| 25 | Α | Yeah, but I don't write all my documents. |

| C | > | |
|---|---|--|
| C | > | |
| C | 2 | |
| O | 0 | |
| Ň | ٥ | |
| ~ | 7 | |

| • | | Okay. Timean wir. Haben, you all just kind of reached in the |
|----|-------------|--|
| 2 | pocket and | l just pulled out a number, right? |
| 3 | | MR. BLALACK: I object to form. Argumentative. |
| 4 | | THE COURT: Sustained. |
| 5 | BY MR. ZA | VITSANOS: |
| 6 | Q | Mr. Haben, you just picked whatever number you wanted, |
| 7 | right? | |
| 8 | А | I disagree. |
| 9 | | MR. ZAVITSANOS: Michael is 273 in? |
| 10 | | MR. KILLINGSWORTH: Yes. |
| 11 | BY MR. ZA | VITSANOS: |
| 12 | Q | All right. Let's go back to 273, page 2. |
| 13 | А | Okay. Let me get it. |
| 14 | Q | Yes, sir. And this is November of '19. Towards the latter part |
| 15 | of the time | line. Okay. So please go to page 8. Now we've seen similar |
| 16 | language i | n other documents. In '16, in '17, in '18. Now we're in '19. |
| 17 | And what y | you all are telling yourselves internally is there's an |
| 18 | opportunit | y every second to achieve high margins, right? |
| 19 | А | I don't know this document. I didn't write it. |
| 20 | Q | That's what it says, right? |
| 21 | А | Where does it say that? |
| 22 | Q | At the top. |
| 23 | А | Oh, I'm sorry. |
| 24 | Q | In big letters. |
| 25 | А | Yep, I see it. |
| | | |

| 5 |
|----|
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |

17

18

19

20

21

22

23

24

1

2

3

4

| | Q | Okay. And the other thing it says is ASO profitability is |
|-------|--------|--|
| drive | n heav | rily by making the customer buy the extended warranty of the |
| rustp | roofin | g. |

MR. BLALACK: Object to form. Argumentative.

THE COURT: Overruled.

THE WITNESS: Where does it say that?

BY MR. ZAVITSANOS:

- Q ASO profitability is driven heavily by add-on sales and shared savings pricing. Mechanisms deployed by nationals, right?
 - A That's what that says.
- Q Yeah. So the PMPM, that's the one fee. But then the add-on fees, like the percentages for this new PCOC mechanism, that's going to help achieve high margins, right?
 - A I don't agree with your statement.
- Q So Mr. Haben, if you are charging more in premiums, and you're paying way less, and you're constantly cutting, premiums are going up and reimbursements are going down, profits are going to be at record levels, right?
 - A I would disagree.
 - O The profits United had in '19 were at record levels, right?
 - A I don't know that.
- Q Exhibit 220. And let's please -- oh, hold on. Exhibit 220, page 1.
- A Okay. I need to get that.
- 25 Q Yes, sir.

| 000828 | | |
|--------|--|--|
| | | |

| 1 | | MR. ZAVITSANOS: Michelle, will you pull up the title and the | |
|----|-----------------------|--|--|
| 2 | date, pleas | se? | |
| 3 | BY MR. ZA | AVITSANOS: | |
| 4 | Q | Okay. | |
| 5 | А | Can I get there, please? | |
| 6 | Q | Yes, sir. | |
| 7 | А | Okay. | |
| 8 | | MR. ZAVITSANOS: And let me ask counsel first, Your Honor, | |
| 9 | if he has a | n objection to 220, and also if he has an objection to 380. | |
| 10 | | MR. BLALACK: I believe 220 has been conditionally | |
| 11 | admitted, Your Honor. | | |
| 12 | | MR. ZAVITSANOS: Yeah, I'm asking for unconditional | |
| 13 | admission | of 220 and the admission of 380. And I just want to ask | |
| 14 | counsel fir | st, before I go through this. | |
| 15 | | MR. BLALACK: No objection to 380. And on 220, no | |
| 16 | objection t | to 220. | |
| 17 | | THE COURT: Exhibits 220 and 380 will be admitted. | |
| 18 | | [Plaintiffs' Exhibit 220 and 380 admitted into evidence] | |
| 19 | BY MR. ZA | AVITSANOS: | |
| 20 | Q | 220, page 8. SSPE utilizes a vendor that prices the claims. | |
| 21 | Now there | 's some proprietary pricing logic. You see that? | |
| 22 | А | I do. | |
| 23 | Q | That sounds official. Would you agree? | |
| 24 | А | It sounds like it's proprietary. | |
| 25 | Q | Okay. Proprietary means we're going to that there's a | |
| | | | |

| 1 | secret way | that we do this, and I can't really tell you. Like the formula to |
|----|-------------|---|
| 2 | Coke, that | 's proprietary, right? |
| 3 | А | Which question are you asking me? |
| 4 | Q | The formula to Coke is proprietary. That's what people |
| 5 | typically s | ay, right? |
| 6 | А | I would assume so. |
| 7 | Q | Okay. Propriety means you're not going to get to go behind |
| 8 | the curtair | and see what the reserve officer is doing, right? |
| 9 | А | I would disagree with that characterization. |
| 10 | Q | Let's now go to Exhibit 380 and see if we can get to the |
| 11 | bottom of | this Data iSight issue. 380. Out |
| 12 | А | Can I get it? |
| 13 | Q | Yes, sir, please. |
| 14 | | MR. ZAVITSANOS: And Michelle, while he's doing that, let's |
| 15 | go to page | e 10, please. Okay. |
| 16 | | THE WITNESS: Can I just |
| 17 | | MR. ZAVITSANOS: Further down, Michelle. |
| 18 | | THE WITNESS: Can I just take a quick peek, please? |
| 19 | | MR. ZAVITSANOS: I just need the part on Data iSight. All |
| 20 | the way do | own. Okay. And Michelle follow me here. Right here, |
| 21 | Michelle. | Highlight this last sentence. |
| 22 | | THE WITNESS: Can I just |
| 23 | | MR. ZAVITSANOS: Sure. |
| 24 | | THE WITNESS: take a look, please. What page are you on? |
| 25 | What page | e? |

| | , |
|--------|---|
| | |
| | |
| | 1 |
| | 1 |
| 00 | 1 |
| 000830 | 1 |
| J | 1 |
| | 1 |
| | 1 |
| | 1 |

| 1 | | MR. ZAVITSANOS: I'm on page 10. |
|----|-------------|---|
| 2 | | [Witness reviews document] |
| 3 | | THE WITNESS: Okay. |
| 4 | BY MR. ZA | AVITSANOS: |
| 5 | Q | Mr. Haben, that sounded pretty darn official. |
| 6 | А | What does? |
| 7 | Q | That definition. I mean it's a bunch of big words, and |
| 8 | acronyms | , and sources, right? |
| 9 | А | It's very complex. |
| 10 | Q | It's very |
| 11 | | MR. BLALACK: Objection. Compound. |
| 12 | | THE COURT: Objection sustained. |
| 13 | BY MR. ZA | AVITSANOS: |
| 14 | Q | This is very complex? |
| 15 | А | It's complex. |
| 16 | Q | Yeah. Have you ever seen has it ever been demonstrated |
| 17 | to you exa | actly how this proprietary method works, sir? Have you ever |
| 18 | seen it op | erate? |
| 19 | А | No, I have not seen the mechanics of it. |
| 20 | Q | What does that last sentence mean? A median conversion |
| 21 | factor is a | pplied. What does that mean? |
| 22 | А | I don't know. You will have to ask Data iSight. |
| 23 | Q | Well, this is a United document. |
| 24 | | MR. ZAVITSANOS: Page 1, please, Michelle. |
| 25 | BY MR. ZA | AVITSANOS: |
| | ī. | |

| 2 |
|----|
| 3 |
| 4 |
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
| 23 |
| 24 |
| 25 |
| |

| Q | This is a United document concerning the out of network | |
|--|---|--|
| cost management programs, right, while you were in charge? | | |
| Α | I don't know the date of this. Does it have a date on it? | |
| Q | I don't know, sir. This is your document. Do you know when | |
| this docum | ent was created? | |
| Α | I'm not super-familiar with it. | |
| | MR. ZAVITSANOS: Well, back to page 10, Michelle. Close | |
| that out. I j | ust want the Data iSight form. I want to point out one other | |
| thing. | | |
| BY MR. ZA | VITSANOS: | |
| Q | Sometimes you bury the truth in a bunch of fancy words, | |
| right, Mr. H | aben? | |
| | MR. BLALACK: Object to form. Argumentative. | |
| | THE COURT: Sustained. | |
| | MR. ZAVITSANOS: Michelle, highlight this. Claims are | |
| edited and | priced using widely recognized something. | |
| BY MR. ZA | VITSANOS: | |
| Q | Do you see that? And other and other CMS guidelines. | |
| Α | I see that. | |
| Q | Like for example, whatever United says 350 percent, that's | |
| the guidelir | ne. That's what we're going to do, right? | |
| Α | I disagree with that characterization. | |
| Q | What does that mean, other CMS guidelines? | |
| Α | I don't know. You'll have to ask MultiPlan. I believe this is | |
| their langua | age. | |

| 1 | Q | Mr. Haben, we are here in trial, and you understand that we | | |
|----|--|--|--|--|
| 2 | are saying that this Data iSight is garbage? You understand that, right? | | | |
| 3 | А | A I disagree with you. | | |
| 4 | Q | Did you think about maybe looking into before you came into | | |
| 5 | Court and explaining to the jury why this really is objective or | | | |
| 6 | proprietary, or how they do this? | | | |
| 7 | | MR. BLALACK: Object to the form. Foundation. Witnesses | | |
| 8 | are on the list. He knows that. That's an improper question. | | | |
| 9 | | THE COURT: Sustained. | | |
| 10 | BY MR. ZAVITSANOS: | | | |
| 11 | Q | Mr. Haben, did you personally look into what any of this stuff | | |
| 12 | means in this definition that was put out in your department while you | | | |
| 13 | were in charge? | | | |
| 14 | А | No, I didn't need to. | | |
| 15 | Q | Well, let's look at | | |
| 16 | | MR. ZAVITSANOS: Michael is 444 in? | | |
| 17 | | MR. KILLINGSWORTH: Yes. | | |
| 18 | BY MR. Z | AVITSANOS: | | |
| 19 | Q | Okay, let's look at another Data iSight calculation. | | |
| 20 | А | Can I go get it? Can I go get it? | | |
| 21 | Q | Yes, sir. That's the one we were talking about earlier. That | | |
| 22 | same issu | e. Let's just remember what we're talking about. | | |
| 23 | | MR. ZAVITSANOS: Up here, Michael or Michelle. | | |
| 24 | BY MR. Z | AVITSANOS: | | |
| 25 | Q | That's that AT&T document we went through earlier, right? | | |

| 1 | A Just let me get there, please. | | | |
|----|---|--|--|--|
| 2 | Q | Q Sure. The same one, right? | | |
| 3 | А | A This is the current one? This is a different binder? | | |
| 4 | Q | Yes, sir. The one that I handed you, sir. | | |
| 5 | А | Okay. The binders look different than what they were before | | |
| 6 | so I'm assuming it's' the same one. | | | |
| 7 | Q | Okay. So this is the one we discussed earlier, right? | | |
| 8 | А | A I'm assuming so. Yeah. | | |
| 9 | | MR. ZAVITSANOS: Let's go to page 2, Michelle. And let's | | |
| 10 | see how this proprietary thing works. From here to here, Michelle. | | | |
| 11 | BY MR. ZAVITSANOS: | | | |
| 12 | Q | This is an this is an EOB for Ruby Crest on an ASO claim | | |
| 13 | for AT&T, | right? | | |
| 14 | | MR. ZAVITSANOS: Highlight the first sentence, Michelle. | | |
| 15 | | THE WITNESS: Does this go with the Ruby Crest | | |
| 16 | BY MR. ZAVITSANOS: | | | |
| 17 | Q | Yes, sir. | | |
| 18 | А | provider or [indiscernible] device? Okay. | | |
| 19 | | MR. ZAVITSANOS: This keep going. Right there. | | |
| 20 | BY MR. ZAVITSANOS: | | | |
| 21 | Q | This service was provided by an out-of-network provider. | | |
| 22 | You paid the provider according to your benefits and data provided by | | | |
| 23 | Data iSigh | nt. Do you see that? | | |
| 24 | A I do. | | | |
| 25 | Q | Okay. Now let's take a look at what Data iSight did here. If | | |

| | 2 |
|---|---|
| | 3 |
| | 4 |
| | 5 |
| | 6 |
| | 7 |
| | 8 |
| | 9 |
| 1 | 0 |
| 1 | 1 |
| 1 | 2 |
| 1 | 3 |
| 1 | 4 |
| 1 | 5 |
| 1 | 6 |
| 1 | 7 |
| 1 | 8 |
| 1 | 9 |
| 2 | 0 |
| 2 | 1 |
| 2 | 2 |
| 2 | 3 |
| 2 | 4 |
| 2 | 5 |

| i | | | | |
|---|--|--|--|--|
| | we go to page 5, all right. Now do you remember we looked at that Data | | | |
| | iSight document and the Medicare break was 174.08? Remember that? | | | |
| | A Yes. | | | |
| | Q | Now okay. 99285, \$862. Allowed amount is 435, right, sir? | | |
| | А | Yes. It's hard to read, but, yes. | | |
| | Q | 435.20. | | |
| | | MR. ZAVITSANOS: Circle that, Michelle. Actually, can you | | |
| | circle the c | one above it? It's a little easier to read. 435.20. Okay. | | |
| | BY MR. ZA | VITSANOS: | | |
| | Q | Now what is 174.08 times 250 percent? | | |
| | А | Can Michael do the math? | | |
| | | MR. ZAVITSANOS: Michael? | | |
| | | MR. KILLINGSWORTH: 435.20. | | |
| | BY MR. ZA | VITSANOS: | | |
| | Q | 435.20. Wow. What a coincidence? Right, sir? | | |
| | А | 1 | | |
| | Q | That is some coincidence that this sophisticated propriety | | |
| | logic computer engine works out to exactly what you want to pay. 250 | | | |
| | percent after you drop the rate, right? | | | |
| | Α | I disagree on the characterization it's a coincidence, and I can | | |
| | explain why. | | | |
| | Q | 174.08 I don't want to put Mr. Killingsworth on the stand, | | |
| | so please say yes. 174.08 times 250 percent equals exactly what Data | | | |
| | iSight objectively determined using all that fancy language is the | | | |
| | appropriate rate, right? | | | |

| 9 |
|----|
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
| 23 |

| А | I'm sorry, I'm trying to do the math in my head. So ask the | | |
|---------------|--|--|--|
| question a | gain. | | |
| Q | You don't take issue with his math; do you? | | |
| А | You asked me to accept it, otherwise you're going to put him | | |
| on the star | ıd. | | |
| Q | Would you like his calculator? | | |
| Α | No. | | |
| Q | It's got some texts there with his girlfriend, don't read those, | | |
| okay. | | | |
| Α | No. | | |
| Q | Okay. All right. So ,Mr. Haben, come on, what's going on | | |
| here? Wha | at's going on here? | | |
| Α | On his texting? | | |
| Q | No. You got me on that one. | | |
| А | All right. You opened the door. What was your question | | |
| again? | | | |
| Q | What's going on here? How come all these how come all | | |
| the Data iS | ight things we've looked at, work out to exactly what you | | |
| want to pay? | | | |
| Α | I can explain why. | | |
| Q | Let's move on, sir. Will you please get Exhibit 230 and just | | |
| take a moment | | | |
| | MR. ZAVITSANOS: Let me ask counsel if he's opposed to the | | |
| first one. | | | |
| | MR. BLALACK: No objection, Your Honor. | | |

| 2 |
|----|
| 3 |
| 4 |
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
| 23 |
| 24 |
| 25 |

| 1 | | THE COURT: 230 will be admitted. |
|----|-------------|--|
| 2 | | [Plaintiffs' Exhibit 230 admitted into evidence] |
| 3 | BY MR. Z | AVITSANOS: |
| 4 | Q | Okay. So |
| 5 | А | Can I just get there, please? |
| 6 | Q | Sure. |
| 7 | А | Okay. |
| 8 | Q | By the way, Mr. Haben, I know that I've been asking you |
| 9 | questions | s about UnitedHealthcare, all these shared savings programs, |
| 10 | those do | not relate to the Health Plan of Nevada or Sierra, correct? |
| 11 | А | No, they do not. |
| 12 | Q | Okay. We're going to talk to someone else about that and |
| 13 | talk to the | em about why they were doing what they were doing. You |
| 14 | understa | nd? |
| 15 | А | Understood. |
| 16 | Q | Okay. Our questions are about the programs you were in |
| 17 | charge of | f, right? |
| 18 | А | Understood. |
| 19 | Q | Thank you, sir. Okay. So now we're at 230. And this |
| 20 | appears t | to be a comparison between UMR and UNET. Just I know I've |
| 21 | asked yo | u this earlier, but just refresh our recollection on what that is. |
| 22 | UNET an | d UMR. |
| 23 | А | UNET is the claims processing platform in the programs I |
| 24 | manage. | UMR is the third-party administrator that I do not have |
| 25 | roepopeil | aility for |

| 1 | Q | Okay. So | |
|----|--|---|--|
| 2 | А | I'm sorry, and they're part of UnitedHealthcare. | |
| 3 | Q | so UMR is under the United umbrella, right? | |
| 4 | А | UnitedHealthcare. | |
| 5 | Q | UnitedHealthcare. And UnitedHealthcare itself is a third- | |
| 6 | party admi | inistrator, right? | |
| 7 | А | For self-employed groups, you could characterize it that way. | |
| 8 | Q | And in addition to UnitedHealthcare, UMR is also a third- | |
| 9 | party admi | inistrator? | |
| 10 | А | Yes, they are. | |
| 11 | Q | So you've got kind of two parts of United, among others, | |
| 12 | acting as t | hird-party administrators? | |
| 13 | А | Generally, yes. | |
| 14 | Q | Right. Okay. And I'm not going to ask why. | |
| 15 | А | Yeah. | |
| 16 | Q | And UNET is a platform, right? | |
| 17 | А | It is a claims platform. | |
| 18 | Q | Yes. Okay, so let's go to page 2. And if we could, if we can | |
| 19 | pull up the | bottom part, the very bottom part. UHC and UMR | |
| 20 | opportunit | ies. All right. First of all, it uses the word opportunity like | |
| 21 | we've bee | n talking about, right? | |
| 22 | А | It does have the word opportunity. | |
| 23 | Q | And it says we're going to continue the strategy of reducing | |
| 24 | dollar and Medicare thresholds, right? | | |
| 25 | Α | Yes, it does say that. | |

| • |
|----|
| 2 |
| 3 |
| 4 |
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
| 23 |
| 24 |
| 25 |

| 1 | Q | We're just going to keep that snowball is going to keep | |
|----|--|---|--|
| 2 | going downhill, right? | | |
| 3 | А | I disagree with that characterization. | |
| 4 | | MR. BLALACK: Objection. Argumentative. | |
| 5 | | THE COURT: Overruled. | |
| 6 | BY MR. ZA | AVITSANOS: | |
| 7 | Q | That snowball is going to keep going downhill, right? | |
| 8 | А | I disagree with that characterization. | |
| 9 | Q | Okay, continuing. It says you're going to redesign for both | |
| 10 | both sid | es, redesign shared savings revenue model to transition into | |
| 11 | total cost | of care model. Do you see that? | |
| 12 | А | I do see that. | |
| 13 | Q | Okay. So you're going to keep making the same amount of | |
| 14 | money, yo | ou're just going to call it something else, right? | |
| 15 | А | I disagree with that characterization. | |
| 16 | Q | And you're doing it all in the name of egregious billing | |
| 17 | practices, | right? | |
| 18 | А | It's not just that. | |
| 19 | Q | What does it mean redesign shared savings revenue model | |
| 20 | to transition into total cost of care model? I'm going to give you the | | |
| 21 | floor, Mr. | Haben, and you explain all you want. | |
| 22 | А | I did not write this document. I believe finance did. So I | |
| 23 | don't knov | v if I can answer their question on what they mean by total | |
| 24 | cost of car | e in the revenue model. | |
| 25 | Q | So you know some of the casinos here in town, I'll get fliers | |

| 10 |
|----|
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |

from them periodically that say, hey, come out to Las Vegas, we'll give you a discounted room rate. And when I show up, I see they're charging me a resort fee. When you add those two together, it's what the old room rate used to be. You follow me?

- A Yeah.
- Q That's what you're doing here, right?
- A I disagree.

MR. ZAVITSANOS: Your Honor, how long have we been going?

THE COURT: It's a good time for a break. It's 2:06, and we started back at 12:52. So let me give you the admonition.

This will be our afternoon recess, or after lunch recess.

During recess don't talk with each other or anyone else on any subject connected with the trial. Don't read, watch, or listen to any report of or commentary on the trial. Don't discuss this case with anyone connected to it by any medium of information, including, without limitation, newspapers, television, radio, internet, cellphones or texting.

Don't conduct any research on your own relating to the case.

Don't consult dictionaries, use the internet or use reference materials.

Don't do any social media. Don't talk, text Tweet, Google issues, or conduct any other type of book or computer research with regard to any issue, party, witness, or attorney involved in the case.

Do not form or express any opinion on any subject connected with the trial until the jury deliberates. It is now 2:07. Let's be back at 2:20 sharp.

| 1 | THE MARSHAL: All rise for the jury. |
|----|---|
| 2 | THE COURT: Sir, you may step down. |
| 3 | THE WITNESS: Thank you. |
| 4 | [Jury out at 2:07 p.m.] |
| 5 | [Outside the presence of the jury] |
| 6 | THE COURT: So a couple of things. Brendon has to reboot |
| 7 | the system to get the audio to work. And you now have 189 people on |
| 8 | the phone. So I'll see you at 2:20. |
| 9 | MR. ZAVITSANOS: Thank you. |
| 10 | [Recess taken from 2:07 p.m. to 2:20 p.m.] |
| 11 | THE COURT: Please remain seated. Can we bring the jury? |
| 12 | MR. ZAVITSANOS: From the Plaintiffs, Your Honor, yes. |
| 13 | MR. BLALACK: Can we bring Mr. Haben, in, Your Honor? |
| 14 | THE COURT: Thank you. |
| 15 | [Pause] |
| 16 | THE MARSHAL: All rise for the jury. |
| 17 | [Jury in at 2:22 p.m.] |
| 18 | THE COURT: Thank you. Please be seated. Plaintiff, please |
| 19 | continue. |
| 20 | MR. ZAVITSANOS: Thank you, Your Honor. If it may please |
| 21 | the Court, counsel. Michelle, will you please pull up Exhibit 376? |
| 22 | BY MR. ZAVITSANOS: |
| 23 | Q Okay, Mr. Haben. In the movie, The Wizard of Oz, when they |
| 24 | complete the tasks that the Grand Wizard tells them to complete, they |
| 25 | come back to the Great Hall. And Toto goes up to the curtain, pulls the |
| | |

| 2 | look beh |
|----|----------|
| 3 | А |
| 4 | Q |
| 5 | started, |
| 6 | these do |
| 7 | works, r |
| 8 | А |
| 9 | a |
| 10 | |
| 11 | pages 2 |
| 12 | bottom. |
| 13 | Keep go |
| 14 | doing. |
| 15 | BY MR. |
| 16 | Q |
| 17 | that? |
| 18 | А |
| 19 | Q |
| 20 | mispron |
| 21 | you see |
| 22 | А |
| 23 | |
| 24 | BY MR. |
| 25 | Q |

curtain. And the wizard says, ignore the man behind the curtain. Don't look behind the curtain? Remember that?

- A I do.
- Q Okay. This Data iSight tool. It's correct that before this trial started, TeamHealth -- before all this stuff was assembled and we got all these documents, TeamHealth attempted to try to understand how it works, right?
 - A I don't know if that's true or not.
 - Q Well, let's look at 376.

MR. ZAVITSANOS: Michelle, there's an email that straddles pages 2 and 3. Can we pull that up, please? The front two, down to the bottom. Right there. Thank you, Michelle. All the way to the bottom. Keep going. Keep going. Nope -- oh, yeah. Okay, I see what you're doing.

BY MR. ZAVITSANOS:

- Q Okay, so. "Subject: Data iSight TeamHealth"; do you see that?
 - A I do.
- Q Okay. And it looks like this Michael -- and I may be mispronouncing it, so forgive me if I do -- McEttrick is with MultiPlan. Do you see that signature line at the bottom?
 - A I do.
- MR. ZAVITSANOS: Michelle, can you highlight, that please?
 BY MR. ZAVITSANOS:
 - And he's a vice president like you, right? With MultiPlan?

| 000842 | | | |
|--------|--|--|--|
| | | | |
| | | | |

| O Okay. And this Mike Bandomer and Susan Dominey; they | y're |
|--|------|

MultiPlan Data iSight, right?

Α

A I don't know who they are.

He is a vice president.

Q Okay. We're going to catch up in just a minute, but let's see what this email says. From Mr. McEttrick to these two people.

with United, right? Oh, excuse me. No. They're with -- they're also with

MR. ZAVITSANOS: Okay. Hold on, Michelle. Don't highlight anything -- actually, let's get rid of all the highlighting. Okay.

BY MR. ZAVITSANOS:

Q "Good afternoon, Susan and Mike. Have you ever met with a provider to provide some general education on Data iSight? Bruce's contact at TeamHealth, Kent Bristow, has requested a meeting with someone from our organization knowledgeable about Data iSight to learn more about the pricing methodology. It would mainly be just HCFA" -- what does that stand for, sir?

- A I'm not sure the acronym. It's what we call [hic-fa].
- Q Okay, whatever.

"It would mainly be just HCFA pricing that impacts

TeamHealth. Bruce was planning on including me in a meeting with

Kent, but I let him know that neither Sean Crandell nor I have ever

discussed this with a provider. We are typically involved on the client side". Do you see that?

A I do.

MR. ZAVITSANOS: Okay. So let's stop right there. Michelle,

| 3 |
|----|
| 4 |
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
| 23 |
| 24 |
| 25 |

2

right here. So if -- render from here to here.

BY MR. ZAVITSANOS:

Q So it looks like what that's saying is because the umpire is on team United, they don't talk about this with doctors, right?

A No --

MR. BLALACK: Objection to form and also foundation.

THE COURT: Sustained.

BY MR. ZAVITSANOS:

Q This is -- this literally says these two people have never discussed this, never, with a provider. "We are typically involved on the client side", right?

A They said they have -- nor they have ever discussed, so I'm assuming that means never.

Q Yeah. That, "neither Sean nor I have ever discussed this with a provider. We are typically involved on the client side. I am okay with handling the call if needed, but figured I would check in case this is something either of you have more experience handling. It is obviously a fine line to walk with providing enough information to satisfy the provider without going too much in detail about a proprietary pricing methodology that impacts their claims," right?

- A That's what that says, yes.
- Okay. So let's see what happened.

MR. ZAVITSANOS: Let's go -- and this is July 8. And we can go to page 1. At the bottom. From here to here. All the way down. BY MR. ZAVITSANOS:

| 1 | Q | Okay. July 10th, 2019. "Mike, if Sean is available this |
|----|-------------|--|
| 2 | morning, | can he join us on the call? Gail really wants you or Sean, and |
| 3 | he knows | Sean has done this with customers." Customers are you, |
| 4 | right? Yo | u're the customer? The insurer is the customer? |
| 5 | А | I didn't write this. I don't know what he means. |
| 6 | Q | Well, the customers of MultiPlan. I mean, we saw it in the |
| 7 | email. Th | ey're normally on the insurer side. The customer is the |
| 8 | insurance | company, right? |
| 9 | А | So it could be us, Aetna, Cigna, Blue |
| 10 | Q | Fair enough. |
| 11 | | MR. ZAVITSANOS: Michelle, highlight this. |
| 12 | BY MR. ZA | AVITSANOS: |
| 13 | Q | "We're trying to keep it high-level with TeamHealth," right? |
| 14 | А | That's what that says. |
| 15 | Q | Meaning we're going to talk in generalities and use those big |
| 16 | fancy term | ns, but we're not going to look behind the curtain to get a look |
| 17 | at who the | e Wizard of Oz really is, right? |
| 18 | А | I disagree. You'd have to ask Bruce. |
| 19 | Q | Well, what we know is you don't fault TeamHealth before we |
| 20 | go to trial | here. We're trying to understand this because he maybe |
| 21 | maybe if v | we're getting it wrong, and maybe there is some substitute. |
| 22 | You don't | fault us for that, do you? |
| 23 | А | I don't know what Kent's intent was. |
| 24 | Q | If that was his intent, Mr. Haben, would you agree with me |

that you don't fault us for trying to figure out before we tie up a court

| 2 |
|----|
| 3 |
| 4 |
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
| 23 |
| 24 |
| 25 |

| 1 | and jurors for a long period of time maybe we got it wrong; let's try to | | |
|----|--|--|--|
| 2 | get to the bottom of this? | | |
| 3 | А | I have no issue with that. | |
| 4 | Q | Okay. And when we did it, we didn't have Toto to go behind | |
| 5 | the curtair | n, right? | |
| 6 | | MR. BLALACK: Objection to form. | |
| 7 | | MR. ZAVITSANOS: Let me rephrase. | |
| 8 | | THE COURT: The objection is sustained. | |
| 9 | BY MR. Z | AVITSANOS: | |
| 10 | Q | When we did that, Mr. Haben, according to this, all we got | |
| 11 | was the ki | nd of high-level stuff we looked at on that description, which | |
| 12 | all circulat | ed internally, right? | |
| 13 | А | I don't know what the discussion was. You'd have to ask | |
| 14 | Bruce. | | |
| 15 | Q | Okay. Now | |
| 16 | | Okay. Okay, Mr. Haben. Let's go to Exhibit | |
| 17 | | MR. ZAVITSANOS: Michael, there's [indiscernible] please. | |
| 18 | BY MR. ZA | AVITSANOS: | |
| 19 | Q | While he's looking for that, let's go to 246, page 3. Okay. | |
| 20 | А | I need I need to go get that. | |
| 21 | Q | Sure. Okay. Mr. Haben | |
| 22 | А | Hold on. Hold on. | |
| 23 | Q | Yes, sir. All right. Now, let me see if we can catch up to | |
| 24 | where we | are here. So we've talked about the wrap networks. We've | |
| 25 | talked abo | out reasonable and customary. We've talked about OCM. Now | |
| | | | |

| 1 | we're at El | NRP, right? That's the latest alleged program, right? ENRP, |
|----|------------------------|--|
| 2 | right, sir? | |
| 3 | А | It's a program that we have, yes. |
| 4 | Q | And this is the one with the single highest discount, right? |
| 5 | А | ENRP prices at a par median rate. |
| 6 | Q | This is the one with the highest discount. 70 to 79 percent, |
| 7 | right? | |
| 8 | А | Yes. |
| 9 | Q | And in fact and Mr. Killingsworth is looking for it there is |
| 10 | a later ver | sion that says discounts up to 85 percent, right? |
| 11 | А | The more the providers charge, the deeper the reduction |
| 12 | based on t | he par median. |
| 13 | Q | There is a later version that says up to 85 percent reduction |
| 14 | under this | ENRP, right? |
| 15 | А | I would have to see it. And I'll take a look at it if you find it. |
| 16 | Q | Now, one thing you told the jury was that ENRP is free, right? |
| 17 | А | We did not charge for ENRP at that time. |
| 18 | Q | Right. And so what you did was we looked at the |
| 19 | document | s that talked about repackaging or redesigning. Remember the |
| 20 | redesigning documents? | |
| 21 | А | I believe so. |
| 22 | Q | Now, let's go to Exhibit 354. |
| 23 | А | It's going to take me a little bit. I got to fold these back. |
| 24 | Q | Yes, sir. |
| 25 | Α | 354? |

| 1 | Q | Yes, sir. |
|----|----------|--|
| 2 | | MR. BLALACK: Hey, John? |
| 3 | | MR. ZAVITSANOS: Yeah. |
| 4 | | MR. BLALACK: May we approach, Your Honor? |
| 5 | | THE COURT: You may. |
| 6 | | MR. ZAVITSANOS: Michelle, take that down, please. |
| 7 | | [Sidebar at 2:37 p.m., ending at 2:37 p.m., not transcribed] |
| 8 | | THE COURT: Thank you, both. |
| 9 | | MR. ZAVITSANOS: May I proceed, Your Honor? |
| 10 | | THE COURT: Yes. |
| 11 | | MR. ZAVITSANOS: Okay. Okay. Michelle, pull that back up. |
| 12 | What exh | ibit was that? |
| 13 | | MS. RIVERS: 354. |
| 14 | | MR. ZAVITSANOS: I'm sorry? |
| 15 | | MS. RIVERS: 3-5-4. |
| 16 | | MR. ZAVITSANOS: 3-5-4. Thank you, Michelle. |
| 17 | BY MR. Z | AVITSANOS: |
| 18 | Q | Okay, so. Okay. So now, we're in 2019 midyear, end of May, |
| 19 | right? | |
| 20 | А | Yes. |
| 21 | Q | And this is written to the CEO of United, Dan Schumacher, |
| 22 | right? | |
| 23 | Α | It's Dan Schumacher is on there, yes. |
| 24 | Q | Dan Schumacher is CEO of UnitedHealthcare? |
| 25 | А | I believe Steve Nelson was the CEO of UnitedHealthcare. |
| | | |

| 000848 | | | |
|--------|--|--|--|
| | | | |
| | | | |

| 1 | Q | What was Mr. Schumacher's title at this time? |
|----|-------------|---|
| 2 | А | I believe he was the I could be wrong. I thought he was |
| 3 | just the co | mmercial book of business CEO. |
| 4 | Q | Fair enough. The commercial book of business CEO, which |
| 5 | covers the | area we're talking about, right? |
| 6 | А | Yes. |
| 7 | Q | Okay. And it looks like after you all launched this ENRP, and |
| 8 | after you - | - after the documents we saw that said, we're going to |
| 9 | redesign t | o take Shared Savings and go to Total Cost of Care. After that |
| 10 | date, this | gentleman is writing to the CEO and says, whatever this Project |
| 11 | Airstream | is which we're going to talk about in a minute. This is one |
| 12 | play to rep | place the Shared Savings earnings stream over time. You see |
| 13 | that? | |
| 14 | А | I do. |
| 15 | Q | So you're migrating over to Total Cost of Care, which is |
| 16 | going to ra | aise the PMPM fee. But like the movie, The Blob, you want |
| 17 | more and | now, you're coming up with something to replace the Shared |
| 18 | Savings ea | arnings stream, right? |
| 19 | | MR. BLALACK: Objection to form. Compound. |
| 20 | | MR. ZAVITSANOS: Let me rephrase. |
| 21 | BY MR. ZA | AVITSANOS: |
| 22 | Q | The highest levels of the company are looking at a play to |
| 23 | replace th | is Shared Savings earnings stream, right? |
| 24 | А | That's what Saurabh has put in there. |
| 25 | Q | And that is Project Airstream. Naviguard, right? |

| 2 |
|----|
| 3 |
| 4 |
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
| 23 |
| 24 |
| 25 |
| |

| 1 | Α | Project Airstream is a member advocacy program. |
|----|-------------|--|
| 2 | Q | Would you please look at Exhibit 477 before we get into |
| 3 | Naviguard | d? Just so we can button this up? |
| 4 | А | I got to go get that. |
| 5 | Q | What's the standard tip on a restaurant bill, Mr. Haben? |
| 6 | А | I don't know what people's standard is. I give 20 percent. |
| 7 | Q | I'm sorry? |
| 8 | А | I don't know what the standard is. I give 20 percent. |
| 9 | Q | Okay. Now, let's go to 477. And this is, I believe, the latest |
| 10 | version of | the out-of-network programs before you left. |
| 11 | А | I don't know the date of this. |
| 12 | | MR. ZAVITSANOS: Well, actually, don't pull it up yet, |
| 13 | Michelle. | Can I ask Counsel if he has an objection to it, Your Honor? |
| 14 | | MR. BLALACK: I have no objection to this exhibit. |
| 15 | | THE COURT: Okay. And the number again? |
| 16 | | MR. ZAVITSANOS: 477. |
| 17 | | THE COURT: 477 will be admitted. |
| 18 | | [Plaintiffs' Exhibit 477 admitted into evidence] |
| 19 | BY MR. Z | AVITSANOS: |
| 20 | Q | Okay. So out-of-network programs; do you see that? |
| 21 | А | I do. |
| 22 | Q | Let's go to page 2. And so if the jury wanted to get where |
| 23 | this five-y | ear period, we're talking about ends up, they should go to |
| 24 | Exhibit 47 | 7, page 2 because that lays out all the programs, the latest and |
| 25 | greatest, ı | right? |
| | | |

| 2 | Q | Well, let me move on. | | | |
|----|---------------|--|--|--|--|
| 3 | | MR. ZAVITSANOS: Now, Michelle, highlight this last one | | | |
| 4 | here. "ENRP". | | | | |
| 5 | BY MR. ZA | AVITSANOS: | | | |
| 6 | Q | By this time, the discount off of our bill charge is 85 percent, | | | |
| 7 | right? | | | | |
| 8 | А | That's what that says. Yes. | | | |
| 9 | Q | That means we're getting 15 percent of our bill charge, right? | | | |
| 10 | А | That also could mean that your bill charges are going up | | | |
| 11 | compared | to par median. | | | |
| 12 | Q | That means we're getting 15 percent of our bill charge, right? | | | |
| 13 | А | To the staffing companies, yes. | | | |
| 14 | Q | Okay. Now, everybody in our society serves a valuable | | | |
| 15 | function, r | ight? | | | |
| 16 | А | Of course. | | | |
| 17 | Q | Okay. Would you agree with me that doctors are at least as | | | |
| 18 | important | as waiters? | | | |
| 19 | А | Everybody's important. | | | |
| 20 | Q | Would you agree with me that emergency room doctors are | | | |
| 21 | at least as | important as waiters? | | | |
| 22 | А | Extremely. | | | |
| 23 | | MR. ZAVITSANOS: Okay. Now, Michelle, what was the last | | | |
| 24 | exhibit we | pulled up? Project Airstream? | | | |
| 25 | | MR. KILLINGSWORTH: 354. | | | |

I don't know what you mean by "ends up".

Α

| 2 |
|----|
| 3 |
| 4 |
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
| 23 |
| 24 |
| 25 |

| 1 | | MR. ZAVITSANOS: 354. |
|----|------------|---|
| 2 | BY MR. Z | AVITSANOS: |
| 3 | Q | Let's go back to 354. |
| 4 | А | Can I put this one away? |
| 5 | Q | Sure. |
| 6 | А | 354? |
| 7 | Q | Yes, sir. |
| 8 | | THE COURT: There's someone on the phone who needs to |
| 9 | mute ther | nself. Hello? This is the judge. There's someone who needs to |
| 10 | mute ther | nselves. Someone's on the phone. I think we're better? Thank |
| 11 | you. Plea | se proceed. |
| 12 | | MR. ZAVITSANOS: Thank you, Your Honor. |
| 13 | BY MR. Z | AVITSANOS: |
| 14 | Q | Okay, Mr. Haben. |
| 15 | | MR. ZAVITSANOS: So Michelle, pull up the top email just so |
| 16 | we can or | ient ourselves again. |
| 17 | BY MR. Z | AVITSANOS: |
| 18 | Q | Now, this is kind of a business term. But when somebody |
| 19 | says, this | is the play, that's a vehicle to make money, right? |
| 20 | Α | I disagree. You'd have to ask Saurabh what he meant. |
| 21 | Q | Well, during your how many accounting courses did you |
| 22 | take to ge | t your degree? |
| 23 | Α | I have no idea. I don't remember. |
| 24 | Q | Well, if typically, it's about 12 to 14 classes over 4 years; |
| 25 | does that | sound about right? |
| | Ī | |

| 1 | A | it feit like that. Yean. | | | |
|----|--|--|--|--|--|
| 2 | Q | So during those 12 to 14 classes in accounting reading | | | |
| 3 | balance sheets and debits and credits, you never heard about what this | | | | |
| 4 | kind of bu | ısiness term; an investment play, a merger play? You never | | | |
| 5 | heard tha | t term? | | | |
| 6 | А | No, not in accounting, no. | | | |
| 7 | Q | Okay. Well, let's look at what the play is. Let's go to the next | | | |
| 8 | page. So | the play is Project Airstream. | | | |
| 9 | | MR. ZAVITSANOS: And let's pull out the date. | | | |
| 10 | BY MR. Z | AVITSANOS: | | | |
| 11 | Q | So this is around the time that you all had gotten to this, the | | | |
| 12 | 15 percen | t, right? This is the end of the journey for purposes of our | | | |
| 13 | five-year | discussion, right, Mr. Haben? | | | |
| 14 | А | I'm sorry. What are you asking me? | | | |
| 15 | Q | Remember we talked about this five-year time period? | | | |
| 16 | А | Yes. | | | |
| 17 | Q | This is at the end of that five-year time period, right? | | | |
| 18 | А | Oh, I'm sorry. Yeah. Because what the time period ends | | | |
| 19 | Q | Well, the time period ends in January 2020. | | | |
| 20 | А | 2020. | | | |
| 21 | Q | This is towards the backend of it, right? | | | |
| 22 | А | Yes. | | | |
| 23 | | MR. ZAVITSANOS: Okay. Let's go to the next page, | | | |
| 24 | Michelle. | All right. Pull that out. Let's see what's going on here. | | | |
| 25 | | MR. BLALACK: Counsel? Just, Counsel. Your Honor, just so | | | |
| | | | | | |

| 000853 | | | |
|--------|--|--|--|
| | | | |
| | | | |
| | | | |

| I | you knov | w may i approach Counsel, Your Honor? |
|----|-----------|---|
| 2 | | THE COURT: You may. Take that down for him. Take it |
| 3 | down. | |
| 4 | | MR. ZAVITSANOS: Ma'am? Take it down, Michelle. |
| 5 | | [Sidebar at 2:48 p.m., ending at 2:48 p.m., not transcribed] |
| 6 | BY MR. 2 | ZAVITSANOS: |
| 7 | Q | Okay. Mr. Haben. All right. So here's what we're going to |
| 8 | do. So | the part I'm going to ask you about, is Multiplan went from |
| 9 | being a | valuable partner |
| 10 | | MR. ZAVITSANOS: Right here. Highlight that, all the way. |
| 11 | BY MR. 2 | ZAVITSANOS: |
| 12 | Q | Multiplan is not a problem, right? |
| 13 | А | It does not say that Multiplan is a problem. |
| 14 | Q | Wrap networks, i.e. "I.E." means it's some Latin thing, in |
| 15 | other wo | ords, right? |
| 16 | А | I don't know what I.E. means, but yeah, I think it means other |
| 17 | words. | |
| 18 | Q | Okay. Wrap networks, in other words, Multiplan, perpetuate |
| 19 | the out-o | of-network problem, right? |
| 20 | А | I didn't write this, but I can try to explain what she's tried to |
| 21 | say. | |
| 22 | Q | No, sir. I'm sorry. Oh, wait a minute, so let me get this |
| 23 | straight. | So even though you don't know what "the play" means, and |
| 24 | even tho | ough I gave you the opportunity earlier to explain why premiums |
| 25 | were go | ing up, and you couldn't, now you want to explain this, right? |
| | | |

| 0 | |
|-------|--|
|)0085 | |
| 85 | |
| 4 | |
| | |
| | |
| | |
| | |
| | |
| | |

| 1 | Α | Well, I know why the networks are an issue, and I can explain |
|----|-------------|---|
| 2 | that. | |
| 3 | Q | Let's keep going, sir. Shared savings fees are making United |
| 4 | Healthcare | e uncompetitive, right? |
| 5 | А | Yes. That's what that says. |
| 6 | Q | I mean, if you want to be competitive, why wouldn't you just |
| 7 | cut the fee | e, right? |
| 8 | А | I think in some cases they did. |
| 9 | Q | Well, okay. Solution? Oh, boy, draining the funding supply, |
| 10 | that sound | I familiar. Draining the funding supply from egregious billers, |
| 11 | by pairing | , |
| 12 | | MR. ZAVITSANOS: Circle pairing. |
| 13 | BY MR. ZA | AVITSANOS: |
| 14 | Q | Referenced-based pricing, ENRP. |
| 15 | | MR. ZAVITSANOS: Circle that, Michelle. |
| 16 | BY MR. ZA | AVITSANOS: |
| 17 | Q | With a consumer protection New Co. removing the risk for |
| 18 | members, | and here's the informed part, and generating a high return on |
| 19 | investmen | t revenue migration strategy, right? |
| 20 | А | Yes. I do see that. |
| 21 | Q | Okay. So Multiplan was the problem, and what you're going |
| 22 | to do is yo | ou're going to go to 15 percent, and you're going to start a new |
| 23 | company, | and you're going to charge for that new company, and you're |
| 24 | going to p | air it, and that's going to generate a high return on investment, |
| 25 | right? | |

| | 3 |
|---|---|
| | 4 |
| | 5 |
| | 6 |
| | 7 |
| | 8 |
| | 9 |
| 1 | 0 |
| 1 | 1 |
| 1 | 2 |
| 1 | 3 |
| 1 | 4 |
| 1 | 5 |
| 1 | 6 |
| 1 | 7 |
| 1 | 8 |
| 1 | 9 |

| | Α | There are some pieces in there that are incorrect, of what you |
|-------|---------|---|
| said. | | |
| | Q | Is there anything on this page that you know to be wrong? |
| | Α | I didn't write this document. |
| | Q | But you can explain? |
| | Α | Because you said something that was incorrect. |
| | | MR. ZAVITSANOS: Okay. Let's go to the next page. |
| Actua | ally, h | old on Michelle. Okay, page 6. Okay, so we're still on the |
| play, | move | this up. |
| BY M | IR. ZA | VITSANOS: |
| | Q | And this NewCo which is Project Airstream, which is which |
| beca | me Na | viguard, in connection with ENRP. And by the way, MultiPlan |
| is no | t invol | ved with the ENRP, right? |
| | Α | No, they are not. |
| | Q | Right. So right off the bat, not only are you paying even less, |
| you'r | e savi | ng \$300 million a year by not paying Multiplan, right? |
| | Α | If everybody converts over to ENRP, we would not have to |
| use a | vend | or. |
| | Q | Yeah. So we're not talking about this ENRP, this new thing, |
| and p | pairing | it with this NewCo, and the purpose of it is a solution; what |
| do yo | ou list | first, in the list of benefits. |
| | | MR. ZAVITSANOS: Michelle, highlight that. |
| BY M | IR. ZA | VITSANOS: |
| | Q | What's first? |
| | Α | I'm sorry, what's oh, retains revenue? |

| 000856 | | | |
|--------|--|--|--|
| | | | |
| | | | |

| 1 | Q | Yeah. |
|----|---------------|---|
| 2 | А | Yes. |
| 3 | Q | Okay. |
| 4 | | MR. ZAVITSANOS: So let's now go to page 21. Right there, |
| 5 | Michelle. | The box, the whole box. |
| 6 | BY MR. ZA | AVITSANOS: |
| 7 | Q | Okay. There is a path to building a \$200 million business in |
| 8 | five years. | |
| 9 | | MR. ZAVITSANOS: Michelle, right here, please. |
| 10 | | MR. BLALACK: John, what's on the document. |
| 11 | | THE COURT: Take that down |
| 12 | | MR. ZAVITSANOS: I'm not going to mention the |
| 13 | | THE COURT: Okay. Thank you. |
| 14 | | MR. ZAVITSANOS: Okay. Pull that back up, Michelle? Thank |
| 15 | you, coun | sel. Pull that back up, please, it's page 21. Okay. Pull it up. |
| 16 | BY MR. ZA | AVITSANOS: |
| 17 | Q | And I'm not going to read the numbers, Mr. Haben, I'm just |
| 18 | going to h | ave Michelle highlight |
| 19 | | MR. ZAVITSANOS: Michelle, follow me, right here, the third |
| 20 | right, all th | ne way across, all the way across. And if you will circle this |
| 21 | last line. (| Okay. And Michelle, will you please highlight this. |
| 22 | BY MR. BL | ALACK: |
| 23 | Q | So I'm not going to mention the number, but that's up on the |
| 24 | screen, rig | ht, sir, in a circle? |
| 25 | А | Which number? |
| Į. | | |

| 1 | Q | The number of what you are projecting this NewCo |
|----|---------------|--|
| 2 | | MR. ZAVITSANOS: Michelle, I need you to keep those |
| 3 | highlights of | on this. And circle that number, please. Thank you, Michelle. |
| 4 | BY MR. ZA | VITSANOS: |
| 5 | Q | Okay. So this Naviguard the project that became |
| 6 | Naviguard, | this is the projection now, right, of what where you want to |
| 7 | end up by 2 | 2024, right? |
| 8 | А | That's from the Ventures Group. |
| 9 | Q | Right. And this is in addition to this migration to the TCOC |
| 10 | fee that we | 've talked about, right? |
| 11 | А | I disagree. |
| 12 | Q | Okay. |
| 13 | | MR. ZAVITSANOS: Take that down, Michelle. Okay. Let's |
| 14 | go to page | 26. |
| 15 | BY MR. ZA | VITSANOS: |
| 16 | Q | Okay. Problem Gap solution detail. Do you see that? |
| 17 | А | I do. |
| 18 | Q | All right. So |
| 19 | | MR. ZAVITSANOS: Highlight, Michelle. |
| 20 | BY MR. ZA | VITSANOS: |
| 21 | Q | What does Gap mean, do you know? |
| 22 | А | I don't know. You'll have to ask who wrote the document. |
| 23 | Q | Is that a [indiscernible] store. It's a joke. Okay. MultiPlan or |
| 24 | other wrap | networks perpetuate the problem, right? |
| 25 | А | That's what that says. |
| | 1 | |

| 000858 | | | |
|--------|--|--|--|
| | | | |
| | | | |
| | | | |
| | | | |

| 1 | Q | And it looks like this, this NewCo |
|----|-------------|---|
| 2 | | MR. ZAVITSANOS: Right here Michelle. Right here, not that, |
| 3 | the next ri | ght, beside it. |
| 4 | BY MR. ZA | AVITSANOS: |
| 5 | Q | This NewCo is designed to replace shared savings. What is |
| 6 | that IOI? | |
| 7 | А | Internal operating income. |
| 8 | Q | Okay. So this new play, that was sent to your CEO, is |
| 9 | designed t | o replace |
| 10 | | MR. ZAVITSANOS: Circle "replace" Michelle. |
| 11 | BY MR. ZA | AVITSANOS: |
| 12 | Q | The shared savings internal operating income, right? |
| 13 | А | That is not what that says. |
| 14 | Q | Oh, the Gap is no revenue model to replace shared savings |
| 15 | internal op | perating income, right? |
| 16 | Α | That's what that does say. |
| 17 | Q | Okay. Well, let 's go down here. The last bullet point, on the |
| 18 | right-hand | side. And this NewCo is Naviguard, you're going to hold |
| 19 | them out a | as being a third party. In other words, they're not going to |
| 20 | have "Unit | ed" in their name, so that people don't associate them with |
| 21 | United, so | that you could tell clients you're going to a third party, just |
| 22 | like you w | ent with Multiplan. But instead of Multiplan getting the |
| 23 | money, yo | u're getting it, right? |
| 24 | А | If you were to ask them who wrote that. |
| 25 | Q | Well, positioning entity as a third party enables United |

| 000859 | | | |
|--------|--|--|--|
| | | | |
| | | | |

| 1 | Healthcare | BNI, revenue retention, and growth potential. MultiPlan, |
|----|-------------|--|
| 2 | Naviguard | , they both do the same thing, let's use Naviguard, it's a third |
| 3 | party. Rig | ht? Just like MultiPlan, we're going to replace one empire with |
| 4 | another or | ne, right? |
| 5 | А | I disagree with how you characterize that. |
| 6 | Q | Mr. Haben, let me just ask you. So what we've been looking |
| 7 | at over the | last few days, do you think this shows unchecked greed? |
| 8 | | MR. BLALACK: Argumentative, Your Honor. |
| 9 | | THE COURT: Overruled. |
| 10 | BY MR. ZA | VITSANOS: |
| 11 | Q | Do you think everything we've looked at, over the last four |
| 12 | days, dem | onstrates uncontrolled, unchecked greed? |
| 13 | А | I disagree. |
| 14 | Q | But you do agree this demonstrates greed? |
| 15 | А | I disagree. |
| 16 | Q | It's egregious. |
| 17 | А | Oh, there's context that has to be put around it. |
| 18 | Q | Well, your lawyer, in opening statement said something like, |
| 19 | these are e | egregious charges that we're seeking in this case. Now do you |
| 20 | agree they | 're egregious, or not? |
| 21 | А | I don't know if he was referring to that, or not. |
| 22 | | MR. ZAVITSANOS: Okay. Take it down, Michelle. So let's |
| 23 | go back. F | lold it. 236, is that in Michael? |
| 24 | | MR. KILLINGSWORTH: Yes. |
| 25 | BY MR. ZA | VITSANOS: |

| c | \supset | |
|---|-----------|--|
| Č | 5 | |
| ٥ | ᢓ | |
| 3 | ά | |
| (| ぢ | |

| 1 | Q | Have you ever given blood? |
|----|-------------|---|
| 2 | А | Can I go and get it? |
| 3 | Q | Yeah. And by the way |
| 4 | А | Okay. |
| 5 | Q | Are you telling the jury that it was 12 to 14 accounting |
| 6 | classes tha | at you took the term enterprise value never came up? |
| 7 | А | I don't remember, that was 30 something years ago. |
| 8 | Q | All right. Enterprise value. TCOC, total cost of care, right? |
| 9 | Right? | |
| 10 | А | Yes. |
| 11 | Q | Okay. That's the new model, that we looked at, right? That's |
| 12 | the new m | odel that we looked at earlier, that we're going to move away |
| 13 | from short | savings, into total cost of care? |
| 14 | Α | No, I disagree. |
| 15 | Q | Okay. Well, I want to go back and cover it; so let's move on. |
| 16 | Have you | ever given blood? |
| 17 | А | Yes, I have. |
| 18 | | MR. BLALACK: Your Honor, objection. Relevance? |
| 19 | | MR. ZAVITSANOS: Well, I was going to get to it. |
| 20 | | THE COURT: No. It's foundational. Overruled. |
| 21 | BY MR. ZA | VITSANOS: |
| 22 | Q | And when they stick that needle in your arm, and they pull |
| 23 | blood out | of it, do they extract it; is that extracting blood? |
| 24 | А | I think so. |
| 25 | Q | Okay. So let's look at 236, and let's go to page 2. |
| | I | |

| 1 | | MR. ZAVITSANOS: Right there, the top of that box. |
|----|-------------|---|
| 2 | BY MR. ZA | AVITSANOS: |
| 3 | Q | Okay. So we're going to ask Ms. Paradise this, but do you |
| 4 | know whe | ther Ms one of Ms. Paradise's favorite words is this word |
| 5 | glidepath | [phonetic]? |
| 6 | А | I don't know; you'd have to ask her. |
| 7 | | MR. ZAVITSANOS: Well, okay. Michelle, highlight that. |
| 8 | BY MR. ZA | AVITSANOS: |
| 9 | Q | It looks like a short term view from 2019, is reduce non-par |
| 10 | spending v | while creating a glidepath away from ASO shared savings |
| 11 | action plar | n in place. Do you see that? |
| 12 | А | I do. |
| 13 | Q | Let's see what the action plan is. |
| 14 | | MR. ZAVITSANOS: So let's go to Exhibit it's the same |
| 15 | exhibit, we | e'll get the page number, please. Let's go to page 11. |
| 16 | Michelle, I | et's pull this whole thing off the shelf. All the way down, all |
| 17 | the way do | own. Keep going. Perfect. |
| 18 | BY MR. ZA | AVITSANOS: |
| 19 | Q | All right. |
| 20 | MR. | ZAVITSANOS: First of all, where is it? There it is, right here. |
| 21 | Highlight I | Haben. |
| 22 | BY MR. ZA | AVITSANOS: |
| 23 | Q | Planning. You're on this planning document, right? |
| 24 | Α | Yes. I see my name. |
| 25 | 0 | Current shared savings revenue for ASO. And what is it in |

| 1 | 2019? What is this? | | |
|----|---------------------|---|--|
| 2 | А | It says 1.1 billion. | |
| 3 | Q | And what's the objective; read it out loud. | |
| 4 | | MR. ZAVITSANOS: Highlight that, Michelle. | |
| 5 | BY MR. ZA | AVITSANOS: | |
| 6 | Q | Will you please read it out loud? Read it out loud. | |
| 7 | | MR. ZAVITSANOS: Come on, highlight it again. | |
| 8 | BY MR. ZA | AVITSANOS: | |
| 9 | Q | Spit all out. | |
| 10 | А | Object | |
| 11 | Q | Come on, I know you can. | |
| 12 | | MR. BLALACK: Objection, Your Honor. | |
| 13 | | THE WITNESS: I can do it, if you don't interrupt me. | |
| 14 | | MR. ZAVITSANOS: I'm sorry. | |
| 15 | | THE COURT: Objection sustained. Disregard the last | |
| 16 | comment, | please. | |
| 17 | BY MR. ZA | AVITSANOS: | |
| 18 | Q | My apology. Go ahead, Mr. Haben. | |
| 19 | А | Are you ready? | |
| 20 | Q | Yes, sir. | |
| 21 | А | "Objective: And created a UHC as ACO model, to contract | |
| 22 | with client | s on total cost of care, and extract" | |
| 23 | Q | Oh, stop. | |
| 24 | А | Can I did you want me to read the whole thing? | |
| 25 | Q | No. I want you to stop right there. | |

| 2 |
|----|
| 3 |
| 4 |
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
| 23 |
| 24 |
| 25 |

| ^ | Okay | | |
|--------------|---|--|--|
| Α | Okay. | | |
| | MR. ZAVITSANOS: Michelle, circle the word "extract." Keep | | |
| going. | | | |
| BY MR. ZA | VITSANOS: | | |
| Q | Go ahead, Mr. Haben. | | |
| А | l'Il start over. | | |
| Q | Yes, sir. | | |
| А | "Objective: Created a UHC as a ACO model, to contract with | | |
| clients on a | total cost of care, and extract economics through an | | |
| administra | tive fee. " | | |
| Q | And that was you all's plan, right? You'd play in the race, for | | |
| the total co | st of care, and extract the economics through an | | |
| administra | tive fee, right? | | |
| А | You would have to ask Sarah, Randy Weinstock, and CBC. | | |
| Q | No. I'm asking the guy who's on the planning committee? | | |
| А | I'm not on that column. | | |
| Q | Did you look at this document, before it went up? | | |
| А | I don't recall the document. | | |
| Q | Well, you see the column that you are part of? | | |
| А | Yes. | | |
| Q | You're going to shift to the total cost of care story? | | |
| | MR. ZAVITSANOS: Highlight that whole thing, Michelle. | | |
| BY MR. ZA | VITSANOS: | | |
| Q | OCM driven approach with reduction in shared savings | | |
| charge fron | n 35 percent, to be determined, and opportunity to run | | |

| 2 |
|----|
| 3 |
| 4 |
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
| 23 |
| 24 |
| 25 |

| additional revenue based on total cost of care. Do you see that? | | | | | |
|--|-----------|--|--|--|--|
| | Α | I do. | | | |
| | Q | Okay. So we're going we're going to charge a higher fee, | | | |
| tota | l cost o | of care, and we're now going to charge for this New Co, that's | | | |
| pos | itioned | as a third party. More, more, more. Right, Mr. Haben? | | | |
| | Α | It doesn't say the position of New Co is a new third party. | | | |
| | Q | Sir, this is the part that you're in charge of; do you see that? | | | |
| Th | is appl | ied fully insured rates and policies to the ASO clients, right? | | | |
| | Α | Yeah. We felt that our ASO clients should have the benefit of | | | |
| wha | at fully | insured clients have. | | | |
| | Q | In other words, on the fully-insured side of the business, by | | | |
| 201 | 9 you v | vere already doing this, right? | | | |
| | Α | Clients were asking for a competitive medical cost reduction, | | | |
| yes. | | | | | |
| | Q | That's not my question, sir. By 2019, on the fully-insured | | | |
| side | , you v | vere already doing this, this total cost of care story, right? | | | |
| | Α | I disagree, that's not applicable to fully insured. | | | |
| | | MR. ZAVITSANOS: May I ask counsel if there is an objection | | | |
| to 4 | 72? Ar | nd Your Honor, I believe this is also on Defendant's exhibit list. | | | |
| | | THE COURT: They have initially objected based on | | | |
| foundation, according to my notes. | | | | | |
| | | MR. ZAVITSANOS: Yeah. This is also on their list. | | | |
| | | MR. BLALACK: No, Your Honor. We're not going to object to | | | |
| this | this one. | | | | |
| | | THE COURT: Oh. | | | |

| 4 |
|----|
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
| 23 |

| 1 | | MR. BLALACK: 472, you said? |
|----|-------------|---|
| 2 | | MR. ROBERTS: Yeah. It's already been admitted. |
| 3 | | MR. ZAVITSANOS: Oh, it has? |
| 4 | | MR. ROBERTS: Yes. |
| 5 | | MR. BLALACK: So no objection. |
| 6 | | THE COURT: 472 is admitted. |
| 7 | | [Plaintiffs' Exhibit 472 is admitted in evidence] |
| 8 | BY MR. ZA | AVITSANOS: |
| 9 | Q | Okay. So |
| 10 | | MR. ZAVITSANOS: Michelle, highlight the three bullet |
| 11 | points. | |
| 12 | BY MR. ZA | AVITSANOS: |
| 13 | Q | Mr. Haben, is this where United is headed? |
| 14 | А | Which part? |
| 15 | Q | All right. I thought I mean, this is this is where you're |
| 16 | headed, ri | ght, 140 percent of Medicare, suggesting to your reasonable |
| 17 | and custor | mary customers when they do review, and if they would insist |
| 18 | of fair hea | Ith, cap it at 50 percent, right? That's where we're headed, |
| 19 | right, sir? | |
| 20 | А | I disagree with your characterization. |
| 21 | Q | Okay. Well, you see where it says recommendations |
| 22 | findings a | nd recommendations? |
| 23 | А | I do. |
| 24 | Q | Okay. I mean, there's talk about 140 percent of Medicare, 110 |
| 25 | percent of | Medicare, right? |
| | I | |

| 000866 | | |
|--------|--|--|
| 66 | | |
| | | |
| | | |
| | | |
| | | |

| 1 | А | I see those. |
|----|--------------|---|
| 2 | Q | Down, down, down, while your profits go up, up, up, right, |
| 3 | sir? | |
| 4 | А | I disagree. |
| 5 | | MR. ZAVITSANOS: Your Honor, may I ask counsel if he has |
| 6 | an objectio | on to 270, please? |
| 7 | | MR. BLALACK: One second. No objection. |
| 8 | | THE COURT: All right. 270 will be admitted. |
| 9 | | [Plaintiffs' Exhibit 270 admitted into evidence] |
| 10 | | MR. ZAVITSANOS: Michelle, pull up page 1. All right. |
| 11 | Michelle, le | et's pull up this section here. |
| 12 | | THE WITNESS: Could I just take a quick peak, please? |
| 13 | | MR. ZAVITSANOS: Yes, sir. Just let me know when you're |
| 14 | ready. | |
| 15 | | THE WITNESS: I will. Okay. |
| 16 | BY MR. ZA | VITSANOS: |
| 17 | Q | Okay. Go to the last page of this document. |
| 18 | | MR. ZAVITSANOS: Close that out, Michelle. Let's go to 270, |
| 19 | page 12. N | lo, I need the whole org chart, please. Okay. |
| 20 | BY MR. ZA | VITSANOS: |
| 21 | Q | Who's at the top? |
| 22 | А | Myself. |
| 23 | Q | Okay. So now let's go back to page 1, the same document, |
| 24 | Exhibit 270 | . And I'm jumping around a little bit. But this is this third |
| 25 | bullet poin | t is not the ASO business, it's the fully insured business, |
| | | |

| | 6 |
|---|---|
| | 7 |
| | 8 |
| | 9 |
| 1 | 0 |
| 1 | 1 |
| 1 | 2 |
| 1 | 3 |
| 1 | 4 |
| 1 | 5 |
| 1 | 6 |
| 1 | 7 |
| 1 | 8 |
| 1 | 9 |
| 2 | 0 |
| 2 | 1 |
| 2 | 2 |
| 2 | 3 |
| 2 | 4 |
| 2 | ᄃ |

2

3

4

| meaning where you're a | acting as the | insurer, right? |
|------------------------|---------------|-----------------|
|------------------------|---------------|-----------------|

- A That is correct.
- Q And this new program, this ENRB, where you're paying 15 percent of the bill charge, has no member protection, right?
- A In this case, it's a reduction of -- we're paying between 30 and 20 percent. And the program has been in place for almost ten years at that point.
- Q Well, you see where it says, "Minimal member noise?" You see that?
 - A I do.
- O Okay. Now, did you -- did you -- under your direction, did you send a letter to all United members that were on the fully insured plans to tell them that if you get balance billed, we'll pay it? Did you do that?
- A They get an EOB that says they can call if they have questions on the reimbursement.
- Q Sir, I'm not talking about this fine print that says, call the office if you have a question. My question is when you cut these rights the way you did, did you notify the membership that if you get balance billed, United will pay for it?
 - A There's a message on the EOB.
 - Q That says that? That says what I just said?
 - A I don't know specifically what it says. But to that point.
- Q Well, the jury can look at the EOB and see if that's on there.

 My question to you is separate and apart from the EOB. While you were

| 1 | in charge, | the head man that we saw, you were at the top |
|----|-------------|--|
| 2 | А | Uh-huh. |
| 3 | Q | did you issue a directive to the members that a letter needs |
| 4 | to go out | that clearly and simply says, if you get balance billed, United |
| 5 | will pay fo | or it? |
| 6 | Α | No. There's no letter that goes out. |
| 7 | Q | And so because there's minimal member noise, maybe |
| 8 | people pa | y for it thinking they have to pay for it, what are you going to |
| 9 | do? | |
| 10 | А | The State's approve these and allow us to do this. |
| 11 | Q | The State of Nevada? Are you telling me the State of Nevada |
| 12 | approved | the CNPRP program? |
| 13 | А | I'm talking in general. I don't operate the State of Nevada. |
| 14 | Q | You don't know, do you, whether the State of Nevada has |
| 15 | anything t | to do with the NRP? |
| 16 | А | I do not. I thought you were asking me in general. |
| 17 | | MR. ZAVITSANOS: If there's long pauses of silence, it's |
| 18 | because I' | m skipping stuff, okay, that I think we've already covered. |
| 19 | | [Pause] |
| 20 | BY MR. Z | AVITSANOS: |
| 21 | Q | Pull up 344, please. So Mr. Haben |
| 22 | А | Can I get it, please? |
| 23 | Q | Yes, sir. Please. |
| 24 | | [Pause] |
| 25 | | MR. ZAVITSANOS: So Michelle, close this out. And let's pull |

24

25

Α

Q

| 1 | out right h | nere, the bottom. |
|----|-------------|---|
| 2 | BY MR. Z | AVITSANOS: |
| 3 | Q | Now, you seem to and if this is unfair, Mr. Haben, please |
| 4 | let me kno | ow. But I thought you gave me a number of I don't knows |
| 5 | when I wa | as asking you for details or on project air streak. Do you know |
| 6 | how that | delays the show? It seems that according to this document, |
| 7 | you were | one of the ones with charges, right? |
| 8 | А | I think when you asked me, you asked me what that |
| 9 | individual | intended in that document, that word or word. |
| 10 | | MR. BLALACK: I don't know what they attempted. |
| 11 | BY MR. B | LALACK: |
| 12 | Q | Yeah. I mean, according to this, John Haben was one of the |
| 13 | two peop | e tasked with this five-year roadmap critical initiative on |
| 14 | project ai | strength, right? |
| 15 | А | Yes. |
| 16 | Q | Page 2. And on page 2, again April 2019, right here. |
| 17 | You're go | ing to reduce the out-of-network restroom to part or below, do |
| 18 | you see th | nat? You see that? |
| 19 | А | I do. And emergency room physicians are the first movers. |
| 20 | Q | Oh, that's incorrect. I haven't |
| 21 | А | Excuse me, lab DME, and emergency room physicians are |
| 22 | the first m | novers, right? |

Okay. That's the part of me that -- but --

That's what that says. Yes.

| 000870 | | | |
|--------|--|--|--|
| | | | |
| | | | |
| | | | |

| 1 | Q | Yes, sir. Okay. Let's parse that out with Horn? And this |
|----|---|---|
| 2 | sounds a little redundant. But it's from a different medic. | |
| 3 | BY MR. ZA | VITSANOS: |
| 4 | Q | And this sounds a little redundant, but it's a different |
| 5 | document. | Let's see. Owe affirmed it, page 5. Very quickly. |
| 6 | | MR. ZAVITSANOS: Right here, Michelle. Problem gap |
| 7 | solution. | |
| 8 | BY MR. ZA | VITSANOS: |
| 9 | Q | And it looks like one of the problems with the NRP and the |
| 10 | reason you | couldn't deploy it full scale is the member balance billing |
| 11 | risk. You s | ee that? |
| 12 | А | Yes, I do see that. |
| 13 | Q | Yes. And this NewCo, this Project Airstream, this what is |
| 14 | it? Anyway | , this NewCo is going to drive customer and revenue |
| 15 | retention, r | ight? |
| 16 | А | That's what that says. |
| 17 | Q | All right. |
| 18 | А | And NPS. |
| 19 | Q | Yeah. So by creating so you've cut you've cut the |
| 20 | reimburser | ment rates under ENRP. The member is now exposed to |
| 21 | balance bil | ling. And now these employers are going to have to pay a |
| 22 | surcharge 1 | for Naviguard to act as a supplement because of these deep |
| 23 | discounts, | to help avoid balance billing. That's what that says? |
| 24 | А | I would disagree with how you characterize that. |
| 25 | | MR. ZAVITSANOS: Okay. Okay. 478, is that in, Michael? |

| ı |
|----|
| 2 |
| 3 |
| 4 |
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
| 23 |
| 24 |
| |

| 1 | THE WITNESS: Which one? |
|----|---|
| 2 | THE COURT: 478. |
| 3 | MR. ZAVITSANOS: Let me ask counsel first, Your Honor. |
| 4 | And if there is |
| 5 | THE COURT: Go ahead. |
| 6 | MR. ZAVITSANOS: Well, let me let me look. |
| 7 | MR. BLALACK: Your Honor, I think we have a foundation and |
| 8 | authentication |
| 9 | THE COURT: You know, it's 3:25. Let's take our last break for |
| 10 | the afternoon. |
| 11 | To the members of the jury, do not talk with each other or |
| 12 | anyone else on any subject connected with the trial during this recess. |
| 13 | Don't read, watch, or listen to any report of or commentary on the trial. |
| 14 | Don't discuss this case with anyone connected to it or by any medium of |
| 15 | information, including without limitation, newspapers, television, radio, |
| 16 | internet, cell phones, or texting. |
| 17 | Do not conduct any research on your own relating to the |
| 18 | case. Don't consult dictionaries, use the internet, or use reference |
| 19 | materials. Don't post on social media, don't talk, text, Tweet, Google |
| 20 | issues, or conduct any other type of research with regard to any issue, |
| 21 | party, witness, or attorney involved in the case. |
| 22 | Most importantly, do not form or express any opinion on any |
| 23 | subject connected with the trial until the matter is submitted to you. |
| 24 | Let's be back sharp at 3:40. And then we'll be |
| 25 | THE MARCHAL. All rice for the jury |

| 1 |
|----|
| 2 |
| 3 |
| 4 |
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
| 23 |
| 24 |
| |

| | THE COURT: we'll go to 4:45 today. |
|---|--|
| 2 | [Jury out at 3:25 p.m.] |
| 3 | [Outside the presence of the jury] |
| ļ | THE COURT: The room is clear. Plaintiff, do you have |
| 5 | anything for the record? |
| 6 | MR. ZAVITSANOS: I do, Your Honor. And this 478 merits a |
| 7 | special discussion. And if I could where's Mr. Fineberg? |
| 3 | So Your Honor, this document was not produced by |
|) | UnitedHealthcare. We found this by accident. And I'm going to let Mr. |
|) | Fineberg respond to this or address this further. I will note, the request |
| | for production's number 6, 7, 18, and 32, would make this document |
| 2 | responsive. And I do not think it is appropriate for them to lodge any |
| 3 | objection to this document in light of the fact that this was never |
| ŀ | produced, and it is a very material document. I'm going to let Mr. |
| 5 | Fineberg explain how we found it. |
| 6 | MR. FINEBERG: Our clients found it in the ordinary course of |
| 7 | business through communications with payors. They were looking up, |
| 3 | researching, trying to understand how recent claims were being paid. |
|) | They were directed to Naviguard. Went on the internet, found the |
|) | website, located the document. That link is no longer active. That link |
| | was found within the last week. |
| 2 | MR. ZAVITSANOS: And the link was taken down during the |
| 3 | course of this case. |
| L | MR_FINERERG: We found the document. We have now |

produced it to the other side and added it to our exhibit list.

| • | 4 |
|----|---|
| į | 5 |
| (| 6 |
| • | 7 |
| : | 8 |
| , | 9 |
| 10 | 0 |
| 1 | 1 |
| 1: | 2 |
| 1: | 3 |
| 14 | 4 |
| 1! | 5 |
| 1 | 6 |
| 1 | 7 |
| 18 | 8 |
| 19 | 9 |
| 2 | 0 |
| 2 | 1 |
| 2 | 2 |

| MR. BLALACK: Okay. Your Honor |
|--|
| THE COURT: Are you prepared to respond? Because if you |
| want a chance to |
| MR. BLALACK: Well, I can respond with what I know, Your |
| Honor, which is the document that's listed on this exhibit list is Plaintiffs' |
| Exhibit 478, is I have no idea what it is. But it's labeled Naviguard sub- |
| funded internal talking points. And then at the bottom, it's dated |
| January 2021, internal only use. So I don't know who created it, where it |
| came from, whose possession it was. And it appears to be some kind of |
| internal document. But it wasn't something that we have. So I'm not |
| able to address authentication of it or foundation for it. |
| MR. ZAVITSANOS: And can we reply, Your Honor? Your |
| Honor, the very first can I approach? |
| THE COURT: Only if you show it in here. |
| MR. ZAVITSANOS: At the very top, Your Honor |
| THE COURT: Hang on. You're talking over each other. |
| MR. BLALACK: I believe I referenced January 2021. And |
| what I referenced is listed up there. |
| MR. ZAVITSANOS: Oh, no, no, no. That the rest of the |

MR. ZAVITSANOS: Oh, no, no, no. That -- the rest of the sentence about January 2021 is important. And here's what it says. This is on the very first page, first sentence. "The latest updates are highlighted in yellow as of January 4, 2021." There are very few highlights on this document, meaning there was an earlier version.

Now, I do not intend to ask all of the highlights. But Your Honor, this -- this is a document that unequivocally should have been

| 1 | produced in response to the request for production. |
|----|--|
| 2 | THE COURT: Well, let's see where we get with the witness. |
| 3 | And we'll deal with it from there. |
| 4 | MR. ZAVITSANOS: Okay. |
| 5 | THE COURT: So it's 3:29. Please be back in 11 minutes. |
| 6 | MR. ZAVITSANOS: Yes, Your Honor. |
| 7 | MR. ROBERTS: Thank you, Your Honor. |
| 8 | THE COURT: And we'll go to 4:45. |
| 9 | [Recess taken from 3:29 p.m. to 3:40 p.m.] |
| 10 | [Outside the presence of the jury] |
| 11 | THE COURT: Thanks, everyone. Please remain seated. |
| 12 | What I wanted to bring up off the record is that we are going four days |
| 13 | with Mr. Haben. It was represented it would be three. I'm not going to |
| 14 | let you and you're asking him questions in a repetitive way. I'm not |
| 15 | going to let you jam them up that the Defendant doesn't get to put their |
| 16 | case on. |
| 17 | MR. ZAVITSANOS: Yes, Your Honor. I yes, Your Honor. |
| 18 | THE COURT: Thank you. Let's bring in the jury. |
| 19 | MR. BLALACK: I think we need Mr. Haben, Your Honor. |
| 20 | THE COURT: Thanks, everybody, for being ready right at |
| 21 | 3:40. |
| 22 | [Jury in at 3:42 p.m.] |
| 23 | THE COURT: Thank you. Please be seated. Plaintiff, please |
| 24 | proceed. |
| 25 | MR. ZAVITSANOS: Thank you, Your Honor. May it please |

| 37,000 | | | |
|--------|--|--|--|
| | | | |
| | | | |

| 1 | the Court. | Okay, Mr. Haben, we're almost done. I think I have probably | |
|----|------------------------|---|--|
| 2 | 30 to 40 minutes left. | | |
| 3 | BY MR. ZAVITSANOS: | | |
| 4 | Q | All right. Okay. Can you please pull out Exhibit 478, please, | |
| 5 | and take a | moment to look at that for yourself? | |
| 6 | А | Okay. | |
| 7 | Q | While you're looking at that, we just looked at a document | |
| 8 | that identi | fied you as one of the people in charge of Project Naviguard, | |
| 9 | right? | | |
| 10 | А | The prior | |
| 11 | Q | You said about this crew? | |
| 12 | А | Yes. | |
| 13 | Q | Okay. Does this document appear to be an update of talking | |
| 14 | points aro | und Naviguard? | |
| 15 | А | I did not create this. I don't know who did. So I don't know it | |
| 16 | I could ans | swer that question. | |
| 17 | Q | Well, just read it to yourself. Does it appear to be an update | |
| 18 | involving t | alking points about Naviguard? | |
| 19 | А | It's a document that has talking points about Naviguard. | |
| 20 | Q | Which is the project that you were in charge of, right? | |
| 21 | А | Yes. | |
| 22 | Q | Okay. And in looking at this, do you see anything in here | |
| 23 | that seems | out of order or inconsistent with what you understood the | |
| 24 | purpose of | f Naviguard was? | |
| 25 | Α | I have not read this whole document. I'm not familiar with it. | |

| 000876 | | |
|--------|--|--|
| O) | | |
| | | |
| | | |
| | | |

| Q | Yeah. So I'm just trying to finish on time, but if you need |
|------------|---|
| time to lo | ok at it, my question is whether you see anything in there that |
| jumps out | t at you that seems inconsistent with what you understood the |
| purpose o | of Naviguard was. |
| | |

So I don't -- you're asking me about the entire document?

A I haven't read it. It's a 15-page document with a lot of detail, so I couldn't answer that question.

- Q Look at the section about why you all are developing Naviguard and just read that to yourself and tell me if that seems consistent with what the purposes of Naviguard were.
 - A What's your question again about it?
- Q Yes, sir. My question is in looking at that section I just directed you to, does that seem consistent with what you understood the purpose of Naviguard was?
 - A Yes.

MR. ZAVITSANOS: Okay. Your Honor, we move for the admission of 478.

MR. BLALACK: I object on authentication and foundation grounds.

THE COURT: You've got to lay a more thorough foundation.

BY MR. ZAVITSANOS:

- Q In looking at the description of what Naviguard is, Mr. Haben, does that seem consistent with what you understood Naviguard to be?
 - A Is that the section above, What is Naviguard?
 - Q Yes. Yes, sir. Yes, sir.

| 1 | А | Okay. Let me read it. |
|----|------------|---|
| 2 | Q | Yes, sir. |
| 3 | | [Witness reviews document] |
| 4 | А | Okay. Can you ask your question again? |
| 5 | Q | Yes, sir. Does the section about what is Naviguard, does that |
| 6 | seem con | sistent with what you understood Naviguard was going to be |
| 7 | while you | were in charge of it? |
| 8 | А | Yes. |
| 9 | | MR. ZAVITSANOS: I move for the admission of 478, Your |
| 10 | Honor. | |
| 11 | | THE COURT: You need to authenticate it, as well. |
| 12 | BY MR. Z | AVITSANOS: |
| 13 | Q | Does this identify that it is a Naviguard document, sir? |
| 14 | А | I don't know. |
| 15 | Q | Well, does it say up at the top, Naviguard ASO? |
| 16 | А | I'm sorry. It says Description of Naviguard ASO. |
| 17 | Q | Yes, sir. |
| 18 | А | That's the header. |
| 19 | Q | Yes, sir. And look at page three. Are those folks that work |
| 20 | with Unite | ed Healthcare? |
| 21 | А | Which section? The SMEs and contacts? |
| 22 | Q | Yes, sir. |
| 23 | А | The first four, I believe, or three, are Naviguard individuals. |
| 24 | Q | All right. |
| 25 | A | The next two are United Healthcare E&I individuals. |

| 1 | Q | Okay. | |
|----|---|---|--|
| 2 | А | And the bottom three are UnitedHealthcare underwriting. All | |
| 3 | of them are not part of my group. | | |
| 4 | Q | All of them are? | |
| 5 | А | Are not part of my team. | |
| 6 | Q | Okay. But they appear to be under the United umbrella? | |
| 7 | А | Not all of them. | |
| 8 | | MR. ZAVITSANOS: Okay. Your Honor, I move for the | |
| 9 | admission | of 478. | |
| 10 | | MR. BLALACK: I haven't changed our position, Your Honor. | |
| 11 | | THE COURT: Good enough. Objection is overruled. He was | |
| 12 | in charge of the program. He's testified that it was not inconsistent, that | | |
| 13 | it explained why Naviguard was developed, and at least most of the | | |
| 14 | people listed on there were associated with the program. I find that | | |
| 15 | there's a foundation and it's been authenticated. | | |
| 16 | [Plaintiffs' Exhibit 478 admitted into evidence] | | |
| 17 | BY MR. ZA | AVITSANOS: | |
| 18 | Q | Okay, Mr. Haben. I'll just try to this quickly as I can. | |
| 19 | А | Okay. | |
| 20 | Q | Okay. So this is a talking points memo and later in time. | |
| 21 | And it looks like at this point | | |
| 22 | | MR. ZAVITSANOS: Michelle, can you pull out this third | |
| 23 | bullet point? | | |
| 24 | BY MR. ZAVITSANOS: | | |
| 25 | | Now is it fair to say Mr. Haban, that as of the time you left | |

| 2 |
|----|
| 3 |
| 4 |
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
| 23 |
| 24 |
| 25 |

| which I th | ink you said was August of this year? |
|---|---|
| А | Yes. |
| Q | There were still a bunch of clients that had reasonable and |
| customary | in their plans, right? |
| А | I don't know how many had. |
| Q | Well, there were some. Will you agree with me on that? |
| There was | \$ |
| А | There was more there was more than one. |
| Q | More than okay. Fair enough, sir. Okay. So one of the |
| things you | were doing is the key account and by the way, key account |
| is sometin | nes abbreviated KA, right? |
| А | That's correct. |
| Q | Okay. So if the jury sees KA in the documents, they'll that |
| means key | y account, right? |
| А | Yeah, most likely. |
| Q | And NA means national account, right? |
| А | Yes, another abbreviation. |
| Q | Okay. So the key account and national account sales |
| strategy for Naviguard was to roll out and support E&I sales strategies | |
| by providi | ng a better option for clients who have remained on |
| reasonable and customary, right? | |
| А | I see that. |
| Q | Okay. So for those clients, at least one, in the ASO contacts |
| that remai | ned on reasonable and customary, you were trying to sell |
| Naviguard | I to basically do what MultiPlan used to do, right? |
| | A Q customary A Q There was A Q things you is sometim A Q means key A Q strategy for by providing reasonable A Q that remains |

| C | |) |
|---|---|---|
| (| |) |
| (| |) |
| C | χ |) |
| C | χ |) |
| • | _ | ٦ |

| 1 | Α | That's incorrect. |
|----|-------------|--|
| 2 | Q | Okay. Well, let me just move on and I'm not going to go |
| 3 | through th | ne whole document, at least. Let me see if there's anything |
| 4 | else we ne | eed to cover here. Okay. Let's move on. All right. And like I |
| 5 | said, Mr. H | laben, if I'm quiet, that means I'm skipping stuff, all right? |
| 6 | | MR. ZAVITSANOS: Michael, is 360 in? |
| 7 | | MR. KILLINGSWORTH: No. |
| 8 | BY MR. ZA | AVITSANOS: |
| 9 | Q | Okay. Mr. Haben, will you look at Exhibit 360, please? |
| 10 | А | Three six zero? |
| 11 | Q | Yes. |
| 12 | | MR. ZAVITSANOS: And while you're doing that, let me ask |
| 13 | Counsel | Your Honor, may I ask Counsel if there's an objection to 360? |
| 14 | | THE COURT: Yes. |
| 15 | | MR. BLALACK: No objection, Your Honor. |
| 16 | | THE COURT: All right, 360 will be admitted. |
| 17 | | [Plaintiffs' Exhibit 360 admitted into evidence] |
| 18 | BY MR. ZA | AVITSANOS: |
| 19 | Q | Okay. Mr. Haben, I'll just go through. I have a few loose |
| 20 | ends befo | re we get to what's happening in the State of Nevada, okay? |
| 21 | So 360 is a | an email. Let's pull up the top, please. And this is an email to |
| 22 | you, amor | ng other people, right? And Ms. Paradise. |
| 23 | А | Yes, I believe so. |
| 24 | Q | Okay. So this appears to be a revenue |
| 25 | | MR. ZAVITSANOS: Pull up the this section here, Michelle. |
| | | |

| 2 | BY MR. ZAVITSANOS: | | |
|----|---|---|--|
| 3 | Q | The subject matter are national accounts, SSP. Is that shared | |
| 4 | savings programs? | | |
| 5 | А | I believe so. | |
| 6 | Q | Okay. And I think we said this earlier, but when we see SSP, | |
| 7 | sometime | s that means all the programs, right? | |
| 8 | А | It actually depends on the author of | |
| 9 | Q | Yes, sir. I understand. | |
| 10 | А | Because people get confused. | |
| 11 | Q | Yes, sir. Okay. And here, this says even though there is an | |
| 12 | SSP program, this is talking about all of them, right? | | |
| 13 | А | I don't know what Craig's is actually covering. | |
| 14 | Q | Well, let's take a look real quick. | |
| 15 | | MR. ZAVITSANOS: Close this off, Michelle. And from here | |
| 16 | to here, please. | | |
| 17 | BY MR. ZAVITSANOS: | | |
| 18 | Q | And it looks like on these, on the plans that you still had as of | |
| 19 | this time in 2019, there were still some plans where you were earning a | | |
| 20 | percentage of the shared savings, right? You still had some OCM clients | | |
| 21 | at this time? | | |
| 22 | А | I believe so, yeah. | |
| 23 | Q | And what's going on here is that the revenues were down | |
| 24 | because t | here was a decrease in billed charges, right? | |
| 25 | А | Yes, caused by many factors. | |

I want to see what the subject matter is.

| C | |) |
|---|---|---|
| C | |) |
| C | |) |
| C | X |) |
| Ċ | χ |) |
| Ň | |) |

| | Q | Okay. So billed charges are coming down and that's |
|-------|--------|--|
| affec | ting y | our revenue on the shared savings plans where you're getting |
| a pei | centa | ge of the savings, right? |

A Yes.

Q Let's go to page two. And one of the things that happened to cause the revenue to go down is that one of these out of network groups went in network, right?

- A That is correct.
- Q And you lost \$42 million of revenue as a result.
- A That is correct. And I was the negotiator on that contract.
- Q Okay. So let's close that out and let's go to page four.

MR. ZAVITSANOS: Okay. Michelle, let's -- simpler if you just pull out the whole thing. We'll just do this quickly. All the way up. Thank you.

BY MR. ZAVITSANOS:

- Q Okay. So let's do this quickly. So this is a memo going through all the factors why revenue is down from shared savings, right?
 - A I don't remember the context of all of this.
- Q Well, this is number 11, and the jury can go through the others. But I just want to point out a couple of things. You with me?
 - A Yes.
- Q Okay. So if we go to C, it says, "based on the data we have received from the out of network team, it appears that billed charges through April of 2019 are actually down seven percent versus the assumed eight percent increase. I believe this gap is driving a large

| 3 |
|----|
| 4 |
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
| 23 |
| 24 |
| 25 |
| |

| 1 | percentag | e of the projected miss." Do you see that? |
|---|-------------|--|
| 2 | А | I do. |
| 3 | Q | The "projected miss" being you had assumed you were |
| 1 | going to r | nake so much from these percentage of reduction, but because |
| 5 | the billed | charge dropped, you were going to make less, right? |
| 6 | Α | Yeah. I didn't make those assumptions. I believe Finance |
| 7 | made tho | se assumptions. |
| 3 | Q | Fair enough. But whoever did, that's kind of what it's saying |
| 9 | there, righ | nt? |
|) | Α | I think so. I'm not sure. |
| ı | Q | Okay. So and all I'm not going to go through it and read |
| 2 | all this. T | he jury can do this on their own time. It's Exhibit 360. But all |
| 3 | of this stu | ff that's going on here |
| 1 | | MR. ZAVITSANOS: Right here, Michelle. |
| 5 | BY MR. Z | AVITSANOS: |
| 5 | Q | is causing a significant drop. Right here. This is causing a |
| 7 | significan | t drop in SSP revenue projection, right? |
| 3 | Α | Yes, that's what that says. |
| 9 | Q | Okay. So Mr. Haben, do you agree that while you are telling |
|) | the outsid | e world that the problem is that billed charges are too high, |
| 1 | internally, | United is saying the problem is that billed charges are too |
| 2 | low? | |
| 3 | Α | I disagree. I can explain. There is |
| 1 | Q | No. No, sir. That's it's all right. You'll get a chance, I |
| 5 | promise. | Let's move on. Okay. |
| | | |

| | 2 | |
|--------|---|--|
| 000884 | | |
| | | |
| | | |
| | | |
| | | |

| 1 | MR. ZAVITSANOS: Michael, 378 is in, right? |
|----|--|
| 2 | MR. KILLINGSWORTH: It is not. |
| 3 | MR. ZAVITSANOS: Oh, okay. Let me ask Counsel real quick |
| 4 | if he has Your Honor, may I ask Counsel if he has a |
| 5 | THE COURT: Yes. Sure. |
| 6 | MR. ZAVITSANOS: objection? |
| 7 | THE COURT: Yes, please. |
| 8 | MR. BLALACK: One moment, Your Honor. |
| 9 | MR. ZAVITSANOS: I'm sorry? |
| 10 | MR. BLALACK: One moment. |
| 11 | MR. ZAVITSANOS: Okay. |
| 12 | MR. BLALACK: No objection, Your Honor. |
| 13 | THE COURT: Two I'm sorry, 378 will be admitted. |
| 14 | [Plaintiffs' Exhibit 378 admitted into evidence] |
| 15 | MR. ZAVITSANOS: Okay. Mr. Haben, I just needed to admit |
| 16 | it. We're not going to look through it. I think it's a little repetitive of what |
| 17 | we've talked about. Your Honor, may I ask Counsel if he has an |
| 18 | objection to 421, please? |
| 19 | THE COURT: You may. |
| 20 | MR. ZAVITSANOS: Thanks, Your Honor. |
| 21 | MR. BLALACK: Court's indulgence. One second. No |
| 22 | objection, Your Honor. |
| 23 | THE COURT: 421 will be admitted. |
| 24 | [Plaintiffs' Exhibit 421 admitted into evidence] |
| 25 | MR. ZAVITSANOS: Okay. Mr. Haben, likewise, this one is a |
| | |

| _ | |
|---------------|---|
| \subseteq | • |
| \subseteq | • |
| \subseteq | • |
| α | • |
| α |) |
| \mathcal{C} | 1 |

| 1 | little repeti | tive. But I just want to identify one thing just so we get a little |
|----|---------------|---|
| 2 | clarity. Mi | chelle, will you pull out the bottom fourth. "And the following |
| 3 | benefits pr | ogram adoption." |
| 4 | BY MR. ZA | VITSANOS: |
| 5 | Q | Okay. So this is a document entitled Medical Cost Reduction |
| 6 | Best Practi | ces. Do you see that? |
| 7 | А | I do. |
| 8 | Q | Okay. So I'm not going to go through it. I just want to ask |
| 9 | one thing. | There's a sentence here that says, "Perform continuous |
| 10 | evaluation | and reduction of out of network reimbursement levels for SG |
| 11 | and KA-FI. | " Do you see that? |
| 12 | А | I do. |
| 13 | Q | SG stands for what? |
| 14 | А | Small group. |
| 15 | Q | Small group. |
| 16 | А | That's fully insured, by the way. |
| 17 | Q | And right. Hold on. Small group. And KA is key accounts? |
| 18 | А | Yes. Key accounts says fully insured and ASO. This is the |
| 19 | fully insure | ed side. |
| 20 | Q | Okay. So let me just make sure we're clear here. SG is small |
| 21 | groups, KA | A is key accounts, FI is fully insured, right? |
| 22 | А | Yes. They're both fully insured. |
| 23 | Q | All right. Okay. |
| 24 | | MR. ZAVITSANOS: You can take that down, Michelle. |
| 25 | BY MR. ZA | VITSANOS: |

| C | |) |
|---|---|---|
| C | |) |
| C | |) |
| C | χ |) |
| C | χ |) |
| C | 7 |) |

| 1 | Q | Do you all have an ink budget in United? Is that why you use |
|----|-------------|--|
| 2 | all these a | cronyms? Okay. Let me move on. |
| 3 | А | It is a science of its own. |
| 4 | Q | Yes, sir. Okay. |
| 5 | | MR. ZAVITSANOS: Michael, is 379 in? It is, right? Yes. |
| 6 | | MR. KILLINGSWORTH: Yes, it's in. |
| 7 | | MR. ZAVITSANOS: It is. Okay. |
| 8 | BY MR. ZA | AVITSANOS: |
| 9 | Q | Okay. Now, Mr. Haben, will you please let me |
| 10 | | MR. ZAVITSANOS: I'm sorry, Your Honor. Let me ask |
| 11 | Counsel, if | f I may, on 478. |
| 12 | | THE COURT: Yeah. It's in. |
| 13 | | MR. ZAVITSANOS: Oh, that's in. That's in. |
| 14 | | MR. BLALACK: That's in. Are we on 379, Your Honor? I'm |
| 15 | lost. | |
| 16 | | MR. ZAVITSANOS: I'm on I just need to get a bunch of |
| 17 | document | s admitted. So 478 I think has been admitted. |
| 18 | | MR. KILLINGSWORTH: Yes. |
| 19 | | THE COURT: 478 is admitted. |
| 20 | | MR. ZAVITSANOS: All right. So here's what I'd like to do. |
| 21 | Let's put u | p all right. So here's what I'd like to do. I want to put up |
| 22 | Exhibit 464 | 4, which we looked at a little while ago. |
| 23 | | MR. KILLINGSWORTH: 464 has not been admitted. |
| 24 | | MR. ZAVITSANOS: I'm sorry? |
| 25 | | MR. KILLINGSWORTH: 464 has not been admitted. |
| | | |

| 2 | an objection to 464? |
|----|---|
| 3 | THE COURT: You may. Yes. |
| 4 | MR. BLALACK: No objection, Your Honor. |
| 5 | THE COURT: 464 will be admitted. |
| 6 | [Plaintiffs' Exhibit 464 admitted into evidence] |
| 7 | MR. ZAVITSANOS: Okay. |
| 8 | MR. BLALACK: Counsel, this is an AEO document, so |
| 9 | MR. ZAVITSANOS: Yes. I'm not going to get opinion on this |
| 10 | MR. BLALACK: Okay. |
| 11 | MR. ZAVITSANOS: All right. Let's put up, Michelle, 464, |
| 12 | page 1 next to 478, page 14. |
| 13 | THE WITNESS: Page what? |
| 14 | MR. ZAVITSANOS: Page 14. |
| 15 | MR. BLALACK: Counsel Your Honor, could I provide |
| 16 | counsel this version? |
| 17 | THE COURT: Yes. |
| 18 | MR. BLALACK: This just may help capture it, if you need it. |
| 19 | MR. ZAVITSANOS: Okay. I'm not going to need that. |
| 20 | MR. BLALACK: Fair enough. |
| 21 | MR. ZAVITSANOS: Okay. So Mr. Haben Michelle, let's pul |
| 22 | this part out here, talking about OCM. Just this column here. |
| 23 | BY MR. ZAVITSANOS: |
| 24 | O I think everybody's got it but OCM is Data iSight_right? |

MR. ZAVITSANOS: Your Honor, may I ask Counsel if he has

Yes. I believe so.

| 1 | | MR. ZAVITSANOS: Michelle, will you please highlight this, |
|----|--------------|--|
| 2 | "member | proprietary reference-based pricing". |
| 3 | BY MR. Z | AVITSANOS: |
| 4 | Q | And that's what we talked about before the break, right? The |
| 5 | Data iSigh | nt is a vendor proprietary reference-based pricing, right? |
| 6 | А | That is correct. |
| 7 | Q | And when you set up Naviguard |
| 8 | | MR. ZAVITSANOS: Michelle, pull up this number two. And |
| 9 | let's put it | : I want to compare number two, which is the Naviguard |
| 10 | system, c | ompared to the Data iSight system. Can you move it down, |
| 11 | please? | |
| 12 | | THE WITNESS: Which document is this one in? |
| 13 | BY MR. Z | AVITSANOS: |
| 14 | Q | This is 478. Okay. So let's see if we can figure this out. So |
| 15 | when it co | omes to Data iSight, the way you were pitching it was that it |
| 16 | was a pro | prietary reference-based pricing, right? |
| 17 | А | Data iSight is a proprietary reference-based pricing. |
| 18 | Q | And then, when you created Naviguard to replace Data |
| 19 | iSight, wh | nat you called it was that the pricing is based on proprietary |
| 20 | reimburse | ement logic, situation factors, industry benchmarks, and |
| 21 | geograph | ically adjusted. Highlight that whole sentence there. Right? |
| 22 | That sour | ds identical to what we saw about Data iSight, right? |
| 23 | А | It is not, though. |
| 24 | Q | It sounds similar? Will you agree with that? |
| 25 | Α | No. I don't agree with that. |

| 1 | Q | Is what happened here that you replaced one Wizard of Oz | | | | |
|----|---|--|--|--|--|--|
| 2 | with anoth | er? | | | | |
| 3 | MR. BLALACK: Object to form. Argumentative. | | | | | |
| 4 | | MR. ZAVITSANOS: Let me rephrase, Your Honor. | | | | |
| 5 | | THE COURT: Objection sustained. | | | | |
| 6 | | MR. ZAVITSANOS: Let me rephrase. | | | | |
| 7 | BY MR. ZA | VITSANOS: | | | | |
| 8 | Q | Is what you did, Mr. Haben, when you figured out that Data | | | | |
| 9 | iSight was | just pulling out a number and doing what you wanted, you | | | | |
| 10 | just used t | he same language to promote Naviguard? | | | | |
| 11 | А | I disagree. I can explain it. | | | | |
| 12 | Q | No, sir. Okay. Almost done, Mr. Haben. Let me just put this | | | | |
| 13 | back, pleas | se. | | | | |
| 14 | Α | Are you done with those documents? | | | | |
| 15 | Q | We're done with this document. Yes, sir. Okay. | | | | |
| 16 | | MR. ZAVITSANOS: Your Honor, can I ask Counsel if he has | | | | |
| 17 | an objection | on to 467? | | | | |
| 18 | | MR. BLALACK: Yes, we do, Your Honor. Foundation. | | | | |
| 19 | | THE COURT: Okay. | | | | |
| 20 | | MR. ZAVITSANOS: And Your Honor | | | | |
| 21 | | MR. BLALACK: And also, Your Honor, may we approach on | | | | |
| 22 | this one, Y | our Honor? | | | | |
| 23 | | THE COURT: You may. | | | | |
| 24 | | MR. BLALACK: Very good. Okay. | | | | |
| 25 | | [Sidebar at 4:07 p.m., ending at 4:08 p.m., not transcribed] | | | | |
| | 1 | | | | | |

| 1 | | MR. ZAVITSANOS: Your Honor, may I confer with Mr. |
|----|---|--|
| 2 | Leyendec | ker for one second, so I don't forget. |
| 3 | | THE COURT: You may. |
| 4 | | [Counsel confer] |
| 5 | | MR. ZAVITSANOS: May I proceed, Your Honor? |
| 6 | | THE COURT: Yes. |
| 7 | | MR. ZAVITSANOS: Thank you, Your Honor. |
| 8 | BY MR. Z | AVITSANOS: |
| 9 | Q | Okay. Let's talk about Nevada now and how this state fits |
| 10 | into every | thing we've just talked about, okay? |
| 11 | А | Okay. |
| 12 | Q | All right. And this is this is my final point. All right. So |
| 13 | Exhibit 66 we looked at it some time ago. | |
| 14 | А | Can I go get it, please? |
| 15 | Q | Yes, sir. |
| 16 | | MR. ZAVITSANOS: And Your Honor, while Mr. Haben is |
| 17 | reviewing | that, may I ask counsel, please, if he's opposed to the |
| 18 | admissior | n of 462 and 426, which are |
| 19 | | MR. BLALACK: 462 and 4 |
| 20 | | THE COURT: 26. |
| 21 | | MR. ZAVITSANOS: 426. |
| 22 | | MR. BLALACK: 26. Yes, Your Honor, foundation on both of |
| 23 | those. | |
| 24 | | MR. ZAVITSANOS: Okay. |
| 25 | | THE COURT: Okay. |
| | | |

| 2 | BY MR. ZAVITSANOS: | |
|----|--|--|
| 3 | Q | All right. Let's start here. So this we've looked at this |
| 4 | earlier. Le | et's go to page 2. |
| 5 | | MR. ZAVITSANOS: And, Michelle, please pull out the first |
| 6 | few parag | raphs. Okay. |
| 7 | BY MR. ZA | AVITSANOS: |
| 8 | Q | This is the document, Mr. Haben, that talked about we will |
| 9 | continue t | his growth by advancing our already industry leading gross |
| 10 | margins b | y \$5 PMPM, while continuing well, do you see that? |
| 11 | А | I do. |
| 12 | Q | And that's what you wrote down here in 2016, right? |
| 13 | А | I see that. |
| 14 | Q | Okay. And this is a 2017 business plan. It was prepared in |
| 15 | 2016. | |
| 16 | А | I believe |
| 17 | Q | Right? |
| 18 | А | I believe it was. |
| 19 | Q | All right. Now let's go to Exhibit 462. And remember we |
| 20 | looked at | documents talking about the West Region that you were |
| 21 | involved in? | |
| 22 | А | I was involved with? |
| 23 | Q | Well, remember the document that had your name talking |
| 24 | about a meeting involving the West Region? | |
| 25 | Α | You're going to have to refresh my memory. |

MR. ZAVITSANOS: I'll get to it, Your Honor.

| 2 | Region inc | ludes the State of Nevada, right? |
|----|---|---|
| 3 | А | Yes, it does. |
| 4 | Q | Okay. And this document here, 462, if we does it talk about |
| 5 | financial p | erformance in the West Region, which includes Nevada? |
| 6 | А | I am not familiar with this document, nor did I write it. |
| 7 | Q | I understand, Mr. Haben. My question is in looking at this |
| 8 | document | which was produced by United in this case, if you will look at |
| 9 | in fact, let's do this, sir. Let's go to Exhibit 423. Is 423 in, Michael? | |
| 10 | | THE COURT: I don't think so. |
| 11 | BY MR. ZA | VITSANOS: |
| 12 | Q | I don't need to admit it. I just need you to go to 423. Look at |
| 13 | the cover. | |
| 14 | А | Let me get it, please. |
| 15 | Q | Yes. |
| 16 | | MR. KILLINGSWORTH: 423 is not in. |
| 17 | | MR. ZAVITSANOS: Yes. |
| 18 | | THE CLERK: 423 is not in. |
| 19 | | THE COURT: 423. |
| 20 | | MR. ZAVITSANOS: I'm just going to use it to refresh his |
| 21 | recollectio | n, Your Honor. |
| 22 | | THE COURT: Thank you. |
| 23 | | MR. ZAVITSANOS: I don't need to admit it. |
| 24 | BY MR. ZA | VITSANOS: |

I think it was yesterday. Let me ask it this way. The West

Q

Do you see that Ms. Paradise -

25

Q

| 2 |
|----|
| 3 |
| 4 |
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
| 23 |
| 24 |
| 25 |

| 1 | А | Hold on. |
|----|-------------|--|
| 2 | Q | Oh, I'm sorry. Ms. Paradise reported to you? |
| 3 | А | Yes, she did. |
| 4 | Q | And do you see that Ms. Paradise was involved in this non- |
| 5 | par out-of- | network meeting on October 17, 2019, involving the West |
| 6 | Region, wh | nich includes the State of Nevada? |
| 7 | А | I see that she's in this meeting. |
| 8 | Q | And she reported to you during this time? |
| 9 | А | Yes, she did. |
| 10 | Q | Okay. Now let's go back to 462, which is the document I was |
| 11 | asking you | about. That's the same West Region that Ms. Paradise was |
| 12 | involved ir | that meeting, that we just looked at right? |
| 13 | А | The West Region? |
| 14 | Q | Yes, same West Region, right? |
| 15 | А | Yes, Becky was asked to come with me. |
| 16 | Q | Okay. Which again includes the State of Nevada, right? |
| 17 | Α | West Region includes the State of Nevada. |
| 18 | Q | And if you turn please to page 23, and page 26, on the right |
| 19 | hand side | of the page, do you see this is talking about the financial |
| 20 | performan | ce in the State of Nevada? |
| 21 | Α | Which part on 26? |
| 22 | Q | Okay. Let's go I gave you two pages. That wasn't fair. Let |
| 23 | me do it th | is way. Let's go to page 23 first. And do you see there's a |
| 24 | heading? | I'm not going to read it, up at the top. Do you see the State of |
| 25 | Nevada me | entioned? |

| 000894 | | | |
|--------|--|--|--|
| | | | |
| | | | |
| | | | |

| 1 | А | The abbreviation for Nevada is at the top. |
|----|---------------|--|
| 2 | Q | Yes, sir, NV, right? |
| 3 | А | Yes. |
| 4 | Q | Okay. And then we go to page 26. And do you see that the |
| 5 | fourth bull | et point on that document in the text on the side of the page |
| 6 | А | In the orange or in the blue? |
| 7 | Q | In the I'm a little colorblind, Mr. Haben. I think that's |
| 8 | orange. | |
| 9 | А | Upper right? |
| 10 | Q | Yes, sir. Do you see that mentions the State of Nevada and |
| 11 | the financi | al performance for the State of Nevada? |
| 12 | А | I'm sorry, which bullet, the fourth? |
| 13 | Q | The I'm sorry, sir, the fourth bullet, yes, sir, from the top. |
| 14 | The first lir | ne. |
| 15 | А | It's got referenced Nevada in the fourth bullet. |
| 16 | | MR. ZAVITSANOS: Okay. Your Honor, we move for the |
| 17 | admission | of 462. |
| 18 | | MR. BLALACK: Object to the foundation, Your Honor. The |
| 19 | witness ha | s never seen it, didn't write it, didn't participate in developing |
| 20 | it. The fact | t that it references the State of Nevada doesn't establish a |
| 21 | foundation | |
| 22 | | THE COURT: Lay more foundation. |
| 23 | BY MR. ZA | VITSANOS: |
| 24 | Q | Yes. The people on the front page are employees of |
| 25 | UnitedHea | Ithcare; is that correct? |
| | | |

| 1 | А | On 462, I believe so. |
|----|-------------|---|
| 2 | Q | And one of the things UnitedHealthcare was doing not only |
| 3 | in 2019, b | ut every year, is measuring the financial performance of a |
| 4 | number o | f programs, including the out-of-network programs for the |
| 5 | different r | egions, right? |
| 6 | А | I don't know if they were measuring the out-of-network |
| 7 | programs | by region. |
| 8 | Q | Well, you were measuring performance, region by region, |
| 9 | right? | |
| 10 | А | I was not. |
| 11 | Q | Well, your company was, sir. |
| 12 | А | The company was. |
| 13 | Q | Yes, sir. And this document that we're looking at right now |
| 14 | is talking | about the financial performance in the West Region, which |
| 15 | includes t | he State of Nevada, right? |
| 16 | А | I believe it does. |
| 17 | Q | Yes. And all four of these people on the front are United |
| 18 | employee | s, right? |
| 19 | А | I don't know Tammy, and I don't know I don't know |
| 20 | Tammy. | |
| 21 | Q | Do you know the other three? Derrick Daniels, Sachin Shah |
| 22 | А | Sachin Shah. I know |
| 23 | Q | Sachin Shah. |
| 24 | А | I know who they are. |
| 25 | Q | Okay. |

| 1 | MR. ZAVITSANOS: Your Honor, we move for the admission |
|----|--|
| 2 | of 462. |
| 3 | MR. BLALACK: Same position, Your Honor. The fact that the |
| 4 | witness knows some people who work for United that are referenced in |
| 5 | the document doesn't lay a foundation in our opinion. |
| 6 | THE COURT: The objection is overruled. 462 will be |
| 7 | admitted. |
| 8 | [Plaintiffs' Exhibit 462 admitted into evidence] |
| 9 | BY MR. ZAVITSANOS: |
| 10 | Q Okay. Now I need to do this in two stages. This is the first |
| 11 | stage is this document, and then we're going to talk about one other |
| 12 | document, and then I think I'm done. Okay. All right. That's the West |
| 13 | Region, right? |
| 14 | A Yes. |
| 15 | Q And there's the great State of Nevada? |
| 16 | A Yep. Yes. |
| 17 | Q Okay. And if we go to page 23 excuse me, let's go to page |
| 18 | 26. And let's pull out |
| 19 | MR. ZAVITSANOS: Michelle, will you please pull out, you |
| 20 | see those bullets on the side in orange? Pull out the bottom, fourth the |
| 21 | fourth one from the top, please. |
| 22 | BY MR. ZAVITSANOS: |
| 23 | Q Okay. Primary year over year internal operating income |
| 24 | pressure. Status from our top two outperforming markets in '19, |
| 25 | California and Nevada, right? |

| 3 |
|----|
| 4 |
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
| 23 |
| 24 |
| 25 |

| А | That's what that says. | | |
|---|---|--|--|
| Q | Okay. So the best financial performers, the most margin in | | |
| the west was California and Nevada, according to this, right? | | | |
| А | I am not a finance person. I did not write it. I don't know | | |
| what they | mean. | | |
| O. | Well, let's go to page 23, please. | | |
| | MR. ZAVITSANOS: Michelle, please pull out the top | | |
| paragraph | only, with the heading. | | |
| BY MR. ZA | VITSANOS: | | |
| Q | Our 2019 performance delivering on commitments what | | |
| went right. | Do you see that? | | |
| А | I do. | | |
| Q | Okay. In 2019, internal operating income 99 million favorable | | |
| to budget. | Meaning you made 99 million more than you had budgeted, | | |
| right? | | | |
| А | Again, I'm not a finance person, I did not write it. I don't | | |
| know what | they mean. | | |
| Q | Sir, 99 million favorable to budget, does that not mean to | | |
| you 99 million more than you expected? | | | |
| А | I'm assuming that's what it means to them, but I don't know. | | |
| | MR. ZAVITSANOS: And Michelle, highlight the stuff inside | | |
| the parenthesis. And what states drove that windfall? | | | |
| | MR. BLALACK: Objection to that characterization. | | |
| | MR. ZAVITSANOS: Let me rephrase. | | |
| BY MR. ZAVITSANOS: | | | |

| 1 | Q | What states drove this \$99 million favorable to budget? |
|----|---|--|
| 2 | А | It says driven by California, Nevada, Colorado. |
| 3 | Q | All right. Now let's look at one last document. Let's go |
| 4 | please to - | - can you please get 426? And take a moment to look at that to |
| 5 | yourself, p | lease. And if you could, please turn to page 5, and tell me if |
| 6 | this again | deals with the West Region. |
| 7 | А | It says the West Region. |
| 8 | Q | And is that Dan is Dan Rosenthal mentioned on this |
| 9 | document? | |
| 10 | А | Yes, he is. |
| 11 | Q | Was he your boss? |
| 12 | Α | Not at that time, no. |
| 13 | Q | Was he the CEO according to this document? |
| 14 | А | Of the West Region, yes. |
| 15 | Q | Okay. And this is another financial performance report for |
| 16 | 2019, just like the one we saw? | |
| 17 | А | I don't know what it is. I've never seen it before. |
| 18 | Q | Well, look at the first page, sir. Excuse me, the second page. |
| 19 | Does it appear to be a Summit of the West Region that took place in | |
| 20 | October 2019? | |
| 21 | А | That's what it says. |
| 22 | Q | And if you will turn, please, to and the West Region |
| 23 | obviously | includes Nevada, right? |
| 24 | А | Yes. |
| 25 | Q | And this is the same year this is the same year in the |

| 1 | document | we just looked at about California, Nevada, and I think |
|----|--|--|
| 2 | Colorado exceeding the budget | |
| 3 | А | Yes. |
| 4 | Q | right? |
| 5 | Α | Yes. |
| 6 | Q | Okay. Would you please turn to page 12? Does that have |
| 7 | financial r | esults for the West Region, which includes Nevada for 2019, up |
| 8 | until that point? | |
| 9 | Α | That says West Region financial results. Again |
| 10 | | MR. ZAVITSANOS: Your Honor, I move for the admission of |
| 11 | 426, please. | |
| 12 | | MR. BLALACK: Object to the foundation, Your Honor. The |
| 13 | witness di | dn't write it, hasn't seen I, wasn't part of the West Region, |
| 14 | didn't work for this business. That's enough. | |
| 15 | | THE COURT: You'll have to lay a little bit more additional |
| 16 | foundatio | n. |
| 17 | | MR. ZAVITSANOS: Thank you, Your Honor. |
| 18 | BY MR. Z | AVITSANOS: |
| 19 | Q | Okay. Would you please turn to page 8, sir? Are you there? |
| 20 | Okay. I do | on't know how many this is, but it's about somewhere between |
| 21 | 20 to 30 individuals. Are all of those individuals United employees? | |
| 22 | А | I don't know for a fact that they are or not. |
| 23 | Q | Are some of them United employees? |
| 24 | А | Yes. |
| 25 | Q | Okay. The next page, page 9. Mr help me with this |

| 1 | pronunciation again. | |
|----|---|---|
| 2 | А | Sachin Shah. |
| 3 | Q | Sachin Shah. Is he a United employee? |
| 4 | А | Yes, he is. |
| 5 | Q | Was he the Chief Financial Officer for the West Region? |
| 6 | А | Yes, he was. |
| 7 | Q | Does this appear to be a report by Sachin Shah and Dan |
| 8 | Rosentha | regarding the financial performance of the West Region for |
| 9 | 2019? | |
| 10 | А | I don't know. I have never seen this before. |
| 11 | Q | Does it well, do you see the page we just left off, on page |
| 12 | 12, does this appear to be the West Region Financial Result for 2019? | |
| 13 | А | That's what it says. |
| 14 | Q | Okay. Any reason to doubt that this is a United document? |
| 15 | А | No. |
| 16 | Q | Okay. |
| 17 | | MR. ZAVITSANOS: Your Honor, I move for the admission |
| 18 | of excuse me, Your Honor, 426. | |
| 19 | | MR. BLALACK: Stand on our objection, Your Honor. |
| 20 | | THE COURT: Objection is overruled. 426 will be admitted. |
| 21 | | [Plaintiffs' Exhibit 426 admitted into evidence] |
| 22 | BY MR. ZAVITSANOS: | |
| 23 | Q | Okay. Now |
| 24 | | MR. BLALACK: Counsel Your Honor, I just wanted to ask |
| 25 | counsel this also, is one of the AEO documents. So depending on wha | |

| 1 | you want to do, I wanted to | |
|----|--|--|
| 2 | | MR. ZAVITSANOS: Okay, let me I'll do it the way we've |
| 3 | done it, okay. | |
| 4 | | MR. BLALACK: Okay. Just let me know, and I can help you. |
| 5 | | MR. ZAVITSANOS: Yes, sir, okay. |
| 6 | BY MR. ZA | AVITSANOS: |
| 7 | Q | All right. So let's orient ourselves here. We just looked at a |
| 8 | document | that said that the top performers in the West Region were |
| 9 | California, Nevada and Colorado, right? | |
| 10 | А | I believe |
| 11 | Q | For 2019? |
| 12 | А | I believe so, yes. |
| 13 | Q | 2019 was at the tail end of the five year period that I began |
| 14 | your exan | nination with, right? |
| 15 | А | I believe so, yes. |
| 16 | Q | So let's see what the result was of this five year timetable |
| 17 | we've bee | n talking about in the West Region that includes the State of |
| 18 | Nevada, okay? | |
| 19 | А | Okay. |
| 20 | Q | Let's go to page 12, please. |
| 21 | | MR. ZAVITSANOS: Michelle, can you flip that? Okay. |
| 22 | Michelle, I need you to pull out this part here. | |
| 23 | BY MR. ZAVITSANOS: | |
| 24 | Q | Okay. So in terms of expansion in the West Region, in 2019, |
| 25 | the budge | t was negative 36 cents per member per member, right? |

| \subset |) |
|--------------|---|
| \subset |) |
| \subset |) |
| C |) |
| \subset |) |
| \mathbf{r} |) |
| | |

| 1 | | MR. ZAVITSANOS: Michelle, can you highlight that at the |
|----|------------|--|
| 2 | bottom? | |
| 3 | BY MR. Z | AVITSANOS: |
| 4 | Q | Right, sir? |
| 5 | А | That's what that says. |
| 6 | Q | Okay, that's what |
| 7 | А | It's per member per month. You said per member per |
| 8 | member. | |
| 9 | Q | I'm sorry. Thank you, sir. Per member per month. The 2020 |
| 10 | budget. | In 2019, the growth exceeded by \$23.93 per member per |
| 11 | month, ri | ght? |
| 12 | А | I don't know what that means. So I can't answer that |
| 13 | question. | • |
| 14 | Q | Right, sir? |
| 15 | А | I don't know what that means. I didn't write this. |
| 16 | Q | Well, what it says is, I mean you blew the doors off what you |
| 17 | did in '16 | , in the West Region, right? |
| 18 | | MR. BLALACK: Objection. Foundation. |
| 19 | | MR. ZAVITSANOS: Let me rephrase, Your Honor. |
| 20 | BY MR. Z | AVITSANOS: |
| 21 | Q | You exceeded, and you were ahead of everybody by \$5 |
| 22 | nationall | y in '16. But in '19, almost five times as much, led by what you |
| 23 | all were o | doing in this state, right, Mr. Haben? |
| 24 | А | I have no context. You all will have to ask Dan. |
| 25 | | MR. ZAVITSANOS: Pass the witness, Your Honor. |
| | | |

THE COURT: All right. So do you wish to begin cross examination or are you going to wait for your case-in-chief?

MR. BLALACK: Your Honor, I'll take guidance from you. We can get started now. We'll need to clean up the obstacle course before we start. But in addition to that, I think we probably have a handful of housekeeping measures. So if you want to let the jurors go, Your Honor, and then we can start fresh.

THE COURT: All right. So it sounds like we're going to let you guys go a little early tonight, which is a treat, given the fact that we're now driving home in the dark.

So during this recess don't talk with anyone else or each other about any subject connected with the trial. Don't read, watch, or listen to any report of or commentary on the trial. Don't discuss this case with anyone connected to it by any medium of information, including, without limitation, newspapers, television, radio, internet, cellphones or texting.

Don't conduct any research on your own relating to the case. You can't consult dictionaries, use internet or use reference materials.

Don't post on social media, don't talk, text Tweet, Google, or conduct any other type of book or computer research with regard to any issue, party, witness, or attorney involved in the case.

Most importantly, do not form or express any opinion on any subject connected with the trial until the matter is submitted to you.

Thank you for your attention all day. Have a great day. See you tomorrow. I'll bring the lawyers in at 9:15, so we can be prompt at 9:30.

| 1 | THE MARSHAL: All rise for the jury. |
|----|--|
| 2 | [Jury out at 4:30 p.m.] |
| 3 | [Outside the presence of the jury] |
| 4 | THE COURT: Okay. |
| 5 | MR. BLALACK: Two things, Your Honor. I wanted to oh, |
| 6 | I'm sorry. |
| 7 | THE COURT: The room is clear. |
| 8 | MR. BLALACK: The first item I want to raise, Your Honor, in |
| 9 | relation to deposition transcripts that will be presented during the case. |
| 10 | And I'm going to give you a really trial level summary, and then I'm |
| 11 | going to ask Mr. Levine to explain it in more detail, so the Defense can |
| 12 | respond. I mean, to cut to the chase of what I'm going to ask for, and |
| 13 | then he can explain why. |
| 14 | It is my expectation that all the work we've been doing to |
| 15 | designate, counter-designate, objections, that process has been going or |
| 16 | for a [indiscernible]. It is going to result in a substantial revision of all of |
| 17 | that work. |
| 18 | THE COURT: Substantial what? |
| 19 | MR. BLALACK: Revision because it is inconceivable that all |
| 20 | that evidence is going to be offered. I think Mr. Levine will explain why. |
| 21 | And what's going to happen is that my colleagues on the other side are |
| 22 | going to substantially reduce what it is they previously designated to the |
| 23 | Court that have been offered down to something dramatically less. I |
| 24 | expect if they did not, we've got a different conversation that I'm going |
| 25 | to talk about in a minute. |

Assuming that happens, we're going to then be faced with the prospect of responding to a new set of designations and reevaluating our prior objections and what we had planned for this. So, in other words, we're going to have to go back and kind of redo some of that work. If that's unavoidable, we're going to do it. What I object to is any situation in the course of the trial where that happens, I want 24 hour notice, the night before the transcript has to be read because once we get their final final designations, we have to then do our work to decide what's our final position is going to be on objections and counterdesignations, and that's got to be presented to Your Honor, and Your Honor has to rule, and here any argument, and then there has to be cutting of the tape.

That's going to be a process that's going to require a couple three days from the time we get the final word when something is going to be played. And what I don't want to have happen is get jammed with something that's presented to us at 5:00 on the night before they want to play it, and we have to scramble to get something done by the next morning, and then we're trying to resolve objections and cutting in order to meet the schedule for the trial.

So to avoid that outcome, I'm going to give you the punch line now, and then I'll ask Mr. Levine to explain more in detail. What we're asking is give us three days before any -- the final designation before they're going to be played, three days in advance so we have a chance to review the new target, respond, and then we can present everything to Your Honor in time for you to rule. But we still have time

to orderly cut the videos when it needs to be played, but not have things be done overnight. And with that introduction, I'll ask Mr. Levine to give you just a little more context.

THE COURT: Well, and tell me, how many people do you have working on your team?

MR. BLALACK: We have six --

THE COURT: I'm going to be there are 20 on each side --

MR. BLALACK: -- six or seven -

THE COURT: -- full time.

MR. BLALACK: -- to eight, something like that.

THE COURT: You don't have others working remotely full time on the case?

MR. BLALACK: Not full time. I mean, I'm calling on other lawyers too for sure, Your Honor, but they're not all doing deposition designations. And, in fact, most of those lawyers spent a good deal of time in the last month to get to the point we are now, which is to designate and review the designations. And what I'm worried about is we're about to redo a lot of the work. So I'll Mr. Levine explain.

MR. LEVINE: Good afternoon, Your Honor. And just to give you a sense of the scope, last Wednesday -- it was actually Thursday, after midnight on Wednesday, when we broke for the four day weekend, Plaintiffs filed their designations. We also filed earlier on Wednesday our designations, including objections to the affirmative designations and counters. Plaintiffs' designations were from 32 different transcripts, 24 different witnesses. We spent substantial time objecting to those

transcripts -- to do those designations, excuse me, and the sort of counter-designations. Then Plaintiffs had objections to those counters.

That was the process we laid out. We agreed that we would file those things last Wednesday. Those were supposed to be the final designations, and then at some point we were going to schedule time with Your Honor to address the objections. And after that, if they were addressed, then the video can be cut.

THE COURT: What I normally do is just take your objections and give you rulings. We don't argue it.

MR. LEVINE: That would be fine as well, Your Honor.

THE COURT: Yeah.

MR. LEVINE: That would be fine as well. But we cannot cut the video --

THE COURT: I got it.

MR. LEVINE: -- until Your Honor rules on those things -- on those objections. And, as we understood Your Honor wanted to have the Plaintiffs' play their appropriate designations at one point, then the counters be played afterwards at another point. So assuming those are the final designations and Your Honor rules on the objections, I think would be fine.

Last night we received as to one of those 32 transcripts what we'll call the final designations, which deleted 166 line items from the table for that one witness and added 23 line items of designations for that one witness. And I don't mean lines of the transcript, I mean excerpts that were on a table of excerpts. And while one is not a big

deal, if that's all it is. If it's one, we can adjust, and I think they wanted to play that on Friday, and we can, in that time period look at what they've done, determine whether based on what they've deleted if we need to counter with anything they deleted. Based on what they've added, determine whether we want to object to anything they added, submit it Your Honor to rule, and then I think we will have time to cut the video as the process calls for.

That's fine. If it's going to be happening on a broader scale, we need a protocol in place giving some order, and efficiency, and fairness to this, frankly, so we can proceed accordingly. So that's the issue and that's why we're raising it to Your Honor.

THE COURT: Thank you. And the spokesperson.

MR. MCMANIS: Yes, Your Honor. Jason McManis. Let me start first with the 32 witness issue. You heard counsel say that these designations have been going on for over a month now, I think. The reason we had 32 witnesses is at the time the subpoena issue was unresolved. We had to preserve our ability to be able to call witnesses if they're not going to be here. Obviously, Your Honor, if we could have live witnesses here, that's our preference. And so that's the reason for the initial broad scope of those designations.

As to the designations that were sent last night, I think you just heard the numbers, 166 of the revisions were deletions from the original designations. And the reason for that is we have a tight time schedule. They were up here yesterday telling Your Honor that we needed to move things along more quickly, we needed to streamline

things down so that they had an opportunity to present their case.

We want to avoid repetition. We want to cut down any depositions to only that which needs to be played and not simply the same things that have been covered by a live witness here on the stand. So absolutely, we're going to continue to cut down and streamline those designations. And I don't think cutting out substantial portions really adds a significant workload to either side.

THE COURT: So you have 32 witnesses designated. How many are actually going to testify?

MR. MCMANIS: I think we're probably looking somewhere between 3 to 5 max.

MR. LEYENDECKER: Yeah, less than half a dozen, Your Honor.

MR. MCMANIS: Yeah. Three to five.

MR. LEYENDECKER: In light of the way things are going and our colleague who loves to hear his own voice, we're cutting. So my guess is half a dozen or less.

THE COURT: All right. Can you give us a definitive answer tomorrow of what -- that preference? You know, the most important witnesses and down, and when you can get them knew designations.

MR. MCMANISL Yes, we can. So if I could -- yes, we can, Your Honor. And if I could address the new designations issue. The, quote/unquote, "new designations that were added they really fall into two primary categories. One is an example of there was already a Q and A designated about an exhibit, but the line saying here's the document,

you know, marked as Exhibit 13, wasn't part of the original admissions.

And so there was cleanup to make sure that you can actually understand what's going on.

And then the other category is really specific to the witness that we sent last night, Mr. Rosenthal. And that had to do with the argument that Your Honor heard yesterday with respect to the Yale study, the foundation objections, and our ability to prove up those documents through Mr. Rosenthal. They are directly in response to that argument, Your Honor.

And so those are the -- that's the only reason that we had any new designations. I think, otherwise, everything that was in there it was significantly turned down and no new subjects are being added to any of the designations.

THE COURT: Okay. So you'll have an update for us tomorrow.

MR. MCMANIS: Yes, Your Honor.

THE COURT: Thank you. And in reply please, Mr. Levine.

MR. LEVINE: That should work well. I mean what we're looking for is a fair and efficient process, and give advance notice, and we're able to see --

THE COURT: Right.

MR. LEVINE: -- the five or six witnesses who they intend to designate tomorrow. And if they're going to revise the designations, let us know that --

THE COURT: Right.

| 000911 | | | |
|--------|--|--|--|
| | | | |
| | | | |
| | | | |

| | • | · , |
|---|---------------|----------------|
| THE COURT: You've got a crack [| phonetic] ted | ch team you |
| have a crack tech team. I don't see why it wo | uld take thre | e days, but we |
| do have Thursday as a holiday. So when you | get the repo | ort tomorrow, |
| that should give you a chance Thursday to pa | are things do | wn or |
| redesignate if necessary | | |

MR. LEVINE: -- so that we can adjust accordingly and --

Now to give you guys an update from the Chief Judge, I get texts on my Fitbit, so she's not crazy about us working on a Saturday, because there just isn't enough security in the building, and she likes the idea of having a schedule to work overtime in the evenings. So I'm going to ask you guys to talk about that, give me some ideas tomorrow. Because my staff -- I have one person on vacation. So I just have to make sure that we can do that without too much inconvenience to the court staff across the board. Okay.

MR. BLALACK: Well, thank you, Your Honor. And we would -- we'll confer on that. We would certainly welcome more time in the day --

THE COURT: Yeah.

MR. BLALACK: -- if it's available.

THE COURT: Well, you know, I can try to get my calendars covered next week. I've already done a preliminary review of them because with Business Court things can't go just anywhere. So I'm working on my end as well.

MR. BLALACK: Well, thank you, Your Honor. And I just -- I do think I need to make my record if I can.

| 6 |
|----|
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |

| | THE | COURT: | Of course. |
|--|-----|--------|------------|
|--|-----|--------|------------|

| MR. BLALACK: And I do think notwithstanding Mr. |
|--|
| Zavitsanos' valiant efforts to get done as fast as possible, in light of how |
| things have played out, I think and I haven't broken the news to Mr. |
| Haben yet, but I think it's unlikely he finishes tomorrow, assuming |
| there's going to be redirect. |

So, you know, I just think we're in a situation where unless something dramatic happens, and I don't see how -- unless -- they're going to have to really pare down their case for us to be able to put on our defense in the time we have. So I'm going to, again, state my concern about the pace. I'll come back and revisit the question of a clock on Friday or at the end of the day, Wednesday after we finish or make progress with Mr. Haben.

THE COURT: Right.

MR. BLALACK: But if we're -- if it's Friday morning, and we haven't gotten to our second witness yet, after two weeks of trial, I think we're going to be in a difficult spot.

THE COURT: All right.

MR. ZAVITSANOS: Brief response, Your Honor?

THE COURT: Yeah.

MR. ZAVITSANOS: So, Your Honor, last night we eliminated three witnesses we were going to call based on --

THE COURT: Have you notified them?

MR. ZAVITSANOS: No.

THE COURT: Okay.

| 2 |
|----|
| 3 |
| 4 |
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
| 23 |
| 24 |
| 25 |

| MR. ZAVITSANOS: No, this is our internal | | | |
|---|--|--|--|
| THE COURT: Okay. | | | |
| MR. ZAVITSANOS: secret list. So we've cut three off. | | | |
| And, Your Honor, I know Your Honor has heard me say this now a | | | |
| number of times, I just I beg the Court's indulgence to wait until the | | | |
| second witness gets on and | | | |
| THE COURT: Who will be your second witness? | | | |
| MR. ZAVITSANOS: Rebecca Paradise. And, Your Honor, I | | | |
| think you're going to see a dramatic change of pace. And so it's going to | | | |
| be real fast. And I recommit to Your Honor, that we're going to finish by | | | |
| the time that we set with enough time for the Defendants to put on their | | | |
| full defense. I'm very confident. I mean, we, I think, got from Mr. Haben | | | |
| a substantial amount of the information that we need for the | | | |
| UnitedHealthcare side. | | | |
| Now we have the witness that's going to be for Health Plan | | | |
| of Nevada and Sierra, Your Honor, you can put me on the clock on that. | | | |
| I'm not going to take more than two hours. | | | |
| THE COURT: I'm going to hold you to it. | | | |
| MR. ZAVITSANOS: Okay. Yes. | | | |
| THE COLURT OF A 1 1 | | | |

THE COURT: Okay. And where are you on jury instructions, because I have both sets. At some point, and it should be early next week, you should tell me the agreed version, and we'll set a time to argue the --

MR. BLALACK: Your Honor, I believe we have met and conferred on some group of instructions, which there is a joint

| 000914 | | | |
|--------|--|--|--|
| 4 | | | |
| | | | |

| 1 | agreement |
|----|---|
| 2 | THE COURT: Okay. |
| 3 | MR. BLALACK: and a vast majority of the substantive ones |
| 4 | that are in dispute. But I think we have some [indiscernible]. |
| 5 | THE COURT: We're going to tackle that early next week. |
| 6 | MR. BLALACK: Understood, Your Honor. Thank you. |
| 7 | THE COURT: Okay. |
| 8 | MR. MCMANIS: Your Honor, can I clarify one thing? |
| 9 | THE COURT: Yes, of course. |
| 10 | MR. MCMANIS: On the depositions, we should have we |
| 11 | should be able to give them notice to get through next Monday at least |
| 12 | by tomorrow, and we'll continue to work on that for whoever those |
| 13 | [indiscernible]. |
| 14 | THE COURT: Thank you. Okay. What else. |
| 15 | MS. LUNDVALL: Your Honor, one last point as far as our jury |
| 16 | instructions. Opposing is counsel is correct, there has been efforts of |
| 17 | meeting and conferring to try to agree to a set that we can present that |
| 18 | would be agreed upon, but also the disputed. And there are also |
| 19 | supplemental instructions then that are going to be tendered to the Court |
| 20 | based upon the evidence that been admitted thus far. |
| 21 | THE COURT: Good enough. |
| 22 | MS. LUNDVALL: Which is standard and everything. |
| 23 | MR. BLALACK: And I would expect that would happen with |
| 24 | us as well, Your Honor. |
| 25 | THE COURT: All right. Anything else? |

| 1 | MR. BLALACK: Not from us, Your Honor. Thank you. |
|----|--|
| 2 | THE COURT: Then everybody stay safe and healthy. See |
| 3 | you tomorrow. Lawyers be here at 9:15. |
| 4 | MR. BLALACK: Thank you, Your Honor. |
| 5 | MR. ZAVITSANOS: Thank you, Your Honor. |
| 6 | THE COURT: Thanks. |
| 7 | [Proceedings adjourned at 4:45 p.m.] |
| 8 | |
| 9 | |
| 10 | |
| 11 | |
| 12 | |
| 13 | |
| 14 | |
| 15 | |
| 16 | |
| 17 | |
| 18 | |
| 19 | |
| 20 | |
| 21 | ATTEST: I do hereby certify that I have truly and correctly transcribed the audio-visual recording of the proceeding in the above entitled case to the |
| 22 | best of my ability. |
| 23 | Xissia B. Cahill |
| 24 | Maukele Transcribers, LLC |
| 25 | Jessica B. Cahill, Transcriber, CER/CET-708 |
| | |

| 9 |
|---------------|
| $\overline{}$ |
| 0 |
| 0 |
| 0 |
| 0 |
| |

| | | Electronically Filed 11/12/2021 9:57 AM Steven D. Grierson CLERK OF THE COURT |
|----|--|--|
| 1 | RTRAN | Otens. Sum |
| 2 | | |
| 3 | | |
| 4 | | |
| 5 | DISTRIC | ICT COURT |
| 6 | CLARK COU | UNTY, NEVADA |
| 7 | FREMONT EMERGENCY SERVICE | / S) CASE#: A-19-792978-B |
| 8 | (MANDAVIS) LTD., ET AL., |) DEPT. XXVII |
| 9 | Plaintiffs, |) DEI I. XXVII |
| 10 | vs. | { |
| 11 | UNITED HEALTHCARE INSURANCE COMPANY, ET AL., | |
| 12 | Defendants. | } |
| 13 | | |
| 14 | | IORABLE NANCY ALLF COURT JUDGE |
| 15 | WEDNESDAY, N | NOVEMBER 10, 2021 |
| 16 | RECORDER'S TRANSCRI | IPT OF JURY TRIAL - DAY 10 |
| 17 | APPEARANCES: | |
| 18 | For the Plaintiffs: | PATRICIA K. LUNDVALL, ESQ. |
| 19 | | JOHN ZAVITSANOS, ESQ. JASON S. MCMANIS, ESQ. |
| 20 | | JOSEPH Y. AHMAD, ÉSQ. KEVIN LEYENDECKER, ESQ. |
| 21 | | D. LEE ROBERTS, JR., ESQ. |
| 22 | l I | K. LEE BLALACK, ESQ. JEFFREY E. GORDON, ESQ. |
| 23 | | DANIEL F. POLSENBERG, ESQ. |
| 24 | | |
| 25 | RECORDED BY: BRYNN WHITE, O | COURT RECORDER |

| 1 | <u>INDEX</u> |
|----|-------------------------------------|
| 2 | |
| 3 | Testimony10 |
| 4 | |
| 5 | |
| 6 | WITNESSES FOR THE PLAINTIFFS |
| 7 | JOHN HABEN |
| 8 | Cross-Examination by Mr. Blalack 10 |
| 9 | |
| 10 | |
| 11 | |
| 12 | |
| 13 | |
| 14 | |
| 15 | |
| 16 | |
| 17 | |
| 18 | |
| 19 | |
| 20 | |
| 21 | |
| 22 | |
| 23 | |
| 24 | |
| 25 | |
| | |

| 1 | | INDEX OF EXHIBITS | |
|----|--------------------|-------------------|-----------------|
| 2 | | | |
| 3 | | | |
| 4 | FOR THE PLAINTIFFS | MARKED | <u>RECEIVED</u> |
| 5 | 154 | | 45 |
| 6 | | | |
| 7 | | | |
| 8 | | | |
| 9 | | | |
| 10 | FOR THE DEFENDANT | MARKED | RECEIVED |
| 11 | 5502 | | 105 |
| 12 | 5503 | | 119 |
| 13 | 5499 | | 126 |
| 14 | 4569 | | 139 |
| 15 | 4570 | | 147 |
| 16 | | | |
| 17 | | | |
| 18 | | | |
| 19 | | | |
| 20 | | | |
| 21 | | | |
| 22 | | | |
| 23 | | | |
| 24 | | | |
| 25 | | | |
| | | 2 | |
| | | - 3 - | |

| 1 | Las Vegas, Nevada, Wednesday, November 10, 2021 |
|----|--|
| 2 | |
| 3 | [Case called at 9:19 a.m.] |
| 4 | [Outside the presence of the Jury] |
| 5 | THE COURT: Good morning, everyone. |
| 6 | MR. ROBERTS: Good morning. |
| 7 | THE COURT: Calling the case of Fremont Emergency versus |
| 8 | UnitedHealthcare. State appearances for the record. |
| 9 | MR. ZAVITSANOS: Yes, Your Honor. Good morning. John |
| 10 | Zavitsanos for the healthcare providers. |
| 11 | MR. MCMANIS: Good morning, Your Honor. Jason |
| 12 | McManis for the healthcare providers. |
| 13 | MR. LEYENDECKER: Good morning, Your Honor. Kevin |
| 14 | Leyendecker for the healthcare providers. Mr. Ahmad and Dr. Scherr are |
| 15 | here, but they may have just stepped out. |
| 16 | MR. ZAVITSANOS: And Ms. Lundvall I think is running a few |
| 17 | minutes late, Your Honor. |
| 18 | THE COURT: Thank you. For the defense, please. |
| 19 | MR. BLALACK: Good morning, Your Honor. Lee Blalack on |
| 20 | behalf of the Defendants. |
| 21 | MR. GORDON: Good morning, Your Honor. Jeff Gordon on |
| 22 | behalf of the Defendants. |
| 23 | MR. POLSENBERG: Good morning, Your Honor. Dan |
| 24 | Polsenberg also for the Defendants. |
| 25 | MR. BLALACK: And Mr. Roberts will join us later, |

| Y | Λı | ır | Н | \sim | n | \cap | r |
|---|----|----|---|--------|---|--------|---|
| | | | | | | | |

THE COURT: Thank you.

All right. So let's have an update from the Plaintiff.

MR. ZAVITSANOS: Your Honor, I don't think we have any updates other than we made additional progress last night and cutting additional -- both time with witnesses and witnesses. So I remain optimistic that we're going to meet the deadline that we represented to the Court.

MR. LEYENDECKER: One other point, Your Honor. At this point we think we're just going to play two tapes in our case; Mr. Rosenthal and Mr. Schumacher. And they've got some objections to Rosenthal, but they haven't yet reduced them to the specific objection for page and line. I've talked to Mr. Gordon and the -- and the goal would be to get you today, by day's end, the list of those clips with the page and line objections, and a highlighted transcript so that you can go through and break a tie however you see it.

THE COURT: Good enough. Thank you.

MR. BLALACK: So I -- that's how I see it. No comment on the progress of the trial. I'll address that -- we'll see how we do here, and I'll address that later, Your Honor.

THE COURT: Okay. Good enough.

Do we have anything else to take up before we bring in the jury? It's --

MR. BLALACK: Not from us.

MR. ZAVITSANOS: Your Honor, could I just ask a question

| | • |
|---|---|
| | 4 |
| | 5 |
| | 6 |
| | 7 |
| | 8 |
| | 9 |
| 1 | 0 |
| 1 | 1 |
| 1 | 2 |
| 1 | 3 |
| 1 | 4 |
| 1 | 5 |
| 1 | 6 |
| 1 | 7 |
| 1 | 8 |
| 1 | 9 |
| 2 | 0 |
| 2 | 1 |
| 2 | 2 |
| 2 | 3 |

25

1

2

3

| on the again, with this with the scheduling issue, because I know |
|--|
| Your Honor is working very hard to try and fit additional time in where |
| we can. I don't know what the Court's appetite would be for this, but in |
| connection with the jury charge, I don't know if Your Honor is if your |
| preference is to do it here in the court, but obviously we have offices |
| downtown that would that are near the courthouse, and certainly from |
| our standpoint, we have no objection to everybody meeting in one of the |
| offices. We can even do it at their office. I have no objection to that. |

THE COURT: Well, it has to be on the record. The settling of the jury instructions --

MR. ZAVITSANOS: Yes.

THE COURT: -- has to be on the record.

MR. ZAVITSANOS: Okay. I'm --

THE COURT: So --

MR. ZAVITSANOS: I'm just raising that and so I --

THE COURT: Yeah. We worked remotely for like eight months last year. So it can be done remotely, but it does have to be on the record.

MR. BLALACK: Yeah. Your Honor --

THE COURT: Response?

MR. BLALACK: -- we're -- we are also open to some sort of mechanism, whether that's somewhere off site with a court reporter or remote to have the jury charge conference in a way that doesn't occupy time for proof.

THE COURT: I'm going to see --

| C | > |
|---|---|
| C | > |
| C | > |
| Œ | 2 |
| Ñ | 5 |
| Ń | 5 |

| 1 | MR. BLALACK: So we're open to |
|----|--|
| 2 | THE COURT: how it goes |
| 3 | MR. BLALACK: those as well. |
| 4 | THE COURT: And pardon my interruption. |
| 5 | MR. BLALACK: No. I'm sorry, Your Honor. |
| 6 | THE COURT: I want to see how it goes today and Friday, but |
| 7 | I think we should consider longer days next week, whether we start at |
| 8 | 8:30 or 9. And then we can work for an hour afterwards. |
| 9 | MR. BLALACK: All right. |
| 10 | THE COURT: I can get approval for that overtime. |
| 11 | MR. BLALACK: Okay. |
| 12 | THE COURT: Let the jury go at 4:45. |
| 13 | MR. BLALACK: That that would |
| 14 | MR. ZAVITSANOS: And |
| 15 | MR. BLALACK: be good. |
| 16 | MR. ZAVITSANOS: one additional follow-up, Your Honor, |
| 17 | on that. And this is just to kind of chew on it, for lack of a better term, to |
| 18 | the extent that the court reporter's unavailable and if we do meet off site, |
| 19 | we would have no problem in splitting the cost that the other side to |
| 20 | range for another court reporter to transcribe that portion of it. I'm just |
| 21 | offering it. I mean |
| 22 | THE COURT: You could |
| 23 | MR. ZAVITSANOS: our preference would be |
| 24 | THE COURT: Yeah. |
| 25 | MR. ZAVITSANOS: to have obviously, though our |
| | |

| 1 | preference would be to have the current court reporter. But I'm just | | | | |
|----|--|--|--|--|--|
| 2 | throwing out options. That's all. | | | | |
| 3 | THE COURT: Why don't you guys talk about it and let me | | | | |
| 4 | know Friday? | | | | |
| 5 | MR. ZAVITSANOS: Okay. | | | | |
| 6 | MR. BLALACK: We're glad to do that, Your Honor. | | | | |
| 7 | THE COURT: Thank you. | | | | |
| 8 | Anything else? Any other housekeeping matters? | | | | |
| 9 | MR. ZAVITSANOS: Not from the Plaintiff, Your Honor. | | | | |
| 10 | MR. BLALACK: Not from us, Your Honor. | | | | |
| 11 | THE COURT: Okay. | | | | |
| 12 | MR. BLALACK: Would you like me to bring Mr. Haben in and | | | | |
| 13 | get him seated or would you | | | | |
| 14 | THE COURT: That would be great. | | | | |
| 15 | THE MARSHAL: Well, we're still missing some jurors, | | | | |
| 16 | Your Honor. | | | | |
| 17 | THE COURT: We're still missing a few jurors. | | | | |
| 18 | MR. BLALACK: Okay. | | | | |
| 19 | THE COURT: So why don't you guys just it's 9:23. At ease | | | | |
| 20 | until 9:30. | | | | |
| 21 | MR. BLALACK: Thank you, Your Honor. | | | | |
| 22 | MR. ZAVITSANOS: Thank you, Your Honor. | | | | |
| 23 | THE COURT: And I'll be back. | | | | |
| 24 | MR. BLALACK: Thank you. | | | | |
| 25 | [Recess taken from 9:23 a.m. to 9:31 a.m.] | | | | |

| 000027 | | | |
|--------|--|--|--|
| | | | |
| | | | |
| | | | |
| | | | |

| 1 | THE MARSHAL: We're back in session. |
|----|--|
| 2 | THE COURT: Please remain seated. |
| 3 | And can we bring in the jury? Everybody ready? |
| 4 | MR. BLALACK: I believe we are. Would you like me to bring |
| 5 | in Mr. Haben, Your Honor? |
| 6 | THE COURT: Yes, please. |
| 7 | MR. ZAVITSANOS: And, yes, Your Honor, we're ready. |
| 8 | [Pause] |
| 9 | THE COURT: And just a polite reminder to everyone. We |
| 10 | have to stop at 11:50. I have a meeting in this courtroom from 12 to 1. |
| 11 | MR. BLALACK: Your Honor, just for planning, is there a |
| 12 | particular target I should hit for trying to break for a break? |
| 13 | THE COURT: You know |
| 14 | THE MARSHAL: All rise |
| 15 | THE COURT: when you get |
| 16 | THE MARSHAL: for the jury. |
| 17 | THE COURT: to a natural breaking point, let me know. |
| 18 | MR. BLALACK: Will do. Thank you, Your Honor. |
| 19 | [Jury in at 9:32 a.m.] |
| 20 | THE COURT: Thank you. Please be seated. Good morning, |
| 21 | everyone. |
| 22 | GROUP RESPONSE: Good morning. |
| 23 | THE COURT: Welcome to Wednesday. We're going to have |
| 24 | to take a longer lunch today from 11:50 to about ten after 1 p.m. So we'll |
| 25 | just have one short break in the morning. |
| | |

| 2 |
|----|
| 3 |
| 4 |
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
| 23 |
| 24 |
| 25 |

| | | And, with that, cross-examination, please. |
|--------|----------|---|
| | | MR. BLALACK: Thank you, Your Honor. |
| | JC | OHN HABEN, PLAINTIFFS; WITNESS, PREVIOUSLY SWORN |
| | | CROSS-EXAMINATION |
| BY M | IR. BL | ALACK: |
| | Q | Good morning, Mr. Haben. |
| | Α | Good morning. |
| | Q | I wasn't sure I was going to get to speak with you. |
| | Α | Thank you. |
| | Q | But I want to promise you that I am not going to take three |
| days | to cor | mplete your examination. And I'm going to promise the jury |
| l'm n | ot goi | ng to do it. And I'm promising counsel I'm not going to do it. |
| | So le | t me start by this, Mr. Haben, do you recall Mr. Zavitsanos |
| tellin | ıg you | last week that in another life I was in the Marine Corps? |
| Α | Yes, | l do. |
| | Q | Well, when I was in boot camp at Parris Island, South |
| Caro | lina m | y drill instructor would frequently ask my platoon a question, |
| and t | then b | efore we could give an answer, he would shout out the |
| answ | ver to ι | us in front of us. And I always had the impression that my |
| drill | instruc | ctor didn't really care what the answer to the question was and |
| he w | as rea | lly just doing it for show. |
| | Have | you ever had an experience like that? |
| | Α | Yes, I have. |
| | Q | I don't think that sort of process is a very useful process for |
| learn | ning fa | cts. So I want to make sure the jury gets to hear your answers |

25

Α

I did.

| ' | lo key que | stions and not just what the lawyers have to say. Is that okay |
|----|-------------|--|
| 2 | with you? | |
| 3 | А | Yes, sir. |
| 4 | Q | Now, Mr. Zavitsanos and I are not witnesses, and we are not |
| 5 | under oath | n, but you are. Do you take that obligation seriously, sir? |
| 6 | А | Very seriously. |
| 7 | Q | I hope to do my examination what I hope to do in this |
| 8 | examination | on is to cover some basic questions about UnitedHealthcare's |
| 9 | out-of-net | work program. And then I'm going to give you an opportunity |
| 10 | to respond | I to each of the allegations that my colleague, Mr. Zavitsanos, |
| 11 | made agai | nst you during the questioning. But first I'd like to start with |
| 12 | your back | ground; is that okay? |
| 13 | Α | Yes, sir. |
| 14 | Q | Let's start, sir, where you live. |
| 15 | Α | I live in Edina, Minnesota. |
| 16 | Q | Are you married? |
| 17 | Α | I am. |
| 18 | Q | How long have you been married? |
| 19 | Α | Over 30 years. |
| 20 | Q | Do you have any children? |
| 21 | Α | We have two sons. |
| 22 | Q | How old are your boys? |
| 23 | А | The oldest is 23 and the youngest is 21. |

Did you attend college?

| 1 | Q | Did you receive a college degree? |
|----|-------------|--|
| 2 | А | I did. That was a bachelor's of business administration and |
| 3 | major in a | ccounting at the University of Wisconsin-Eau Claire. |
| 4 | Q | And after graduating from college, did you go on to any |
| 5 | other stud | ies or did you go immediately into the workforce? |
| 6 | А | I think as I alluded either yesterday or the day before, I tried |
| 7 | to take the | CPA twice and failed that. No, but nothing beyond that. |
| 8 | Q | Where did you start working after graduating? |
| 9 | А | Right after college I actually went into UnitedHealthcare. |
| 10 | Q | What year was that? |
| 11 | А | 1989. |
| 12 | Q | Now, you testified last week that you retired from |
| 13 | UnitedHea | althcare sometime this year? |
| 14 | А | I did. |
| 15 | Q | Okay. So were you employed with UnitedHealthcare |
| 16 | continuou | sly from 1989 until when you retired? |
| 17 | А | No. I spent two years at a third-party administrator, and then |
| 18 | came back | to United. |
| 19 | Q | What years were those? |
| 20 | А | 1999 to 2001. |
| 21 | Q | So excluding the time you were aware, 1999 to 2001, how |
| 22 | many tota | I years were you employed with UnitedHealthcare? |
| 23 | А | Just over 30 years. |
| 24 | Q | What was your first position at UnitedHealthcare? |
| 25 | Α | It was what's called billing and reconciliation. We received |

| \subset |) |
|---------------|---|
| 826000 |) |
| $\overline{}$ | • |
| ሯ | ` |
| 'n | ′ |
| Ň |) |
| α |) |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

| 1 | premium | ns from employer groups, and we would have to reconcile to the |
|----|------------|--|
| 2 | member | ship on the actually, it was a green bar of paper, and we'd |
| 3 | have to p | physically account for who they're paying for and who they're |
| 4 | terminat | ing, who they're adding on, et cetera. |
| 5 | Q | Okay. And what was your job position when you retired |
| 6 | earlier th | is year? |
| 7 | А | I was Vice President of the out of network programs. |
| 8 | Q | When did you first take on responsibility for out of network |
| 9 | program | s at UnitedHealthcare? |
| 10 | А | Probably in about 2003. |
| 11 | Q | Did you maintain a leadership role for out of network |
| 12 | program | s continually between 2003 and your retirement this year? |
| 13 | Α | Yes, I did. |
| 14 | Q | Okay. Now, Mr. Haben, I want to explain a little more to the |
| 15 | jury abo | ut the five Defendants in this case and how you do, or you don't |
| 16 | relate to | those Defendants, okay? |
| 17 | Α | Okay. |
| 18 | Q | So I believe you testified last week that you were employed |
| 19 | by Unite | dHealth Networks; is that right? |
| 20 | Α | That's correct. |
| 21 | Q | Okay. Now, the five Defendants in this case are |
| 22 | UnitedH | ealthcare Insurance Company, UnitedHealth Services, United |
| 23 | Medical | Resources, or UMR, Sierra Health and Life, and Health Plan of |
| 24 | Nevada. | Do you understand that? |
| 25 | А | Yes. |

| 1 | Q | Okay. Are you an employee of any of these five Defendants? |
|----|--------------|--|
| 2 | А | I am. |
| 3 | Q | Which one? |
| 4 | А | UnitedHealthcare Services. I was. I am no longer. |
| 5 | Q | That's a fair question. Thank you. |
| 6 | Α | Yeah. |
| 7 | Q | Have you ever worked for Sierra Health and Life Insurance |
| 8 | Co? | |
| 9 | А | I have not. |
| 10 | Q | Have you ever worked for Health Plan of Nevada? |
| 11 | А | I have not. |
| 12 | Q | Have you worked for UMR? |
| 13 | А | I did not. |
| 14 | Q | Okay. Now, Mr. Haben, you testified last week that you |
| 15 | signed a se | everance agreement when you retired. Do you remember that |
| 16 | testimony? | • |
| 17 | А | Yes, I do. |
| 18 | Q | I believe you said that that agreement required you to |
| 19 | cooperate | with any lawsuits filed against UnitedHealthcare? |
| 20 | А | Yes, it does. |
| 21 | Q | What does that agreement require you to do? |
| 22 | А | To provide truthful testimony and information. |
| 23 | Q | Does that agreement condition your severance payments as |
| 24 | a retiree or | n giving testimony helpful to my clients in this case or any |
| 25 | other case | ? |

| 8 |
|---------|
| 9 |
| |
| \circ |
| Ó |
| ယ |
| Õ |
| _ |

| 1 | Α | It does not. |
|----|-------------|---|
| 2 | Q | Now, last week Mr. Zavitsanos mentioned that the time |
| 3 | period at i | ssue in this case ran from July 1, 2017 through January 31st, |
| 4 | 2020. And | d I take it you were the Vice President of Out of Network |
| 5 | Programs | for UnitedHealth Networks during that entire time? |
| 6 | А | Yes, I was. |
| 7 | Q | Okay. What were your responsibilities as Vice President of |
| 8 | Out of Net | twork Programs during that period? |
| 9 | А | At a high level, it was to help our clients achieve competitive |
| 10 | medical co | ost reimbursement. So we would meet with the sales |
| 11 | organizati | ons, the healthcare economics folks, the finance teams to get |
| 12 | informatio | on about, you know, hey our satisfied clients, they demand |
| 13 | more. Yo | u know, what could we do to help address medical expend? |
| 14 | Q | You mentioned a couple of entities there. You said |
| 15 | healthcare | e economics. What is healthcare economics? |
| 16 | А | At a high level, I mean they're actuaries or individuals that |
| 17 | know clair | ms economics. They can look at the claims data. They |
| 18 | understan | d the industry. And they'll provide actuary analytics. |
| 19 | Q | And you mentioned a salesforce; is that correct? |
| 20 | А | Yeah. |
| 21 | Q | Okay. And there's a separate sales organization in |
| 22 | UnitedHea | althcare? |
| 23 | А | Yes, there is. |
| 24 | Q | So when you mentioned healthcare economics and the sails |
| 25 | force, are | those groups within your group of out of network programs |

| 0 | |
|---|--|
| 8 | |
| ಹ | |
| Č | |

| 1 | personnel [*] | ? |
|----|------------------------|--|
| 2 | А | No, they're not. |
| 3 | Q | Now, how many people did you supervise during the period |
| 4 | at issue in | this case, just generally, in the out of network program crew? |
| 5 | А | Just about 80 to 90 people. |
| 6 | Q | Did anyone report directly to you? |
| 7 | А | Yes. |
| 8 | Q | Who was that? |
| 9 | А | In that time period, Becky Paradise and Sarah Peterson, and |
| 10 | then Sarah | retired. |
| 11 | Q | Now, had you ever had responsibility, you personally, for the |
| 12 | out of netv | vork programs for Sierra Health? |
| 13 | А | No. |
| 14 | Q | Have you ever had responsibility for the out of network |
| 15 | programs | for Health Plan of Nevada? |
| 16 | А | No. |
| 17 | Q | Have you ever had responsibility for the out of network |
| 18 | programs | for UMR? |
| 19 | А | I have not. |
| 20 | Q | Do you know if UMR, Sierra, and Health Plan of Nevada use |
| 21 | out of netv | work programs that were different from the programs you |
| 22 | managed | for UnitedHealthcare? |
| 23 | А | There was some similarities. |
| 24 | Q | Okay. Are there differences? |
| 25 | А | Yes, there are. |

| 0 |
|-----------|
| \geq |
| \approx |
| ဃ |
| N |
| |
| |
| |

| 1 | Q | Okay. Now, you were asked a few questions by |
|----|-------------|---|
| 2 | Mr. Zavitsa | nos about UMR yesterday. Do you recall those questions? |
| 3 | А | Yes, I do. |
| 4 | Q | Do you know if UMR has any out of network programs that |
| 5 | are similar | to those of UnitedHealthcare? |
| 6 | А | There are some similarities, yes. |
| 7 | Q | Are there any that are different? |
| 8 | А | Yes. |
| 9 | Q | And have you ever supervised any out of network programs |
| 10 | operated b | y United Medical Resources, or UMR? |
| 11 | А | No, I have not. |
| 12 | Q | So if the jury wanted to understand what the out of network |
| 13 | programs | were for Sierra, Health Plan of Nevada, or UMR, you would not |
| 14 | be the pers | son to speak to? |
| 15 | А | I would not be. |
| 16 | Q | Okay. Now, you testified for three days in response to |
| 17 | questions | from Mr. Zavitsanos. Did any of your testimony regarding out |
| 18 | of network | programs relate to Sierra or Health Plan of Nevada? |
| 19 | Α | No, they did not. |
| 20 | Q | Now, where did your organization, UnitedHealthcare |
| 21 | Networks s | sit in the broader UnitedHealth corporate structure? |
| 22 | А | So we were if you're saying UnitedHealthcare |
| 23 | UnitedHea | Ith Group corporate structure, there's Optum, there's |
| 24 | UnitedHea | Ithcare. Inside UnitedHealthcare, there's many organizations. |
| 25 | UnitedHea | Ith Networks is an organization inside the UHC arm. I believe |

| 1 | the legal e | ntity is UnitedHealth Services. |
|----|--------------|--|
| 2 | Q | And you mentioned there's a number of entities. Is one of |
| 3 | the entities | s within United within UnitedHealth be what's called the E&l |
| 4 | group, or l | Employer & Individual group? |
| 5 | А | Yes. |
| 6 | Q | What does that group what is the function of that group? |
| 7 | А | As we talked before, they're the commercial book of |
| 8 | business. | E&I stands for Employer & Individual. And I think we covered |
| 9 | some indiv | vidual business yesterday. |
| 10 | Q | Are you were you ever an employee of E&I? |
| 11 | А | No. |
| 12 | Q | And is there a separate group that's responsible for |
| 13 | governme | nt programs, benefit programs, that UnitedHealthcare |
| 14 | participate | es in? |
| 15 | А | Yes. |
| 16 | Q | And what's that called? |
| 17 | А | There's a Medicare and a Medicaid group. |
| 18 | Q | Were you ever employed by any of those groups? |
| 19 | А | No. I would have not been. |
| 20 | Q | Now, in July 2017, in the beginning of this period, to whom |
| 21 | did you re | port? |
| 22 | А | July of 2017, I reported to Dan Rosenthal. |
| 23 | Q | What was his title? |
| 24 | А | He was the President of UnitedHealth Networks. |
| 25 | Q | And just, again, to make sure the jury's clear, when you say |

| 4 |
|----|
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
| 23 |
| 24 |
| 25 |

| 1 | President (| of UnitedHealth Networks, you don't mean president of all of |
|----|-------------|--|
| 2 | United? | |
| 3 | А | No. |
| 4 | Q | And you don't mean president of the commercial |
| 5 | businesse | s? |
| 6 | А | No. That was a separate individual. |
| 7 | Q | So he was president of the group known as UnitedHealth |
| 8 | Networks | within which you participated? |
| 9 | А | That is correct. |
| 10 | Q | Okay. Now, did it did you report to Mr. Rosenthal |
| 11 | continuou | sly until January of 2020, which is the end of the period at |
| 12 | issue in th | is case? |
| 13 | А | No, I did not. |
| 14 | Q | To whom did you report after Mr. Rosenthal? |
| 15 | А | Vicki Miller. Her name's Katherine V. Miller. And that was |
| 16 | around 20 | 18. |
| 17 | Q | Now, Mr. Haben, I'm now going to ask you to define for the |
| 18 | jury some | key healthcare terms and concepts. We've talked about some |
| 19 | of these, b | ut I want to see if you just can do it in a more straightforward |
| 20 | way than y | you were able to do before. So let's walk through a couple of |
| 21 | basic term | s to make sure we all agree what they are before we start |
| 22 | looking at | some [indiscernible]. |
| 23 | Have | e you heard the terms fully-insured health plan and self- |
| 24 | insured he | ealth plan? |
| 25 | Α | I have. |

| 35 | | | |
|----|--|--|--|
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| Q | What is | a fully- | insured | health | plan? |
|---|---------|----------|---------|--------|-------|
|---|---------|----------|---------|--------|-------|

A A fully-insured health plan or business is a health plan that's responsible for the medical cost risk.

- Q And what is a self-funded health plan?
- A Is self-funded health plan employer groups that are assuming the risk of the medical cost payments. They fund the claims payment.
- Q What are principal differences between a self-funded plan and a fully-insured plan?

A As I kind of touched on, so fully insured, there's the risk, the medical loss risk, associated with that. That's part of the health plan, part of UnitedHealthcare. For self-funded or ASO they have the medical cost risk. And they look to third-party administrators like us to do the administration of not only claims but many other services.

Q Sir, I'll represent to you that in this case one of the plans for when claims were submitted and are in dispute relates to the Las Vegas Metropolitan Police Department. And I'll represent to you that it's an ASO plan or self-funded plan.

- A Okay.
- Q If that employer is a self-funded plan and one of its employee seeks medical care in the emergency room, is the administrator of that plan responsible for paying those medical costs or is the money used to pay those claims coming from the Las Vegas Metropolitan Police Department?
 - A The funds are coming from the Las Vegas Police Department.

| | _ | |
|---|-----------|--|
| C | \supset | |
| C | \supset | |
| C | \supset | |
| C | Ō | |
| C | v | |
| Č | מכ | |

| 1 | Q | Okay. Now, if you have a different situation, let's say an |
|----|-------------|--|
| 2 | employer | that has a fully-insured plan, their if one of their employees |
| 3 | goes to th | e emergency room and incurs medical costs, the funds are |
| 4 | coming fro | om where? |
| 5 | А | They're coming from the UnitedHealthcare health plan. |
| 6 | Q | Not the employer? |
| 7 | А | Not the employer group. |
| 8 | Q | Now, have you ever heard the term third-party administrator, |
| 9 | or TPA? | |
| 10 | А | Yes, I have. |
| 11 | Q | And what is a TPA? |
| 12 | А | As I indicated before, they're the administrator for self- |
| 13 | funded em | nployer groups. So the employer groups look to that |
| 14 | administra | ator to do services, which include claims payment and |
| 15 | enrollmen | t, billing, directory, many other things. |
| 16 | Q | And does the TPA have any responsible for assembling and |
| 17 | providing | a network of providers for the employers who hire you? |
| 18 | А | Yes, they do. |
| 19 | Q | Okay. How is a TPA different, if at all, from a health |
| 20 | insurance | company? |
| 21 | А | The TPA does not incur the medical cost risk. We're like a |
| 22 | health ins | urance company. That's one of the primary components. |
| 23 | Q | Okay. Now, Mr. Haben, I'd like to show you a few slides that |
| 24 | I shared w | rith jury in the opening that illustrates the differences in these |
| 25 | plans, to h | nelp make sure we can agree on what it is how these two |

| 3 |
|----|
| 4 |
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
| 23 |
| 24 |
| 25 |
| |

2

| types of models | work, | okay? |
|-----------------|-------|-------|
|-----------------|-------|-------|

A Yeah.

O The first one I'm going to show you -- I'm going to ask Shane to bring up -- is slide 9. Can you see it? It will come up. Can you see it on your screen when it comes up?

A Yes. I can see it. Thank you.

Q All right. Now, sir, I've depicted here what's labeled as a "fully insured health plan arrangement." Can you describe for the jury what -- who the parties are and how the funds are transferring between those parties?

A So -- and thank you for fixing the screen, whoever did that, because I can actually see things.

Q Well, I can assure you it wasn't me.

A Thank you. On the left-hand side there are three entities, the insurance company at the top, the employer group who buys the health plan from the insurance company, and the employee, in cases of medical treatment, the patient is the third entity at the bottom.

Q And do you see dollars associated with arrows, flowing toward the staffing company, in that slide?

A I do.

Q Can you describe what those two different groups of payments are?

A So there's the claims payment that comes from the insurance company. I think we might have touched on that before, that could -- that's the allowed amount, and I can explain that later. And then there's

| 2 |
|----|
| 3 |
| 4 |
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
| 23 |
| 24 |
| 25 |

| the | patient | cost | share. | So | again, | like v | ve | talked | on, | earlier, | that's | the |
|-----|----------|-------|---------|-------|---------|--------|------|--------|-----|----------|--------|-----|
| со- | pay, the | co-ir | nsurano | ce, a | any ded | ductib | ole. | ı | | | | |

THE COURT: I just want to interrupt for a second. Everyone can see him okay? Thank you.

THE WITNESS: I'm sorry.

THE COURT: Thank you.

MR. BLALACK: If I need to move that, Your Honor, just let me know.

THE WITNESS: No, I --

THE COURT: I just need to make sure that Ms. Ross has a line of sight. Thank you.

BY MR. BLALACK:

O All right. So when the employee of this employer seeks care from the emergency room, that is affiliated with Team Health, there would be payments flowing to the staffing company from two sources, one from the insurance company, and the other from the employer/patient; is that fair?

A Yes, that's correct. And both of those together is what's called the "allowed amount."

O Okay. And I want to cover those terms and define those in a moment. I just make sure the jury understands the flow of funds here. All right. I'm showing the next line, which is line 10. This one is labeled "self-funded health plan." So in this model, please explain the parties that are in the flow of funds.

A So similar on the left-hand side you have the claims

| 200 | |
|---------------|--|
| 0 20 20 | |
| | |
| | |
| | |

| 1 | administra | ator at the top, which would be the third-party administrator, | |
|----|---|---|--|
| 2 | you have t | the employer group, and then you have the employee/patient. | |
| 3 | Q | And you still have the same kind of payments being made to | |
| 4 | the staffin | g company? | |
| 5 | А | Yes. | |
| 6 | Q | Except this time, that one of the payments is coming from | |
| 7 | the emplo | yer instead of the insurer? | |
| 8 | А | Yeah. The employer will fund the claims, the administrator | |
| 9 | will release those funds to the provider. | | |
| 10 | Q | Does UnitedHealthcare offer a fully insured health plan? | |
| 11 | А | Yes. | |
| 12 | Q | Does UnitedHealthcare offer administrative services, to | |
| 13 | sponsor a self-funded health plan? | | |
| 14 | А | Yes. | |
| 15 | Q | Does UnitedHealthcare sometimes operate both as an | |
| 16 | insurance company and as a dba? | | |
| 17 | А | Yes, they do. | |
| 18 | Q | Now in responses to questions from Mr. Zavitsanos you | |
| 19 | referred to | the bill charge in the allowed amount. I think you just alluded | |
| 20 | to that; is that right? | | |
| 21 | А | Yes. | |
| 22 | Q | All right. Let's define those terms again, before we get into | |
| 23 | the docum | nent, to make sure everyone's clear, what is a bill charge? | |
| 24 | А | The bill charge is the charge amount that is set by the | |
| 25 | provider, | or the staffing company. | |

| 1 | Q | And what is the allowed amount? | |
|----|--|--|--|
| 2 | А | The allowed amount is what is allowed in that claim in total, | |
| 3 | per the benefit plan. | | |
| 4 | Q | Okay. In your 30 some odd years in the industry, in your | |
| 5 | experienc | e, is the provider's bill charge typically different from the | |
| 6 | allowed amount? | | |
| 7 | А | Yes. | |
| 8 | Q | And why is that? | |
| 9 | А | Typically, the provider rarely ever gets the bill charge | |
| 10 | amount. That's typically what's not expected. | | |
| 11 | Q | And is that because the bill charge is typically much greater | |
| 12 | than the allowed amount? | | |
| 13 | А | Yes. | |
| 14 | Q | Okay. Now what is patient responsibility, Mr. Haben? | |
| 15 | А | As I touched on before, patient responsibility is your co-pay, | |
| 16 | which is usually a flat amount, your co-insurance, which is a percentage | | |
| 17 | of the allowed amount, and then a deductible. | | |
| 18 | Q | How is the patient responsibility calculated? | |
| 19 | А | Co-pay is a flat amount, typically defined everything is | |
| 20 | defined in the benefit plan. The co-insurance is calculated off of the | | |
| 21 | allowed, and then the deductible is an accumulation of both. | | |
| 22 | Q | When you say that the co-insurance is calculated off of the | |
| 23 | "allowed" what do you mean by that? | | |
| 24 | А | So there's the, as we talked before, there's the bill charge | |
| 25 | amount, t | here's an allowed amount, which is defined by the benefit plan | |

| Q | Okay. Now what is patient responsibility, Mr. Haben? | | |
|--|--|--|--|
| Α | As I touched on before, patient responsibility is your co-pay, | | |
| vhich is us | sually a flat amount, your co-insurance, which is a percentage | | |
| of the allow | ved amount, and then a deductible. | | |
| Q | How is the patient responsibility calculated? | | |
| Α | Co-pay is a flat amount, typically defined everything is | | |
| defined in | the benefit plan. The co-insurance is calculated off of the | | |
| allowed, and then the deductible is an accumulation of both. | | | |
| Q | When you say that the co-insurance is calculated off of the | | |
| allowed" what do you mean by that? | | | |
| Α | So there's the, as we talked before, there's the bill charge | | |
| amount, there's an allowed amount, which is defined by the benefit plan. | | | |
| | | | |
| | - 25 - | | |

| | _ |
|---|---|
| | 3 |
| | 4 |
| | 5 |
| | 6 |
| | 7 |
| | 8 |
| | 9 |
| 1 | 0 |
| 1 | 1 |
| 1 | 2 |
| 1 | 3 |
| 1 | 4 |
| 1 | 5 |
| 1 | 6 |
| 1 | 7 |
| 1 | 8 |
| 1 | 9 |
| 2 | 0 |
| 2 | 1 |
| 2 | 2 |
| 2 | 3 |
| 2 | 4 |
| 2 | 5 |

| That is the amount that is allowed for that payment in total, and the |
|---|
| percentage, let's say you have a 10 percent co-insurance, it's calculated |
| off of that allowed amount. |

- Q Not the bill charges?
- A Not the bill charges.
- Q All right. Mr. Haben, I'd like to show you a few slides that illustrate the differences between the bill charge, an allowed amount, and patient responsibility, okay?
 - A Yes.
- Q All right. This first one -- oh, by the way, I should have, I skipped this, I should have mentioned this. Let's go back. On the fully insured self-funded health plan, how is the payment for the risk of paying for medical costs borne in a fully insured plan?
 - A The risk is borne by the insurance company.
 - Q And does the employer pay for it?
 - A They pay a premium for that --
- 7 O So they pay --
 - A -- insurance.
- Q -- an insurance premium?
 - A Yes, they do.
 - O So in this slide what's depicted under the fully insured plan?
 - A So I think as you have here, the employer group is on the left-hand side, they pay a premium, they send those premiums over to the insurance company, the insurance company has the risk of paying those -- paying the medical claims out of the premiums that were

| 1 | received. |
|---|-----------------|
| | I I CCCI V CCI. |

Q And then in a self-funded plan, what is the nature of the assumption of risk and the payment of --

A So the employer group is over on the left-hand side. They pay an administrative fee to do all the functions that I have kind of highlighted, but they have the risk, much like the insurance company did above, of the medical cost.

O Thank you. Now let's go on to slide 13.

MR. BLALACK: Bring that up, Shane.

BY MR. BLALACK:

Q And again, as I was saying, let's just make sure we understand how these terms work in combination with each other, and you calculated patient responsibility.

So first of all I'm showing you, in a hypothetical, a claim for a CPT code 99285, which is an emergency room evaluation and management code, and I'm assuming in this example, an allowed amount of \$200. Do you see that?

A Yes.

Q Now here in the next image, I'm showing you an assumption of a bill charged for that service of \$1,000. Do you see that?

A I do.

Q Okay. Now, I want you to walk the jury through, if you can, how the calculation of patient responsibility occurs when you have a bill charge of a 1,000, and the benefit plan has an allowed amount of 200, can you walk them through that for me?

| 000943 | | | |
|--------|--|--|--|
| | | | |
| | | | |

| A Yes, I can. So you'll see on the left-hand side, sorry, bill |
|---|
| charges of a \$1,000. The benefit plan will define what's allowed for |
| those that type of service. The allowed amount in this situation is |
| \$200. Your co-insurance is calculated off of that 200, so 30 percent o |
| 200 is \$60. |

- Q So in a situation where this emergency room encounter occurred and the charge was a 1,000, under this benefit plan the patient responsibility would be \$60?
 - A That's correct.
- Q Okay. Now are you aware, sir, that in this case, I think Mr. Zavitsanos mentioned it to you, that the female plaintiffs in this case allege that the allowed amounts for the disputed claims in this case, should have been bill charges; are you aware of that?
 - A lam.
- O Okay. Now let's -- what I'd like you to do, is I'm going to change the assumption here so that the bill charge and the allowed amount are the same, so that the allowed amount was a 1,000, not 200 of this claim, okay? If you could walk the jury through how to calculate patient responsibility if the allowed amount was the full charged?
- A Sure. So in this situation bill charge is a 1,000, the allowed amount, based on the benefit plan, would be \$1,000, if you paid that and if that's what the benefit plan said, the co-insurance is 30 percent, 30 percent calculated off the 1,000 is \$300.
- Q So now the -- on a charge of a 1,000 for that account, the patient would be responsible for 300, or 30 percent of the total?

| 1 | Α | That's correct. | | |
|----|--|--|--|--|
| 2 | Q | Now you may and I think you said this. Did you testify a | | |
| 3 | moment ago that what determines the allowed amount is the benefit | | | |
| 4 | plan? | | | |
| 5 | А | Yes. | | |
| 6 | Q | When you refer to the benefit plan, are you referring to the | | |
| 7 | actual documents, the health plan documents? | | | |
| 8 | А | A Yes, I am. | | |
| 9 | Q Okay. What types of documents do you mean? | | | |
| 10 | A For a fully insured, it's the it's commonly known as the | | | |
| 11 | certificate of coverage, and for the self and employee group, it's the | | | |
| 12 | summary plan description, or SPD. | | | |
| 13 | Q | And then is there some sort of document called an | | |
| 14 | administrative services agreement? | | | |
| 15 | А | Yes, there is. | | |
| 16 | Q | And what does an administrative service agreement say? | | |
| 17 | А | So the ASA is the document that is the agreement between | | |
| 18 | the employer group, with the third-party administrator to perform | | | |
| 19 | services on their behalf. | | | |
| 20 | Q | Okay. I just want to make sure I heard you correctly, and that | | |
| 21 | the jury understands this. Did you say that a certificate of coverage is | | | |
| 22 | associated with a fully insured plan? | | | |
| 23 | А | Yes. | | |
| 24 | Q | And did you say a summary plan description would be | | |
| 25 | associated with a self-insured or ASO plan? | | | |

| \supset | |
|-----------|--|
| ${}$ | |
| \supset | |
| တ္ | |
| 4 | |
| תט | |
| | |

Α

Yes.

| 2 | Q | Okay. So if the jury sees a COC, or a certificate of coverage, |
|----|--------------|---|
| 3 | they shoul | d interpret that as being associated with a fully insured plan? |
| 4 | А | That's correct. |
| 5 | Q | And if they see a summary plan description, they should |
| 6 | associate i | t with a self-insured plan? |
| 7 | А | That's correct. |
| 8 | Q | What about an ASA, does that apply to just one, or both? |
| 9 | А | The ASA is typically it's an administrative service |
| 10 | agreement | , it's typically a self-funded employer group. |
| 11 | Q | Now precisely what is a certificate of coverage, what does |
| 12 | that mean? | ? |
| 13 | А | It's the contract between the insurance company and the |
| 14 | employee | of the employer group, and so that is the promise of what is |
| 15 | going to be | e covered for services and other components. |
| 16 | Q | Okay. And in your experience aren't COCs typically filed with |
| 17 | any regula | tory authority? |
| 18 | Α | Yeah. COCs are filed in the states, in terms of where you're |
| 19 | doing busi | ness. The states are very different in how you approach it. |
| 20 | Q | All right. And then it's what type of information is typically |
| 21 | contained | in an administrative services agreement? |
| 22 | Α | The administrative services agreement covers the |
| 23 | responsibi | lities that the third-party administrator would perform on |
| 24 | behalf of th | ne employer group, that could be, obviously, the benefit you |
| 25 | know, the | type of programs they've adopted, requirements for provider |
| | | |

| | directory. | It might b | e clinical, r | member ser | vices, many o | other things |
|--|------------|------------|---------------|------------|---------------|--------------|
|--|------------|------------|---------------|------------|---------------|--------------|

- O Okay. Is it fair to call it an administrative service agreement contract?
 - A Yes.

- Q And the parties to the administrative service agreement are who?
- A It's between the employer group and the third-party administrator.
- Q In your experience, sir, are health plan documents usually identical for all UnitedHealthcare's clients?
 - A No.
- Q Okay. And why do health plan documents typically differ, in your experience, by client?
- A You could ask me to get into details, but I'll give you at a general high level --
 - Q That's fine.
- A -- that self-funded employer groups have different needs, they're different sizes in what they want to have performed. Some of them bring their own benefit plan in, and say, I want you to do this, and some will ask for some type of recommendation. For fully insured, like I said before, there are state rules you have to follow, and so the states will approve or deny a benefit plan, and you have to follow those, and there could be a variety inside a state.
- Q And then the clients can choose among those options that are in the state --

| 000 | | |
|--------|--|--|
| 000947 | | |
| • | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |

| 1 | A | Yes. |
|----|-------------|---|
| 2 | Q | that are offered? But it sounds like clients of employers |
| 3 | who purch | ase health insurance for their employees, seek to tailor their |
| 4 | plans to th | e needs of their particular workforce; is that fair? |
| 5 | А | Very much so. |
| 6 | Q | And is it what's the relationship between the size and |
| 7 | sophisticat | tion of the employer to come, once that occurred? |
| 8 | А | The bigger the employer group, the greater variety, and you |
| 9 | can deal w | rith unions, bargain groups, municipalities. They're very |
| 10 | different. | |
| 11 | Q | All right. Let's talk about some other e-concepts, employers |
| 12 | in the heal | th insurance and healthcare market. What is a "participating |
| 13 | provider"? | |
| 14 | А | A participating provider has a contract with the health plan to |
| 15 | be in their | network, we commonly call that "par." |
| 16 | Q | Okay. And does that contract typically include some rate, or |
| 17 | amount of | reimbursement for services rendered to the members of the |
| 18 | health plar | n? |
| 19 | А | Yes, it does. |
| 20 | Q | And in those contracts do they typically indicate that if |
| 21 | services ar | e rendered to a member of the plan, covered services, and |
| 22 | reimburse | ments are made at the agreed rates, that the participating |
| 23 | provider w | vill accept that payment in full satisfaction of the insured? |
| 24 | А | Yes. Along with the patient cost share. |
| 25 | Q | And would a participating provider agreement, or network |

| 1 | agreement, would that typically include a term in the contract, like a lien |
|---|--|
| 2 | of time, in which the contract would be in place? A Yeah. There's a period of time where that contract it would |
| 3 | A Yeah. There's a period of time where that contract it would |

- A Yeah. There's a period of time where that contract -- it would say, here's the start date, here's the end date, and there's options for renewals, depending on the contract.
 - Q What is a non-participating provider?
- A A non-participating provider is a provider that does not have a contract with the insurance company to be in their network.
- Q I think you just said that participating providers are called "par providers," that's a shorthand phrase?
 - A Correct.
 - Q And are non-participating providers often called non-par?
 - A Correct.
- Q When a healthcare provider is out-of-network, does that provider ever have a direct contract with UnitedHealthcare that specifies the reimbursement that UnitedHealthcare will pay for the services the provider vendors to a United member?
 - A No.
- Q Is the very definition of a non-network provider, a provider who has no contract?
 - A That they're not in our broad network.
- O Now when you were at the company did UnitedHealthcare receive a claim coming out of that work provider, that's what I'm asking about, if you were there and a claim came in from an out-of-network provider, how did the company -- how did you all decide how much to

| | - 11 | | | | | | | | _ |
|---|-------|--------------|-------|--------|--------|------|--------------|----------|-----|
| ı | allow | OΠ | that | UIIT-U | t-netw | /∩rk | വ | ลเท | ገ ለ |
| | anovv | \mathbf{O} | tiiat | out o | | | \mathbf{v} | <i>.</i> | |

- A It's all based on what's defined in the benefit plan.
- Q What do you mean by that?

A Well, you have to look at the summary plan description, where the certificate of coverage, depending on what that patient has for coverage, and then you would look at what's the allowable amount for that type of service, and then you would reimburse that amount.

- Q In response to questions from Mr. Zavitsanos, you frequently referred to the term "balance billing," do you recall that?
 - A Yes, I do.
 - Q What is balance billing?

A That is when the provider will bill the patient, and if I can explain a little bit further, is there's two components, the cost share, the co-pay, co-insurance, and deductible, and then there's anything that's above the allowed amount to the bill of charges.

- Q So this would be the provider or the staffing company seeking reimbursement for amounts above the allowed amount?
 - A That is correct.
- Q Is a provider that participates in UnitedHealthcare's network, can that provider legally balance bill the United member under their contract?
 - A I'm sorry, say that again.
- Q I'm sorry. Let me -- that was a poor question. If a provider is in UnitedHealthcare's network, is a par provider --
- A Yes.

| \subseteq | 2 | |
|-------------|--------|--|
| | ξ | |
| CROOL | ה ס | |
| | | |
| | | |
| | | |
| | | |
| | | |

| 1 | Q | or the network provider; that's the assumption, can that |
|----|-------------|---|
| 2 | network p | rovider, legally, under its agreement, balance bill the patient |
| 3 | who is the | United member. |
| 4 | | MR. ZAVITSANOS: I'm sorry, Your Honor. I don't mean to |
| 5 | interrupt h | ere, but that opinion on an ultimate issue, it also calls for legal |
| 6 | conclusion | n. If counsel would rephrase |
| 7 | | MR. BLALACK: Sure |
| 8 | | MR. ZAVITSANOS: I would have no objection. |
| 9 | | THE COURT: Rephrase. |
| 10 | BY MR. BL | ALACK: |
| 11 | Q | In your understanding of the relationship between |
| 12 | UnitedHea | Ilthcare and its participating or network provider, that's the fact |
| 13 | [indiscerni | ble]. |
| 14 | А | Yeah. |
| 15 | Q | In your understanding are the network providers who signed |
| 16 | up with Ur | nitedHealthcare permitted to balance bill members who are in |
| 17 | the netwo | rk? |
| 18 | А | No. Only for their co-pay, co-insurance and deductible. |
| 19 | Q | Now during the period at issue in this case, if a provider was |
| 20 | out-of-net | work, and I'm not talking about in the network, out-of-network, |
| 21 | and was lo | ocated in the State of Nevada, could the provider legally |
| 22 | balance bi | II the patient, to your understanding? |
| 23 | Α | Yes. |
| 24 | Q | Now what is United Healthcare's position on whether out-of- |
| 25 | network p | roviders should balance bill under United's terms? I'm not |

| Α | We believe that the reimbursement amount is reasonable, |
|------------|---|
| based on t | he allowed amount, and they should not bill the member. |
| | MR. BLALACK: Can we approach with counsel, real quick, |
| before I m | ove into my next section? |
| | |

THE COURT: You may.

asking whether they can, but whether they should?

[Sidebar at 10:05:43 a.m., ending at 10:06 a.m., not transcribed] BY MR. BLALACK:

Q Sir, I'd now like to ask you -- we were talking about whether United believed it was appropriate for out-of-network providers to balance bill United's members for an amount above the amounts allowed for an out-of-network service. Do you remember me asking you that question?

A Yes, I do.

O Okay. What is United Healthcare's position about the reasonable value of out-of-network service? I'm just asking for your corporate general view on that question.

A Yeah, we try to set the value for out-of-network services at a reasonable rate, typically what providers accept in the market.

Q And is one of the criteria you use the Medicare rate plus the small market?

A Yes.

MR. ZAVITSANOS: Objection. Leading.

MR. BLALACK: Okay. Let me ask it this way, sir. What is --

THE COURT: Re-ask.

| 2 |
|----|
| 3 |
| 4 |
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
| 23 |
| 24 |
| |

| 1 | | MR. BLALACK: I'll rephrase, Your Honor. |
|----|-------------|---|
| 2 | BY MR. BI | _ALACK: |
| 3 | Q | What is United's view about how to determine a reasonable |
| 4 | value of a | n out-of-network service? |
| 5 | А | We will look at Medicare and we will pay above that with a |
| 6 | reasonabl | e premium above that. |
| 7 | Q | And you said what providers accept in the market, you've |
| 8 | reference | d several times during the course of your responses to Mr. |
| 9 | Zavitsano | s, I think you referred to some of the documents to a term |
| 10 | called "pa | r medium"; do you remember saying that? |
| 11 | А | Yes, I do. |
| 12 | Q | What do you mean when you say I'm not sure the jury |
| 13 | knows wh | at par medium is. What is par medium? |
| 14 | А | It's a I'm trying not to get, like, too detailed, but it's |
| 15 | basically v | what is accepted in the market, so there's |
| 16 | | MR. ZAVITSANOS: Your Honor, can we approach for a |
| 17 | second? | |
| 18 | | THE COURT: You may. |
| 19 | | MR. BLALACK: Yup. |
| 20 | [| Sidebar at 10:08 a.m., ending at 10:10 a.m., not transcribed] |
| 21 | | THE COURT: Okay. There was an objection. Counsel's |
| 22 | going to n | nove on, and we'll take it outside your presence later. Thank |
| 23 | you. Plea | se go ahead. |
| 24 | BY MR. BI | _ALACK: |
| 25 | Q | So now, Mr. Haben, I'd like to make sure the jury |

| _ | _ | |
|---|---|--|
| ۶ | ≺ | |
| č | ₹ | |
| ũ | 5 | |
| Č | ת | |
| C | S | |

| 1 | understan | ds about some information about the claims in dispute in this | |
|----|---|--|--|
| 2 | case and how this relates. I want to show you a slide that I showed the | | |
| 3 | jury in opening statement, okay? And ask you about it, okay? | | |
| 4 | А | Understood. | |
| 5 | | MR. BLALACK: This will be slide 23, Shane. | |
| 6 | BY MR. BL | ALACK: | |
| 7 | Q | Now, sir, in this case the Plaintiffs have alleged that they are | |
| 8 | entitled to | reimbursement of billed charge equaling \$13,242,789; do you | |
| 9 | see that? | | |
| 10 | А | I do. | |
| 11 | Q | And you've described for the jury what bill charges are | |
| 12 | already, correct? | | |
| 13 | А | I have. | |
| 14 | Q | Okay. And then they identified and the parties have agreed | |
| 15 | that the all | owed amounts on those claims were \$2,843,448. Do you see | |
| 16 | that? | | |
| 17 | А | I do. | |
| 18 | Q | And you described what allowed amount is, right? | |
| 19 | А | I have. | |
| 20 | Q | In that middle column you'll see that the average amount of | |
| 21 | charge at i | ssue in those two claims is referenced there along with the | |
| 22 | average ar | mount of the allowed, it's 1,145 was billed, 246 in allowed. Do | |
| 23 | you see th | at? | |
| 24 | А | I do. | |
| 25 | Q | Okay. In the far-hand column, far right-hand column, sir, I'm | |
| | 1 | | |

| expressing those same numbers as a percentage of the Medicare rate |
|--|
| Do you see that? |

A I do.

- Q And what is the amount of the plaintiffs' bill charges when expressed as a percentage of the Medicare rate?
 - A 763 of Medicare.
- Q And then what is the amount, of the allowed amount for the amount that United pay for these disputed claims when expressed as a percentage amount here?
 - A 164 percent of Medicare.
- Q And sir, as a former executive in UnitedHealthcare, in your opinion, is the bill charged at issue here a reasonable amount for the value of these services?
 - A No, it is not.
- Q And in your experience based on running out-of-network programs for many years, and the valuation of what is a reasonable rate in healthcare, do you believe that the 164 percent or \$246 on average or 2.8 million dollars in allowed, it represents reasonable value in your experience?
 - A Yes, it is.
- Q Now for three days Mr. Zavitsanos took this jury through kind of all over the place on various out-of-network programs, and I think the jury probably understands what those programs are from that, that questioning, but it was not linear, and I want to try to make sure the jury understands clearly what all the out-of-network programs are that

touched claims for out-of-network services, how they worked, when they were in place, and how they related to each other.

So I'm going to devote this portion of the examination to just clearly getting that out so the jury can have confidence they understand when they get to deliberations how each of these programs work and what they related to.

So let me start first, Mr. Haben, by saying when you refer to an out-of-network program, what do you mean? What does that mean?

A Out-of-network program is a program that was designed to be able to address medical expense, medical cost, and developed for the need to have the market, so the employer groups or the fully insured plans.

- Q Why does UnitedHealthcare even offer out-of-network programs? What's -- why would you do that?
- A It's to help manage medical expenses and address high bill charges.
- O And is one of the needs that employer groups find that need to be addressed by out-of-network programs the issues with respect to collections activities directed at their employees?
 - A Yes.
- Q Why doesn't UnitedHealthcare simply pay the full bill charge, whatever that is, on every claim submitted by an out-of-network physician?
- A Providers set the bill charges, and they can set it whatever they want to set it at, so we're trying to base it on a reasonable

| ' | | silient to the market. | |
|----|---|--|--|
| 2 | Q | Okay. And in your experience over the last ten years, have | |
| 3 | provider c | harges risen and gone up over that period? | |
| 4 | А | The provider, what we call charge masters, the individual | |
| 5 | provider d | harges, in some cases have gone up. | |
| 6 | Q | Okay. What about hospital-based physicians, particularly | |
| 7 | physicians | s like emergency room, anesthesia; what about them? | |
| 8 | А | Yes, those have increased. | |
| 9 | | MR. ZAVITSANOS: Objection, Your Honor. Best evidence | |
| 10 | rule, foun | dation, and also yeah, those two, Your Honor. | |
| 11 | | THE COURT: You can lay a little more foundation. | |
| 12 | BY MR. BI | _ALACK: | |
| 13 | Q | Sir, in your role as head of the out-of-network programs have | |
| 14 | you over the last ten years reviewed data within UnitedHealthcare | | |
| 15 | regarding | the charges that are being reported by providers on an out-of- | |
| 16 | network b | asis for members of the United Healthcare benefit plan? | |
| 17 | А | Yes, Healthcare Economics has provided me data based on | |
| 18 | that. | | |
| 19 | Q | Okay. And in fact, were you shown charts and reports and | |
| 20 | emails ov | er the last three last week, discussing some of that data and | |
| 21 | what it did | d and didn't show regarding the charges? | |
| 22 | А | Yes. | |
| 23 | | MR. ZAVITSANOS: Can we approach, Your Honor? I'm | |
| 24 | sorry. | | |
| 25 | | THE COURT: You may. | |

| S | = |) | |
|---|---|---|--|
| | 5 |) | |
| Č | 7 | 1 | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| [Sidebar at 10:16 a.m., ending at 10:20 a.m., not transcribed] |
|--|
| THE COURT: Okay. I've tentatively overruled the objection, |
| but we'll hash it out on the next break. Thank you for your professional |
| courtesy. |

BY MR. BLALACK:

- Q All right. Sir, I think we were talking about why didn't UnitedHealthcare simply pay the full billed charges on every claim. I think you answered that question earlier?
 - A Correct.
- Q Okay. Does UnitedHealthcare ever pay providers the bill charged ever?
- A Yeah, if it's a reasonable bill charge amount or in some rare circumstances, if the employer group says please take the member out of the middle, they're getting harassed, they're getting sent to collections, they're -- you know, they're in a touch spot, they will tell us to pay billed charges, but it's very rare.
- Q When you say take the member out of the middle, what's that mean?
- A The member, like we were talking about, getting balance bill between the billed, the what's allowed, and the bill charge amount, and so the member gets a collection notice or a bill from the staffing company, the billing entity, saying you owe us, and they will pursue them.
- Q And in those kind of circumstances you're saying someone from the employer group might contact you; how does that work?

- A So we'll -- we call that member in the middle, we've talked about member advocacy, so the employer group might get a complaint from the employee and say, you know, I'm getting harassed, please help me. The employer group will contact member services, or the employee will contact member services or a vendor, and then they will be asked if they want us to pay bill charges, they have to put that in writing.
- Q All right. So at this point, Your Honor, or excuse me, Mr. Haben, I want to transition to discussing what those programs are and make sure me and the jury understand what they are. So I'm going to utilize one of the exhibits you were shown by Mr. Zavitsanos last week, which is Plaintiff's Exhibit 154, which is already in evidence. I'm going to ask Shane to bring that up, please.
 - A Do I have that here or are you just going to --
- Q It should be in one of those binders on the right probably, and try to find it right there and see if you see a Plaintiffs' Exhibit 154. And if you'd like to work off the hard copy or the screen, whatever works best for you.
 - A I'm tactile.
- Q I'm aware that you like the paper, so we'll work off that. All right. Sir, do you recognize this document, Plaintiff's Exhibit 154, which again is a notice entitled "Core Essentials Out-Of-Network Program Overview?"
 - A Yes.
 - Q This was a document you were shown last week?
- A I believe so.

| C | |) | |
|---|---|---|--|
| (| |) | |
| (| |) | |
| (| ۷ |) | |
| (| 5 | ٦ | |
| C | 2 |) | |

| 1 | Q | All right Can you tell from the document, sir, what the date |
|----|-------------|--|
| 2 | of it is? | |
| 3 | А | February of 2018. |
| 4 | Q | And were you the leader of the United Healthcare's out-of- |
| 5 | network pr | ogram for that time? |
| 6 | А | Yes, I was. |
| 7 | Q | I'll direct you to page 6 of this document, if you go to page 6, |
| 8 | and you'll | see a title that reads "Out-Of-Network Landscape"; do you see |
| 9 | that? | |
| 10 | Α | I do. |
| 11 | Q | And then down below it there's a header underneath that |
| 12 | icon with a | what looks like a dollar sign on the left. |
| 13 | | MR. BLALACK: Shane, could you bring that up? |
| 14 | BY MR. BL | ALACK: |
| 15 | Q | And you'll see there, it says, "typically 90-95 percent of |
| 16 | claims are | captured in the United Healthcare contracted provider |
| 17 | network, a | bout 5-10 percent of claims are out-of-network"; do you see |
| 18 | that? | |
| 19 | А | I do. |
| 20 | Q | What does that mean? |
| 21 | | MR. ZAVITSANOS: Your Honor, may I visit with Mr. Blalack |
| 22 | briefly for | one second? |
| 23 | | THE COURT: Yes, you may. |
| 24 | | [Counsel confer] |
| 25 | | MR. BLALACK: My colleague kindly reminded me this was |
| | | |

| 1 | condition | ally admitted, Your Honor, so I think we need to do the honors | |
|----|---|---|--|
| 2 | and form | ally move it for admitting. | |
| 3 | | THE COURT: And give me the number again. | |
| 4 | | MR. BLALACK: It's 154, I believe, Plaintiffs' Exhibit 154. | |
| 5 | | MR. ZAVITSANOS: And obviously, no objection, Your | |
| 6 | Honor. | | |
| 7 | | THE COURT: All right. Exhibit one-fifty | |
| 8 | | MR. BLALACK: It would still be conditionally admitted if he | |
| 9 | hadn't re | minded me. That's okay. | |
| 10 | | THE COURT: All right. 154 will be admitted. | |
| 11 | | [Plaintiffs' Exhibit 154 admitted into evidence] | |
| 12 | BY MR. B | LALACK: | |
| 13 | Q | All right. Sir, we were looking at that highlighted phrase, 59- | |
| 14 | 95 percer | nt of claims are captured in the UnitedHealthcare contracted | |
| 15 | provider | network, about 5-10 percent of claims are out-of-network; do | |
| 16 | you see t | hat? | |
| 17 | А | I do. | |
| 18 | Q | What does that mean? | |
| 19 | А | So that means, and just kind of rounding, 95 percent of the | |
| 20 | claims th | at are received through UnitedHealthcare for either fully insured | |
| 21 | or ASO business are performed by providers that are inside the United | | |
| 22 | network. | That means they're a par provider, they're a contracted | |
| 23 | provider, they have agreed-upon rates. | | |
| 24 | Q | And so those would be providers where the rate of | |

reimbursements already specified?

| C | Ξ | 2 | |
|---|---|---|--|
| C | |) | |
| C | |) | |
| C | 2 |) | |
| C | 5 |) | |
| | | ^ | |

| 1 | A | Yes. | |
|----|---|--|--|
| 2 | Q | And then what's the five to ten percent that's referenced? | |
| 3 | A So that five percent is the percent of claims that are received | | |
| 4 | and adr | ninistered for providers that are non-par, not in the network, no | |
| 5 | agreed | upon rate. | |
| 6 | Q | Okay. And just I think everyone understands, but you | |
| 7 | underst | and, sir, that the claims at issue in this case are limited to out-of- | |
| 8 | network | c claims, correct? | |
| 9 | А | Correct. | |
| 10 | Q | So that's in that five to ten percent, approximately? | |
| 11 | A | Correct. | |
| 12 | Q | Now if you look at the next column under the clipboard there | |
| 13 | it says, "Out-of-network programs are in place to help control costs when | | |
| 14 | non-contracted providers are chosen, or when a member gets treated by | | |
| 15 | a non-n | etwork provider within a network facility." Do you see that? | |
| 16 | А | I do. | |
| 17 | Q | What does that mean? | |
| 18 | А | So basically, at a high level it means that there are programs | |
| 19 | in place | to address non-par billed charges, there's two avenues that a | |
| 20 | membe | r could typically see a non-par provider. One is by choice, so if | |
| 21 | you bur | mp up knee, you don't have to go right away, and you're like | |
| 22 | schedule surgery, that's your choice if you went to a non-par provider. | | |
| 23 | А | nd then there is a non-par provider that could be a in a par | |
| 24 | facility. | So large, national hospital systems typically use staffing | |
| 25 | compar | nies to support their emergency rooms, anesthesiologists. You | |

| ergency rooms, anesthesiologists. | You |
|-----------------------------------|-----|
| 3 3, 1, 11 1, 11 11 11 13 | |

| would never know when you're getting treated that they're non-par, and |
|--|
| so you would, you know, that is another circumstance where you would |
| step into that. |

- Q So in that last pause there, when a member is treated by a non-network provider within their facility, so just so I'm clear, that would be a scenario where you went to a hospital. Say you looked in your provider handbook, that hospital would be in your network at your participating hospital; is that what I understand that to be?
- A Yes. If you had the luxury of doing that and not being taken by ambulance or emergency, yes.
- Q But you arrived at that facility thinking and knowing the facility was in the network, but you might find out that one of the professionals that works in the hospital is not a member there?
 - A That's is correct.
- Q Now if you look at the next column, right-hand side. And below that is says quote, efforts to control cutting costs, ongoing management and application of existing out-of-network programs, continual evaluation of program performance and new ideas around OON cost containment. Do you see that?
 - A Yes, I do.
 - Q What does that mean?
- A We continuously look at our out-of-network programs to make sure we're paying a fair and reasonable rate, and we're addressing costs.
 - O Okay. And so, it sounds like there's two functions here.

| 000963 | | |
|--------|--|--|
| | | |
| | | |

| There's one th | at's managi | ng the existing | g programs | and then | cost at |
|----------------|---------------|-----------------|------------|----------|---------|
| looking to imp | rove; is that | fair? | | | |

- A That's correct.
- Q Now let me show you another page, page 11, of this document.

MR. BLALACK: Shane, if you could move to that.

THE WITNESS: Sure.

BY MR. BLALACK:

- Q David, and if you could turn to page 11. And do you see a header there, it says none contracted providers?
 - A Yes, they do.
- O Okay. Now there's two columns. One says paid at network benefit level. One says paid at out-of-network benefit level. Do you see that?
 - A I do.
- O This is going to be a little tricky, so I just want to make sure the jury has clarity about what we need when we refer to a benefit level. So first, why don't you describe for the jury what is the network or in-network benefit level?

A The way -- there's a lot of nuances, but the way I kind of explained it to you is claims that are paid at the in-network benefit level are claims to the providers first that are participating in the network. So you get the highest benefit. The lowest co-insurance. The lowest co-pay. And services where you didn't have the choice and if you were going non par. So think about it as I described before. If you go to the

hospital and you were admitted to the ER, there might be providers that are not participating, but you would never know anesthesiologists, ER physicians, you didn't physically make that choice to go see that provider.

On the out-of-network benefit level, those are always the providers that are not in the provider network for United Healthcare. And also, circumstance -- so they're non-par. All of them are non-par. And then we also call that kind of the choice. So my example of let's just say you tweaked your knee. You wanted to go get it scoped. You schedule something two weeks down the road to get it done, but you'd make a decision. I'm going to go to a provider that I've known before but they're not in my network. That's a no choice or that's a choice. You made a conscious choice to go that way.

Those services you usually have a higher out-of-pocket expense. A higher co-insurance deductible, et cetera.

- Q Okay. So just see if I can summarize. Is it the case that all out-of-network benefit level services are out-of-network provider claims?
 - A Yes.
- Q Okay. For in-network benefit level however, can there be out-of-network claim for services under the in-network benefit?
 - A Yes, there can.
 - Q Give me an example on that.
- A As I was talking before, we call it the no choice. You didn't make the choice to go see that doctor. They came in and treated you. It could be an ER physician, anesthesiologist. Those are two common

| examp | les |
|-------|-----|
| | |

- Q Okay. And in this case, it's stipulated that all of the disputed services are out-of-network emergency room services. Do you understand that, Mr. Haben?
 - A Yes, I do.
- Q On which of these two benefit levels, network benefit level, in-network benefit level or out-of-network benefit level are emergency room claims, out-of-network emergency room claims process?
- A At the highest benefit level, which is the in-network benefit level.
- Q So out-of-network emergency room claim is an example of an out-of-network claim that's paid on an in-network benefit level?
 - A That is correct.
- Q All right. Now sir, I'm going to show you -- and in fact, if you look under that left hand column page of in-network, you'll see service categories there. Would you describe for the jury this service category is describing under that benefit level?

A Yeah. As I've talked before, the examples in here are emergency hospital-based physicians, so ER physicians. And they could also be radio -- what we called last -- the other day RAPL, radiology, anesthesiology, pathology, lab, emergency room. And under the service categories, could you describe us some examples there?

A Yeah. So like again, where I've talked before, they're not emergent. You made a decision. It could be ambulatory surgery centers, so that could be where you're going to go get your knee scoped

| or something replaced. | There could be other specialist facilities, et |
|------------------------|--|
| cetera. | |

- Q Now I'd like to talk about some of these programs. And if you would Shane, go to page 12 of this document. Mr. Haben, if you could turn to page 12. And you'll see a big header that reads out-of-network programs. Do you see that?
 - A I do.

- Q Okay. Can you please just tell the jury what is being described on this page of this document?
- A At a high level, those are the programs that we have for our out-of-network program.
- Q And you talked about these programs off and on over the last few weeks; is that right?
 - A That's correct.
- Q Now I want to go to discuss the first of these that I want to talk about is on page 15 of this document. So can you go to page 15? So do you see a title there for maximum reimbursement program?
 - A Yes. Maximum out-of-network reimbursement program.
- Q And look to the right, in the upper right-hand corner. Read to the jury, sir, what that first bullet says.
- A The first bullet says, provide more predictable costs using CMS reimbursement methodology. Typically, 110 percent of CMS are fully insured, and 140 percent of the CMS are self-funded or ASL.
 - Q Thank you. When you say CMS, what is that referring to?
 - A That's Medicare.

| Ç | Ξ | 2 |
|---|---|--------|
| Ċ | Ξ |)) |
| Č | ٥ |) |
| (| 7 | ? |

| 1 | Q Okay. All right. Now, sir, we're going to go page 16. And |
|----|---|
| 2 | Mr. Haben, can you tell the jury what this slide describes? |
| 3 | A This is what we call ENRP. It's the extended out-of-network |
| 4 | reimbursement program. |
| 5 | Q And if you go the right-hand column and pull up that first |
| 6 | bullet. It says lowers costs of noncontracted provider claims, helps to |
| 7 | lower member coinsurance deductible if members receive care outside |
| 8 | of the United Healthcare Network, open paren, or in an emergency |
| 9 | situation where member receive such services, close paren. |
| 10 | MR. ZAVITSANOS: Your Honor, I have an unrelated issue. If |
| 11 | I could approach please? |
| 12 | THE COURT: You may. But it's probably a good time to give |
| 13 | everyone a recess. |
| 14 | MR. ZAVITSANOS: Okay. |
| 15 | THE COURT: So would you rather take the recess now? It's |
| 16 | about time is this a good stopping point? |
| 17 | MR. BLALACK: I'm ready whenever. Yeah, whatever's best |
| 18 | for the jury. |
| 19 | THE COURT: Yeah. We have just been an hour. It's 10:35. |
| 20 | We'll go ahead and take a 15-minute recess. |
| 21 | During the recess, you're instructed to not talk with each |
| 22 | other or anyone else on any subject connected to the trial. Don't read, |
| 23 | watch or listen to any report of or commentary on the trial. Don't |
| 24 | discuss this case with anyone connected to it by any medium of |
| 25 | information. Including without limitation, newspapers, television, radio, |

Don't conduct any research on your own or get -- relating to the case. Don't consult dictionaries, use the internet, or use reference materials. Don't talk, text, tweet, Google issues, or post any social media or conduct any other type of book or computer research with regard to any issue, party, witness, or attorney involved in this case. Do not form or express any opinion on any subject connected with the trial until the matter is submitted to you.

Please be ready at 10:50.

internet, cells phones or texting.

THE MARSHAL: All rise for the jury.

[Jury out at 10:36 a.m.]

[Outside the presence of the jury]

THE COURT: All right. The room is clear. Mr. Zavitsanos?

MR. ZAVITSANOS: Yes, Your Honor. And by standing when I did, I do not mean to waive or open the door to the Court's in limine ruling. I did not stand and object when this came up, because I did not want to draw attention to it. If I may approach, Your Honor, and I can show counsel.

THE COURT: You may.

MR. ZAVITSANOS: This is the slide that he had up. And can I hand this to the Court, Your Honor?

So one of the -- this is the slide that was up immediately before the break. And it concerns -- I'm just going to use the acronym, Your Honor. It concerns the MNRP program. This is something that has been limined [sic] out. This is something that is not part of this case. It

expressly says on that document that the Court -- I just handed the Court, that it only applies to non-emergent claims.

The reason, I believe, that that was put up there, was to suggest that this program for non-emergent claims, which is something that the patient elects to do is the appropriate out-of-network rate. Now that is in the Court's order in limine. In fact, it was their motion in limine that raised this, which I understand to be mutual. And I understand it's in the document, but I did not ask any questions about the MNRP program. And the reason I didn't ask about that, is because of the Court's order in limine.

Now I had, believe it or not, I had even more questions for Mr. Haben on this program and why the rates are so low. But because it was off limits, I didn't ask it. So the only thing I would ask is that -- and I understand this is kind of a work in progress and we're -- and I do not believe counsel intentionally violated the Court's order in limine. I would simply ask that counsel please avoid any explicit reference to MNRP going forward because that has no application here.

MR. BLALACK: Okay. All right. Your Honor, I mean, I'm confused. Because they must have discussed MNRP 20 times over the last week during the course of questioning back and forth. Documents and emails with MNRP all over it. The document I'm using right now, is a document they introduced and offered into evidence and is in evidence. So I'm permitted to question the witness about the document in evidence. The slides that has the chart on it, that has the listing, MNRP is liable, and I think we've shown that question about them in the

case.

Now, I'm doing my best to observe in limine and agreements and rulings, but we've got so many tripwires here where you can't talk about Medicare and then you talk about it a lot and then you talk about it a little. It's impossible to try this case when we don't have clear rulings. And I want to obviously respect the Court's authority, and I want to abide by it vigorously, but we've got to have some rules where it applies to both sides. And if the Court's ruling is neither party will reference the term MNRP a single more time in the case, I'm fine with that. But it can't be a world where documents are shown to the witness. It's got MNRP all over it and then the witness mentions in testimony and the jury hears it and then I can't ask anything about it.

So I just got to have some bright lines that I can follow and adhere to and if they will follow and adhere to it, I'm fine.

MR. ZAVITSANOS: And brief reply, Your Honor. I did not ask one question, not one, about MNRP, not one. I asked about ENRP, and I know the mask sometimes makes it difficult to hear. I did not ask any questions about MNRP. And, Your Honor, I invite counsel to go through the transcript and find where I did. I did not.

I understand it's on the document. This was their limine point, not ours, okay. And I deliberately avoided asking any questions. And frankly, to counsel's comment that the rulings are confusing, they're not. I think we are very clear about what the Court -- the Medicare line is. We're very clear about the rulings. I've not heard any confusion about what we should avoid and what we should not. But this MNRP

issue is clear as day. I mean, this was the subject of one of their limine points. And so --

THE COURT: So I'm going to sustain the objection. But if you open the door, you open the door.

MR. BLALACK: Of course. Okay. And I'm fine with it, Your Honor. As long as both sides stay away from it, I'm fine. No documents showing it. No writing it on the boards or anything like that then I'm fine.

THE COURT: Good enough. Do we have other issues that we don't want at the bench? Let's take those up --

MR. BLALACK: Not from me, Your Honor.

MR. ZAVITSANOS: From us, Your Honor, very briefly. So while we -- during the course of the examination, counsel asked questions about -- and counsel will correct me if I misstate this, but it was a question around charges and elevated charges over a period of time. And the question was whether he had looked at data to support the opinion the charges were escalating.

We have a couple of objections to that. Number one, it's hearsay. Number two, none of those, none of that information was produced. Counsel should be limited to what is in evidence. Number three, this gentleman was not designated as a non-retained expert. And if the Court will remember, there was a pretty vigorous back and forth about a couple of doctors that we designated as non-retained experts that they took issue with. We gave them fair notice that we designated them.

This is brand new. This is getting sprung on us for the first time. He was not designated. And finally, the only evidence in the case -- now this is a weight, not an admissibility issue, but the only evidence in the case is the opposite. The charges were going down. And -- which underscores why I would need the data to be able to decipher it to be able to impact that. Because there's no question that in terms of what would make the most impact on a jury. You know, we all tend to think of how is this going to affect me?

So if the jury's thinking the charges are going up and my premiums are going up, that's going to make more of an impact. And I can't contradict that. I can't challenge it. I can't question that without the underlying data to which he's referring to.

THE COURT: Any response please?

MR. BLALACK: Got a couple. Your Honor, we're not offering any opinion testimony here. He's testifying to his own personal knowledge as an executive in healthcare based on his own experience, working in the company, what he observed and saw. They are free to impeach him by showing that he -- the documents in evidence, I mean, both parties did a list, don't support his understanding or to argue that he has no basis for that. Those are both fair game for crossexamination. But there's not an opinion about this. That's point one.

Well two, their own data that they're relying on, the Fair
Health Data, plus their own charges that they produced in this case for
themselves are indisputable that the charges are going up. So we're not
going to have to debate about who knew what when, because their own

evidence that they are paid and produced from their own files, shows that the charges were going up. And that will be explored in depth with their witnesses and with the expert.

So just to respond, there is no opinion testimony. He's giving personal knowledge testimony based on his own role and time in Humana Healthcare. There are regions of documents on both party's exhibit list that discuss charges going up. And in fact, he was cross-examined about some of them over the last week. And there is raw data that has been produced showing what the charges for the Plaintiffs were and what the charges in this state are during the period in question, which is only in evidence and will be the subject of a substantial factor in expert testimony.

So I think this is a grounds for impeachment, but it's not a basis for arguing about the admissibility of the testimony or impropriety of the claim. So I'll leave that. And unless the Court has anything else for me, I do want to come back to the MNRP point just before we close.

THE COURT: We will.

MR. BLALACK: I got one final point on that.

THE COURT: That's fine. And you reply?

MR. ZAVITSANOS: Brief reply, Your Honor. The question was not about our charges, which again, he was designated as a non-retained expert on that. He's welcome, if he's reviewed our charges, and we welcome that, to go through what our charges were. The question was really more kind of much broader nation why and kind of what's going on in the medical community in general and what they're looking

| _ | | |
|--------|--|--|
| 000974 | | |
| 0974 | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |

at. And that data, Your Honor, has never been produced, never.

THE COURT: Okay. I'm going to overrule your objection.

You can take it up -- you can test his credibility when you redirect him?

MR. ZAVITSANOS: Okay. May I approach, Your Honor? I can take my --

THE COURT: Yes, of course.

MR. BLALACK: The last piece, Your Honor, before we close out and get a little break is Mr. Roberts was kind enough to bring up the transcript's day seven of Mr. Zavitsanos' examination.

THE COURT: Let me -- I can pull it up too.

MR. BLALACK: This is page 48 of 217 on the transcript.

There's a question at line 11. It starts with ASO for Mr. Haben. Mr.

Zavitsanos asks, "Available options for clients instead of MNRP. We'll talk about that later. Majority of ASO clients still use this out-of-network reimbursement methodology, right?" Answer on line 14, "Yes. That's what that says."

So that's an example of this other thing I was remembering.

And not to mention documents and everything else. So that's what my view is.

MR. ZAVITSANOS: I -- when we -- I'm sorry, Your Honor. I didn't mean to go on. Brief response? I was reading from a document from an email. I never asked any questions about what MNRP is. What the program is. What the reimbursement is. It was something from an email that I was reading, okay. And I never -- I did not ask any questions about what MNRP is.

| 0 |
|---------------|
| 0 |
| 0 |
| 9 |
| $\overline{}$ |
| 5 |
| |

| 1 | THE COURT: So thank you for the clarification. The ruling |
|----|---|
| 2 | still stands. |
| 3 | MR. BLALACK: Thank you, Your Honor. |
| 4 | THE COURT: What else do we need to do |
| 5 | MR. ZAVITSANOS: Nothing else from me, Your Honor. |
| 6 | THE COURT: before you got a few minutes. |
| 7 | MR. BLALACK: Thank you, Your Honor. |
| 8 | THE COURT: See you in a few minutes. |
| 9 | MR. BLALACK: Thank you, Your Honor. |
| 10 | [Recess taken from 10:47 a.m. to 10:54 a.m.) |
| 11 | THE MARSHAL: Court is back in session. |
| 12 | THE COURT: Are we ready to bring in the jury? |
| 13 | MR. BLALACK: We're ready, Your Honor. |
| 14 | THE COURT: And please remain seated for me. |
| 15 | MR. ZAVITSANOS: Your Honor, Your Honor and I checked |
| 16 | with counsel. He doesn't have an objection. With the Court's |
| 17 | permission, I neglected to introduce two other client reps today. May I |
| 18 | do that five seconds before counsel starts? |
| 19 | THE COURT: No objection? |
| 20 | MR. BLALACK: Absolutely. That'll be fine. |
| 21 | THE COURT: Thank you. |
| 22 | MR. BLALACK: And Your Honor, you indicated we'll go |
| 23 | until |
| 24 | THE COURT: 11:50. |
| 25 | MR. BLALACK: 11:50? Yeah. Because some of the judges |
| ı | |

| 1 |
|----|
| 2 |
| 3 |
| 4 |
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
| 23 |
| 24 |
| 25 |

| 1 | will come into this courtroom for the meeting. |
|----|--|
| 2 | MR. BLALACK: That'll work perfect, Your Honor. Thank you. |
| 3 | THE MARSHAL: All rise for the jury. |
| 4 | [Jury in at 10:56 a.m.] |
| 5 | THE COURT: Thank you. Please be seated. |
| 6 | MR. ZAVITSANOS: Your Honor, Mr. Zavitsanos wanted to |
| 7 | have the opportunity to introduce one of his clients. He can do that |
| 8 | before I proceed. |
| 9 | THE COURT: Yes. Go ahead, please. |
| 10 | MR. ZAVITSANOS: Thank you, Your Honor. I neglected to |
| 11 | do this earlier. My apologies. With us today, two additional |
| 12 | representatives. Dr. Crystal Sturgis. Can you please stand? And Dr. |
| 13 | Cole Soundrup, who was here previously. Thank you, Your Honor. |
| 14 | THE COURT: Thank you, and thank you for your professiona |
| 15 | courtesy. |
| 16 | MR. BLALACK: Of course. |
| 17 | BY MR. BLALACK: |
| 18 | Q All right. We were about to dig into the next |
| 19 | MR. BLALACK: Pull that off the screen, please. |
| 20 | BY MR. BLALACK: |
| 21 | Q We were about to dig into the next program that was being |
| 22 | described in Exhibit Plaintiffs' Exhibit 154. I believe that was the |
| 23 | Extended Out-Of-Network Reimbursement Program, ENRP. And what I |
| 24 | was going to start with, Mr. Haben, is that upper right-hand bullet. You |
| 25 | see where it says, "Lowers cost of noncontracted provider claims, helps |

lower coinsurance and deductibles when members receive care outside of the UnitedHealthcare Network or in emergency situations where the member receive such care."

What does that mean?

A So ENRP applies to noncontracted providers to address their cost shares. We've kind of gone through some of those examples. For non-par providers, when they've gone outside the UnitedHealthcare network and you seek services or you have services in an ER situation, like a no choice situation.

Q Now, it says underneath that bullet -- you'll see a bullet that reads, "Applies to non-par emergent or non-emergent claims at inbenefit level preferred benefit."

What is that referring to?

A So when we were looking at one of the charts before, kind of on the right -- or left-hand side. Sorry. I'm looking in a mirror. Left-hand side is in-network. No choice. Right. Inside is out-of-network benefit level choice. This would be the in-network benefit level. The left-hand side of that chart, where it's paid at the highest benefit level, there's no choice.

- O Does ENRP apply to out-of-network ER services?
- A Yes, it does.
- Q Now, is the ENRP program -- you see that bullet, where it says -- next bullet, the third bullet, standard for fully insured plan?
- A Yes, I see that.
 - Q What does that refer to?

| 000978 | | | |
|--------|--|--|--|
| | | | |
| | | | |

23

24

25

| 1 | A | As I've explained before, benefit plans outline what | | |
|----|--|---|--|--|
| 2 | programs | apply. It's a standard benefit inside the fully insured benefit | | |
| 3 | plans we a | are allowed and approved by the state. | | |
| 4 | Q | Okay. Does ENRP provide protections for members from | | |
| 5 | balance bi | lling typically? | | |
| 6 | А | The program does not. | | |
| 7 | | MR. BLALACK: Now, if you pull out of that, Shane, and go | | |
| 8 | back and I | ook in the blue box down at the bottom. | | |
| 9 | BY MR. BLALACK: | | | |
| 10 | Q | You'll see a little word, the sentence or phrase that says no | | |
| 11 | client fee. | You see that? | | |
| 12 | А | I see that. | | |
| 13 | Q | Is that correct? There is no fee to charge to clients for the | | |
| 14 | ENRP prog | gram? | | |
| 15 | А | Correct. If the client adopts it, we do not charge them the fee | | |
| 16 | for that program. | | | |
| 17 | Q | Okay. When did UnitedHealthcare first begin offering ENRP | | |
| 18 | as an out of network program to its clients? | | | |
| 19 | А | ENRP is in place been in place for probably about ten | | |
| 20 | years. | | | |
| 21 | ο | Is ENRP still in use today? | | |

- when it was introduced up 'til today?
 - A Yes.

Α

Q

Yes, it is.

And was ENRP offered continually through that period from

| \subset |) |
|-----------|---|
| \subset |) |
| Ċ |) |
| Œ |) |
| | j |
| C | Š |

| 1 | Q | All right. Let's talk about another program. Pull out of this | | |
|----|--|---|--|--|
| 2 | one and go to page 13 of exhibit Plaintiffs' Exhibit 154. And you'll see | | | |
| 3 | a reference | e to a shared savings program. Do you see that, sir? | | |
| 4 | А | I do. | | |
| 5 | Q | If you would just review that slide very quickly and tell me if | | |
| 6 | you think i | t accurate describes the program? | | |
| 7 | А | Could I just take a minute? | | |
| 8 | | [Witness reviews document] | | |
| 9 | А | Okay. | | |
| 10 | Q | And does that slide accurately describe the shared savings | | |
| 11 | program a | s you understand it? | | |
| 12 | А | Yes, it does. | | |
| 13 | Q | Do you see in the upper right-hand corner, there's a bullet | | |
| 14 | | MR. BLALACK: And Shane, can you bubble that out? | | |
| 15 | BY MR. BL | ALACK: | | |
| 16 | Q | It says "UHC contracts with MultiPlan access third-party | | |
| 17 | networks a | as well as fee negotiation services to obtain discounts on out- | | |
| 18 | of-network | c claims." Do you see that? | | |
| 19 | А | I do. | | |
| 20 | Q | What are you referring to when you refer to a third party | | |
| 21 | network? | | | |
| 22 | А | So that's not a network that United has contracted, so | | |
| 23 | MultiPlan | could be a third party network. There are other third party | | |
| 24 | networks o | out there we have used in the past. First Health Group, which | | |
| 25 | is part of A | etna now. What we call non-logoed small discount networks | | |

| 280 | | | |
|-----|--|--|--|
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| Q | So a third party network is not a network that is directed by |
|--------------|---|
| or controlle | ed by United? |

A It is not.

as well.

- Q And what were the names of the various vendors you've used over the years?
- A So we've used multiple vendors, MultiPlan is one of the biggest. First Health Group, so FHG, which is now owned by Aetna. There's other entities called TC3. I couldn't tell you the purpose of the acronym. And other third party networks that are out there.
- Q Okay. The jury's heard several times references to something called a wrap network and that's spelled w-r-a-p?
 - A Yes. That's correct.
 - Q Is a wrap network a third party network, as described here?
 - A Yes. It could be viewed that way.
- Q And just so the jury's clear, would you describe for them how does a wrap network operate? Who are the participants in a wrap network and how does it function?

A So first of all, I don't know why -- who invented the word wrap with a capital W, but think about it wrapping around your par network. Okay. So it's used in what you would call an out-of-network setting, so provider is not in the primary network. So for United's case, it's not in United. Almost kind of like gap fill. It's to help mitigate costs. It wraps around your primary network. It's used for, as I described before, in or out-of-network benefit level. I don't remember the rest of

your question.

Q Okay. Well, let me ask it this way. In a wrap network, who are the parties to the wrap contract or network wrap?

A Well, the -- there's the contract between the contracting entity, like a MultiPlan or First Health Group and the provider. And then they have agreed upon rates. And inside those, those typically say -- those can be used by other entities with some requirements.

Q And then what is the relationship between the health insurer or administrator and the vendor, who enters the wrap network with provider?

A So entities like United, or Aetna, or Cigna, or the Blues will go contract with a vendor like your MultiPlan or a First Health group to access those networks. Typically they have, at least United does, the right to not use certain wrap networks if we deem so.

Q And I was going to ask you that. When you say access the network, what does that mean?

A So we can access the discount arrangements with those third party providers or third party vendors that have contracts with providers.

- Q Are you obligated to access them?
- A No, we're not.
- Q Now, in that sentence describing the shared savings program, in -- excuse me -- in addition to referring to accessing third party networks, it refers to fee negotiation services. Do you see that?
 - A Yes, I do.
 - Q Please describe to the jury what that means.

| A So those are what we call like a prospective fee negotiation, |
|---|
| so usually done before the claim is finally paid. So again, think about it |
| as another layer, almost like a waterfall. You got your primary network |
| of United Healthcare. That's not this. The provider's non-participating in |
| UnitedHealth network. If there's a wrap network agreement, we choose |
| to use that, we'll use that. If that's not available, then in this situation, |
| there's prospective fee negotiation. So then the vendor, you know, like a |
| MultiPlan, or former Concentra, or other entities. There's Zelis, there's |
| entities out there that will go reach out to the provider and say hey, |
| would you take this discount arrangement. They might have a standing |
| agreement with those providers in writing or they might actually |
| physically call and say for this service, we believe this reasonable |
| amount is this. Would you accept that and promise not to balance bill |
| the patient. If they do that, the claim gets priced and sent back. |

- O That was my next question. For both -- well, let me back up. For the shared savings program, what are the components of the program? When someone says what are the components of the shared savings program, what would you say?
- A The components of the shared savings program are the wrap network and the fee negotiation, prospective fee negotiations.
 - Q Two pieces.
 - A Two pieces.
- Q And you've been focusing on prospective negotiation. Is there another kind of negotiation that's different than prospective?
 - A There could be. This -- there could be, just like with outlier

| cost management, where we'll pay what we feel is a reasonable amount |
|---|
| We'll put a statement in the EOB saying, "Hey, call us if you don't agree |
| with that amount," and then there's kind of a retrospective negotiation. |
| There might be situations where the provider says, hey, I think I deserve |
| this and this is why, and they will negotiate. |
| |

- Q Okay. We'll talk about outlier cost management in a moment, but for shared shavings, the negotiation service is a prospective negotiation?
 - A That's correct.
- Q Meaning there hasn't been any payment on the claim at the time MultiPlan engages with a provider?
 - A Right.
- O For both components of this program, fee negotiation and wrap network, if a payment is made under this program and the provider accepts the prospectively negotiated payment for his pay pursuant to the wrap third party network agreement, is there any balance billing permitted of the members?
 - A No, there's not.
- Q So with that, those two scenarios, is the provider agreeing to accept that payment as paid in full?
 - A Yes, they are.
- O Now when would you ever have this fee -- prospective fee negotiation, if you've also got a wrap network in place? Why would you ever get to the fee negotiation with [indiscernible]?
 - A If the provider's not the wrap network.

| 1 | Q | So that would be a fallback service available if the provider in |
|----|--------------|--|
| 2 | question v | vasn't already in the wrap network? |
| 3 | Α | Yeah. Think about a waterfall. If they're not here, if they're |
| 4 | not here, y | ou go here. |
| 5 | Q | Now, does UnitedHealthcare pay a fee to access this wrap |
| 6 | network? | |
| 7 | А | Yes, we do. |
| 8 | Q | And does United pay a fee to for the prospective |
| 9 | negotiatio | n services that MultiPlan provides? |
| 10 | А | Yes, we do. |
| 11 | Q | When did UnitedHealthcare first start offering the shared |
| 12 | savings pr | ogram? |
| 13 | А | I believe back in 2003. |
| 14 | Q | So almost 20 years ago. |
| 15 | А | Almost 20 years ago. |
| 16 | Q | Is the shared savings program still in use today? |
| 17 | А | Yes, clients still ask for that periodically. |
| 18 | Q | Has the shared savings program been in use continually |
| 19 | from back | then, 2003 up to the present? |
| 20 | А | Yes, it has. |
| 21 | Q | Now, if you look down, it says let's see the phrase. |
| 22 | | MR. BLALACK: Third bullet, Shane. |
| 23 | BY MR. BL | ALACK: |
| 24 | Q | Where it says, "SSP is a contracted rate. Providers agree to |
| 25 | write off th | ne discount. No balance billing to the members." Do you see |

| 2 |
|----|
| 3 |
| 4 |
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
| ~~ |

| 1 | that? | | |
|----|--------|----------|--|
| 2 | | Α | I do. |
| 3 | | Q | What's that describing? |
| 4 | | Α | Basically it's what we talked about before. The provider in |
| 5 | that t | hird p | party network has a contract rate. They agree to accept that |
| 6 | rate. | They | agree not to pursue the member. Obviously they can still |
| 7 | pursu | ue it fo | or the coinsurance. |
| 8 | | Q | Is the shared savings program available both to fully insured |
| 9 | client | ts and | to self-funded clients? |
| 0 | | Α | The shared savings program is available, but we have moved |
| 1 | off of | that | for fully insured. |
| 2 | | Q | Okay. Typically across your book of business, which of the |
| 3 | two t | ypes | of products clients most frequently use? |
| 4 | | Α | More frequent on the self-funded side that on the fully |
| 5 | insur | ed sic | de. |
| 6 | | Q | And can shared savings remember I asked you earlier |
| 7 | abou | t whe | ther the ENRP program applied to emergency services? |
| 8 | | Α | Yes. |
| 9 | | Q | Does the shared savings program apply to out of network |
| 20 | emer | gency | room services like those at issue in this case? |
| 21 | | Α | It could. |
| 22 | | Q | And you mentioned that earlier, that there was balancing |
| 23 | billin | g prot | tection in the shared savings program? |
| 24 | | Α | Yes. |
| 25 | | Q | Now, down at the bottom right, you'll see a bullet that reads, |

| ١, | _ | , | | |
|----|---|---|--|--|
| r | X | ١ | | |
| 2 | ÷ | : | | |
| L | X |) | | |
| r | 7 | ١ | | |
| • | _ | • | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

| ı | 337, 337 | E for A50 chems charges a percentage of savings |
|----|--------------|--|
| 2 | administra | ation." Do you see that? |
| 3 | А | I do. |
| 4 | Q | What does that mean? |
| 5 | А | So for the wrap network and the wrap network enhanced, as |
| 6 | we've disc | cussed before, there is a fee that clients agree to pay. |
| 7 | Q | And is that fee percentage the same for every single |
| 8 | UnitedHea | althcare client that chooses shared savings? |
| 9 | А | No. It varies across the board. |
| 10 | Q | What caused it what would cause it to vary? |
| 11 | А | Well, clients negotiate. So we can't just roll a client or |
| 12 | migrate a | client in. We they have to they sit across the table, or they |
| 13 | talk with t | ne sales organization, and they'll negotiate the fee. |
| 14 | Q | Could you explain to the jury, how is that shared savings fee |
| 15 | typically c | alculated? |
| 16 | А | So in the back in 2003, it started at a very simple, and it's |
| 17 | still today, | simple math, billed charges to allowed. So the more the |
| 18 | provider b | ills, the higher the billed charges. But it's the delta I'm sorry. |
| 19 | It's the dif | ference between the billed and the allowed amount. |
| 20 | | MR. BLALACK: Okay. Let me let me try to see if I |
| 21 | understan | d what you're referring to. |
| 22 | | Shane, could you or Ms. White, could we toggle to the |
| 23 | LLC? | |
| 24 | BY MR. BL | ALACK: |
| 25 | Q | So let me see if I can do this. So Mr. Haben, if the billed |
| | ii . | |

| 3 |
|----|
| 4 |
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
| 23 |
| 24 |
| 25 |

| charge equals \$300, and the allowed amount under the benefit plan |
|--|
| equals \$300. In that setting, using that assumption, would there be a |
| shared savings fee that United could earn under the shared savings |
| program? |

- A No.
- Q Why is that?
- A Because the allowed amount equals the billed charge amount and there's no savings.
- O Now, let's do a different example. Let's assume the billed charge equals \$500, and the allowed amount under the benefit plan is still 300. Under this scenario, could United, if the claim in question was resolved using the shared savings program earn a shared savings fee?
 - A Yes.
- Q Okay. Walk the jury through how you would calculate the shared savings fee, the first step, and then we'll take it step by step.
- A So first of all, you've got to calculate the savings. So that would be the difference from the billed to the allowed, which is \$200.
- Q All right. Even I could do that. Now, what would you do next?
- A So then you would take the fee. So let's just say it's 30 percent.
 - Q Okay.
- A And you do 30 percent times the 200, and I believe the math is \$60.
 - Q And again, I think that's correct, amazingly. All right. So

| | _ | | |
|---|---|---|--|
| | Ξ |) | |
| ĺ | |) | |
| ĺ | |) | |
| Ć | c |) | |
| ĺ | χ |) | |
| Ć | χ |) | |

| 1 | does tha | t calculate how it would work? |
|----|------------|---|
| 2 | А | Yes. At a very simple level, yes. |
| 3 | Q | All right. Now, let's use a different example. Let's say the |
| 4 | billed ch | arge is 1,000, and the allowed amount under the benefit plan is |
| 5 | still 300. | Under if that claim was adjudicated using the shared savings |
| 6 | program | , would United be able to earn an administrative fee for that |
| 7 | client? | |
| 8 | А | Yes. |
| 9 | Q | Would you go through the same exercise we went through in |
| 10 | example | 2? |
| 11 | А | Yes. So the savings is \$700. |
| 12 | Q | And that would be multiplied by the fee? |
| 13 | А | Yep, 30 percent. So I believe the math is 210. |
| 14 | Q | Now, do you remember being questioned by Mr. Zavitsanos |
| 15 | about a s | shared savings calculation in one of UnitedHealthcare's |
| 16 | documer | nts where the amount of the shared savings fee was greater than |
| 17 | the amou | unt of the allowed payment under the shared savings program? |
| 18 | А | Yes, I do. |
| 19 | Q | Let me show you another example. Let's assume this time |
| 20 | that the l | oilled charge equals \$1,500 |
| 21 | А | Can |
| 22 | Q | and the allowed amount again |
| 23 | А | Can you move that up, please? |
| 24 | Q | Sorry. |
| 25 | А | Thank you. |

| (| Ξ |) |
|---|---|---|
| (| |) |
| (| |) |
| (| 2 |) |
| (| х |) |
| , | - | ۰ |

| 1 | Q | I must have done something here. The allowed amount | |
|----|--|--|--|
| 2 | under the | benefit plan is still 300. So I assume, based on your prior | |
| 3 | testimony, in that example, UnitedHealthcare could earn a shared | | |
| 4 | savings fe | e? | |
| 5 | А | Yes. That would the difference would be 1,200. | |
| 6 | Q | Which would be multiplied by | |
| 7 | А | 30 percent. | |
| 8 | Q | by 30 percent, which would produce a shared savings fee | |
| 9 | of 400? | | |
| 10 | А | Check my math on that. 360. | |
| 11 | Q | 360. My bad. This is why you're here. | |
| 12 | А | Thank you for using round numbers. | |
| 13 | Q | So this would be an example where the shared savings fee | |
| 14 | would be | higher than the allowed amount? | |
| 15 | А | That's correct. | |
| 16 | Q | Even though in all four examples, the allowed amount does | |
| 17 | not chang | e, correct? | |
| 18 | А | Yes. What changes is the billed charges is going up. | |
| 19 | Q | Thank you for that, sir. | |
| 20 | А | Yep. | |
| 21 | | MR. BLALACK: Ms. White, could we toggle back? | |
| 22 | BY MR. BL | LALACK: | |
| 23 | Q | Now, sir, are the under the shared savings fees, is the | |
| 24 | percentag | e based on savings the only variable being calculated in the | |
| 25 | fees or are | e there any other terms that sometimes clients use for | |

3

4

5

6

8

7

9

10 11

12

13 14

15

16

17

18

19

20 21

22

23

24

25

calculating shared savings fees?

Α For the wrap network and fee negotiation, it's typically a percent of savings.

- Do clients ever ask for and receive fee caps? \mathbf{O}
- Α Yes, they do.
- What is a fee cap? Q

Α The fee cap has been asked for now is out with clients and used frequently. Usually, there's a cap on the amount that would be charged for that specific claim as a fee from the client to United.

Q Okay. Now, when a client pays an administrative shared savings fee to UnitedHealthcare, what is it paying for?

So it's an extremely complicated process. If you've got to think about this is that the claims come -- you're -- no matter what, par and non-par claims come in to United. United will -- has established logic to take those non-par claims and electronically put them into a file, safely save them, save -- send them over to the vendor, so in a secured environment. MultiPlan does what they do. They send the claim back. We have to do adjudication logic inside of that to determine that claim. So there's a lot of infrastructure, a lot of capital costs, a lot of full-time equivalent -- so employees that we employ, both my group and others, to be able to administer that.

Q Okay. Now, can you give the jury just a ballpark sense of how many claims UnitedHealthcare would receive and adjudicate on a given day?

Millions. Α

| 1 | Q | Millions a day? |
|----|---------------|---|
| 2 | А | Millions a day. |
| 3 | Q | Now, let's talk about the next program. |
| 4 | | MR. BLALACK: And Shane, can we bring up page 17 of the |
| 5 | Plaintiffs' E | Exhibit 134, please? |
| 6 | BY MR. BL | ALACK: |
| 7 | Q | And sir, this |
| 8 | А | I'm sorry, what page? |
| 9 | Q | Page 17. |
| 10 | А | Thank you. |
| 11 | Q | And I think you referred to this earlier as the outlier cost |
| 12 | manageme | ent program. Do you see that? |
| 13 | А | I do. |
| 14 | Q | And this is also referred to as SSPE, correct? |
| 15 | А | Correct. |
| 16 | Q | And what's that acronym stand for? |
| 17 | А | SSPE is shared savings program enhanced. |
| 18 | Q | And in response to questions from Mr. Zavitsanos, I thought |
| 19 | you explai | ned, but tell me if I'm wrong. Okay? The primary difference |
| 20 | between th | ne shared savings program and the shared savings program |
| 21 | enhanced | is that outlier cost management is added to the shared savings |
| 22 | program? | |
| 23 | А | That's correct. |
| 24 | Q | Okay. Now, if you look in let's see where it is. Okay. |
| 25 | Under that | blue box, the first bullet, it will say it says, "The application |

| 000992 | | | |
|--------|--|--|--|
| | | | |
| | | | |
| | | | |

| of a repriced allowable determined by our measure, MultiPlan, usi | ng |
|---|----|
| their proprietary methodology, Data iSight." Do you see that? | |

A Yes, I do.

- Q What does that describe?
- A So that describes, as I kind of talked about earlier, Data iSight is the repricing engine, the tool, that accepts the claims in, will determine reimbursement amount, and send it back.
- Q Okay. Now, if you go down to the next bullet, it says, "Applies to claims paid at in-benefit level that have not achieved a discount or reduction through any other OON program." Do you see that?
 - A I do.
- Q So that -- that acronym, I -- capital INN (phonetic), what is that again?
- A So again, as we -- if you go back to that one page, he had the left-hand side, the right-hand side, no choice in-network highest benefit level, choice, lowest benefit level. We are talking about those that are the no-choice claims.
- Q So when this slide was prepared, was outlier cost management only available on the in-network benefit level?
 - A I believe so.
- Q And when it refers to "did not achieve a discount or reduction through any other out-of-network program", what does that mean?
- A So again, think about the waterfall. Now, this is another program at the -- at the end of the waterfall. Obviously, if it's a

| _ | 5 |
|-----------|---|
| ≥ | 5 |
| \subset |) |
| C |) |
| C |) |
| a | 3 |

| 1 | nonparticipating provider, there's no wrap agreement with MultiPlan. | | |
|----|--|--|--|
| 2 | MultiPlan or the vendor then try to negotiate. The provider didn't they | | |
| 3 | didn't come to a resolution on that amount. Then outlier cost | | |
| 4 | managem | ent now is in place to be able to apply what we feel is a fair | |
| 5 | and reaso | nable amount. | |
| 6 | Q | Okay. Now, because this is a program that only applies at | |
| 7 | the in-network benefit level, does outlier cost management apply to out- | | |
| 8 | of-network emergency room claims? | | |
| 9 | А | Yes, it does. | |
| 10 | Q | Okay. Now, how does Data iSight, and I am just focusing on | |
| 11 | well, let me back up. Does Data iSight apply to all out-of-network | | |
| 12 | services o | r just out-of-network ER services? | |
| 13 | А | All out of all services, not just ER. | |
| 14 | Q | So this proprietary methodology that Mr. Zavitsanos | |
| 15 | described | to you is not limited to adjudicating an out-of-network | |
| 16 | emergenc | y room claim? | |
| 17 | А | No, it's not. | |
| 18 | Q | Is the methodology that UnitedHealthcare and Data iSight | |
| 19 | use to adj | udicate an out-of-network emergency room claim at all | |
| 20 | different a | s compared to a non-emergency room out of network? | |
| 21 | А | Methodology is not any different. | |
| 22 | Q | So the Data iSight methodology that is used for a service is | |
| 23 | the same | whether it's out of network or it's in-network I mean, whether | |

MR. ZAVITSANOS: Excuse me, Your Honor. Foundation,

it's ER or non-ER?

24

| 1 | |
|----|---|
| 2 | |
| 3 | |
| 4 | |
| 5 | |
| 6 | |
| 7 | |
| 8 | |
| 9 | |
| 10 | |
| 11 | |
| 12 | |
| 13 | |
| 14 | |
| 15 | |
| 16 | |
| 17 | |
| 18 | |
| 19 | |
| 20 | |
| 21 | |
| 22 | |
| 23 | |
| 24 | |
| ~= | 1 |

| 1 | speculatio | n, and calling for a lay legal opinion. |
|----|-------------|---|
| 2 | | THE COURT: Overruled. |
| 3 | BY MR. BI | _ALACK: |
| 4 | Q | Now, have you ever heard of something, sir, called the ER |
| 5 | override? | |
| 6 | А | Yes, I have. |
| 7 | Q | What is the ER override? |
| 8 | А | So there's the Affordable Care Act out, that's out there in in |
| 9 | the federa | I government that applies to emergency room services, so ER. |
| 10 | And in tha | t, you have criteria you need to meet. So if you think about |
| 11 | kind of the | e waterfall |
| 12 | Q | And let me interrupt you, sir. I'm not going to have you go |
| 13 | through a | Il three of the criteria. What I really just want to understand |
| 14 | and expla | in to the jury is how does the ER override, however that's |
| 15 | determine | d, apply or not apply to a claim that's being priced using the |
| 16 | Data iSigh | nt |
| 17 | А | Sure. |
| 18 | Q | methodology? Do you understand |
| 19 | А | Okay. |
| 20 | Q | what I'm saying? |
| 21 | А | Yeah, I understand what you're saying. Basically, it's a floor. |
| 22 | Right? It's | s to ensure we're compliant with the Affordable Care Act. |
| 23 | Q | So let's kind of walk through an example. Well, let me back |
| 24 | up. Yeste | rday, you talked about a number of different percentages of |
| 25 | Medicare, | benchmarking, and overrides. Do you remember being |

| C |) |
|-----|----|
| C |) |
| C |) |
| c |) |
| C |) |
| () | ٦. |

| 1 | questioned | d about that |
|----|-------------|--|
| 2 | А | Yes. |
| 3 | Q | by Mr. Zavitsanos? Do you recall what the ER override was |
| 4 | when it wa | as instituted? |
| 5 | А | When it first started, I believe it was 350 percent of Medicare. |
| 6 | Q | Okay. And then you, I think, were questioned by Mr. |
| 7 | Zavitsanos | and he indicated it went down at some point? |
| 8 | А | Yes. It went down to 250 percent of Medicare. |
| 9 | Q | Okay. So the ER override started at 350 percent of Medicare |
| 10 | and then it | was reduced to 250 percent of Medicare? |
| 11 | А | Yes, it was. |
| 12 | Q | When was it reduced? |
| 13 | А | I don't remember the exact date. |
| 14 | Q | Okay. Now, let's hypothetically go through an example of a |
| 15 | claim that | is sent to MultiPlan. An ER claim sent to MultiPlan, and it's |
| 16 | going to b | e adjudicated by MultiPlan. How would MultiPlan's |
| 17 | methodolo | gy and pricing recommendation interplay with the ER |
| 18 | override? | |
| 19 | А | So if a claim goes to Multi |
| 20 | | MR. ZAVITSANOS: Objection, Your Honor. Again, |
| 21 | speculatio | n and foundation. |
| 22 | | THE COURT: Overruled. |
| 23 | | MR. ZAVITSANOS: Okay. |
| 24 | | THE WITNESS: So the claim goes to MultiPlan. MultiPlan, |
| 25 | the claim v | vill go in if it's OCM, will go into Data iSight. Data iSight will |
| | | |

| calculate an amount that they feel is the reasonable reimbursement rate. |
|--|
| We tell MultiPlan if that amount is not greater than the floor, which at |
| in the beginning was 350 percent of Medicare, now it changed to 250 |
| percent of Medicare, then price that claim because then they do the |
| pricing and apply that to their Data iSight tool, so we don't have to do it, |
| and then they send that claim back to us. So that claim, if Data iSight is |
| lower than the floor that we give, that claims gets comes back at 250 |
| percent of Medicare or 300. |

- Q And if it's -- converse is the case, if the Data iSight price is higher than the floor, what happens?
- A So the claim goes to Multi -- sorry, I've got to just start in my head of the process. The claim goes to MultiPlan. Eventually, if it gets to Data iSight, if that's what the client has in their benefits, Data iSight prices the claim. Let's say that claim is greater than the floor, then we will pay the Data iSight amount --
 - Q Okay.
 - A -- because that's reasonable.
- Q I want to show you, sir, a slide that we showed the jury in opening, and walk through this to make sure they understand how this ER override works.
- MR. BLALACK: So Shane, can you bring up slide 67, please? BY MR. BLALACK:
- O Okay. So sir, I'm going to lay this out and then have you kind of walk the jury through the mechanics of how the ER override works.

 So we start with an emergency room visit. And that results in -- I'm just

going to quickly just walk the jury through a hypothetical here. So we have an emergency room visit. What happens now?

A So the claims goes from United electronically out to MultiPlan. MultiPlan will see that, they will apply Data iSight. They'll go through, they'll do a compare and say the ER override says you -- the floor, so to speak, is 350. You look at Data iSight, MultiPlan, their Data iSight's lower, so the claim then will get repriced by MultiPlan, which is at 350, because that's the greater, and they will send that back to United. United will then take an administer that claim and pay 350.

Q Let's do now same scenario, except with a Data -- a service that has a Data iSight rate above [indiscernible]. So now we have an emergency room visit.

A Same thing. Claim comes in, goes out the Data iSight electronically from United. Data iSight calculates it based under methodology, says you should pay this recommended reasonable amount is 400. They look at the ER override rule that's there in place. The ER override, just the 150. So United will -- or, I'm sorry, MultiPlan then will reprice the claim at 400 because that's the greater of the two, and then they will send that claim back to United and United will pay that claim at 400.

Q Okay. Thank you, sir. Sir, to your knowledge, were the ER overrides that were used from United Healthcare to Data iSight during the period at issue in this case, that same 350 percent or 250 percent, regardless of who the ER provider was?

- 82 -

A That's correct.

| 3 |
|----|
| 4 |
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
| 23 |
| 24 |
| 25 |

2

| MR. ZAVITSANOS: | Foundation, | Your | Honor. |
|-----------------|-------------|------|--------|
|-----------------|-------------|------|--------|

THE COURT: Overruled.

BY MR. BLALACK:

- Q And was the ER override the same during the period at issue, regardless of what the ER service was?
 - A Yes.
- Q Now, typically, sir, what kind of a clients utilize medical cost spent?
- A Clients that wanted to address medical cost spent, typically self-funded employer groups or the clients.
- MR. BLALACK: And I wanted to ask you if you could bring up that page again, Shane, page 7.

BY MR. BLALACK:

- Q If you look at in the left-hand corner of the box, it says member is balance bill. Do you see that?
 - A I do.
 - Q Could you explain what that is -- means to the jury?
- A So with outlier cost management, the provider has not agreed upon a rate. It's a reasonable reimbursement rate, but there are situations where the member may be balanced billed by the provider. If that is the case, then the vender will engage with the provider to try to settle it.
- Q And is that a negotiation service -- would that be called a negotiation service?
 - A Yes, it is.

| 000999 | | | |
|--------|--|--|--|
| | | | |
| | | | |
| | | | |

| 1 | Q | Would that be called a prospective, or retrospective? |
|----|--------------|---|
| 2 | А | I would call it a retrospective, so after the initial payment's |
| 3 | been made | 9. |
| 4 | Q | And if that negotiation is successful, is does the out-of- |
| 5 | network p | rovider agree to accept payment in full? |
| 6 | А | Yes. We only allow for written agreement, so it can't be a |
| 7 | verbal, so | if the payment I'm sorry, if the reimbursement amount is |
| 8 | agreed to | between the vender and the provider, there's a written |
| 9 | agreemen | t in MultiPlan since the claim back repriced. |
| 10 | Q | Okay. And based on your time period administering that by |
| 11 | outlier cos | t management program, do you have any understanding |
| 12 | about the | three which the rates paid using the outlier cost management |
| 13 | program h | ave been accepted by provider? |
| 14 | А | Accepted; very rarely rejected. |
| 15 | Q | Now, are there client fees for the outlier cost management |
| 16 | program o | r the shared savings program enhanced? |
| 17 | А | Yes, there is a fee for that program. |
| 18 | Q | And are the fees calculated in any way similar, or different |
| 19 | from the s | tandard shared savings fees you described to the jury already? |
| 20 | А | It's the same methodology and the same fee. |
| 21 | Q | Sir, when did UnitedHealthcare first start utilizing outlier cost |
| 22 | managem | ent? |
| 23 | А | I believe it was in 2016 or so. |
| 24 | Q | Okay. And was it used continually during the period at issue |
| 25 | in this case | e, meaning up through January of 2020? |

| 0 | |
|---|--|
| 0 | |
| _ | |
| Ō | |
| | |
| 0 | |

| 1 | Α | I guess it was. |
|----|--------------|--|
| 2 | Q | To your knowledge, is it used today? |
| 3 | А | I believe so. |
| 4 | Q | All right. Let's move onto another program which the jury |
| 5 | heard a lot | about. It's called the position reasonable and customary, or |
| 6 | position R8 | &C program. And if you can go to page 14, please, of this |
| 7 | document. | Now, sir, there's two things described here, physician and |
| 8 | facility, R& | C; are those the same program or are they different? |
| 9 | А | No, they are different. |
| 10 | Q | Okay. Now, because this case I think all parties agreed is |
| 11 | limited to p | physician services, I'm just going to focus on one. Physician, |
| 12 | reasonable | and customary, R& C, okay? |
| 13 | А | Understood. |
| 14 | Q | All right. Now, this was a program you were questioned |
| 15 | about last v | week by Mr. Zavitsanos, correct? |
| 16 | А | Yes. |
| 17 | Q | You see at the bottom left-hand box, it says professional |
| 18 | physician F | R&C? |
| 19 | А | Yes, I do. |
| 20 | Q | Okay. Could you describe what that or explain to the jury |
| 21 | what that is | s describing? |
| 22 | А | So these are the I'm sorry, I've got to make sure I'm |
| 23 | looking at t | the right box. Physician |
| 24 | Q | Let's start with professional/physician R&C. |
| 25 | А | Yeah. So this is where United purchases the claims charge |